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ABSTRACT 
 
It is now increasingly evident that neurodegenerative diseases such as Alzheimer’s disease 
(AD) and Huntington’s disease (HD) trigger immune activation within the CNS and activate 
innate immune responses, which are primarily driven by microglia.   
HD is caused by a CAG repeat expansion in the huntingtin gene (HTT), leading to translation 
of an aberrant and pathogenic mutant HTT. Studies in mouse models have shown that HD 
microglia acquire a hyper-reactive inflammatory phenotype, mediated by a gain of toxicity of 
mutant HTT. Using a HD induced pluripotent stem cell (iPSC) line containing 109 CAG repeats 
in the HTT gene, microglia-like cells were generated with the aim of characterising their 
phenotype. RNA sequencing was used to explore the microglial-specific transcriptional 
changes associated with mutant HTT and pathway analysis carried out to predict any 
downstream processes affected in the HD109 microglia. Several immune-related functions 
including chemotaxis and phagocytosis were subsequently identified as dysregulated or 
impaired. However, upon functional assay validation, no phenotypic abnormalities were 
manifest in the HD109 microglia, with comparisons made against WT Kolf2 and isogenic 
HD109 corrected iPSC-derived microglia. Similarly, the in vitro microglia did not exhibit the 
inflammatory phenotype characteristic of diseased HD microglia and other immune cells.  
 
Loss-of-function variants in the microglia-enriched gene encoding ATP-binding cassette 
transporter A7 (ABCA7) increase Alzheimer’s disease risk. Although it has been suggested to 
play a role in amyloid beta phagocytosis, the precise role of ABCA7 in AD pathogenesis 
remains unknown. To that end, ABCA7 knockout iPSCs were generated using CRISPR/Cas9 
and in preliminary results, loss-of-function mutations in ABCA7 were found to impair 
phagocytosis of E. coli bioparticles and regulate in vitro microglial inflammatory responses.    
 
This thesis demonstrates that iPSC-derived microglia can serve as a platform for exploring the 
inflammatory pathways mediating microglial involvement in AD and HD pathogenesis, thus 
enabling in-depth mechanistic studies that bridge the gap between clinical and animal 
models.    
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 2. MATERIAL AND METHODS  
2.1 Materials 
2.1.1 Cell culture reagents 
Cell culture reagent  Supplier  Catalogue number  
RPMI 1640  Gibco 1185093 
Fetal Bovine Serum  Gibco 10439024  
Glutamax Thermo Fisher 35050-038 
Penicillin/Streptomycin 
(5000U/5000µg) 
Gibco 15070063 
BMP-4 PeproTech 120-05ET 
SCF Miltenyi Biotec 130-093-991 
VEGF PeproTech 100-20 
E8 Flex Medium Life Technologies A2858501 
X-VIVO15 Scientific Laboratory Supplies LZBE02-060Q   
M-CSF BioLegend 574806 
IL-3 BioLegend  578006 
ß-mercaptoethanol Life Technologies 31350 
IL-34 BioLegend 577906 
GM-CSF BioLegend  572902 
Fibronectin  Merck Millipore FC010-10MG 
PBS pH 7.4 Gibco 10010015 
Vitronectin Gibco A31804 
ReLeSR Stem Cell Technologies 05872 
Y-27632 dihydrochloride 
(ROCK inhibitor) 
Tocris 1254 
40 µm cell strainers   Scientific Laboratory Supplies 431750 
D-PBS Life Technologies 14190250 
Trypan Blue solution Sigma Aldrich T8154 
DMEM-F12, no phenol red Thermo Fisher 11039021 
Table 2.1 List of reagents used for cell culture and differentiation.  
 
Cell culture media Composition 
THP-1 maintenance media 
RPMI 1640 + 10% FBS + 2 mM Glutamax + Penicillin/Streptomycin 
50U/50µg  
E8-3G (EB differentiation 
medium) 
E8 + 50 ng/ml BMP4 + 50 ng/ml VEGF + 20 ng/ml SCF 
 X-VIVO factory medium 
X-VIVO15 + 2 mM Glutamax + 50U/50µg Penicillin/Streptomycin + 50 
µM ß-mercaptoethanol + 50 ng/ml M-CSF + 25 ng/ml IL-3  
Microglia differentiation 
medium 
X-VIVO15 + 100 ng/ml IL-34 + 10 ng/ml GM-CSF 
 Table 2.2 List of media used for cell culture and microglial differentiation  
 
2.1.4 Buffers, consumables and kits  
 
 Composition 
DNA lysis buffer 
1 M Tris pH 8.0 (2.5 ml), 0.5 M EDTA (1 ml) , 10% SDS (155 µl), 5 M NaCl 
(200 µl), Deionised water (46 ml) 
ICC Blocking buffer 
(external markers) 
3% Bovine Serum Albumin (BSA), 2% Normal Serum (Goat/Chicken), PBS 
pH 7.4 (up to 50 ml) 
ICC Blocking buffer 
(internal markers) 
3% BSA, 2% Normal Serum (Goat/Chicken), 0.1% Triton X-100, PBS pH 
7.4 (up to 50 ml) 
FACS buffer  0.1% BSA, PBS pH 7.4 
Table 2.3 List of buffers.   
 
Consumable Supplier Catalogue number 
Superscript II Reverse Transcriptase kit Invitrogen 18064014 
RNEasy Mini kit Qiagen 74104 
PowerUp SYBR Green Master Mix Applied Biosystems A25778 
P3 Primary Cell 4D-Nucleofector Kit Lonza V4XP-3032 
Bovine Serum Albumin (BSA) Sigma Aldrich A7906 
Normal Goat/Chicken Serum Dako X0907/X0903 
Triton X-100 Sigma Aldrich T8787 
Formalin (4% FPA) Sigma Aldrich HT5011 
Poly-D-Lysine  Poly-D-Lysine  Poly-D-Lysine  
Sigma Aldrich Sigma Aldrich Sigma Aldrich 
Cytospin funnels  Fisher Scientific 11972345 
Table 2.4 List of consumables and kits used.    
 
 
 2.2 Maintenance and culture of human induced pluripotent stem cells  
2.2.1 Maintenance of human iPSC lines 
Studies were performed using two feeder-free human iPSC lines: Kolf2-C1 and HD109. Kolf2-
C1 iPSC lines were generated from fibroblasts collected from a healthy 55-59-year-old male 
and reprogramming carried out by non-integrating Sendai virus transduction of Oct4, Sox2, 
Klf4 and cMyc. HD109 iPSC lines were derived from fibroblasts collected from a 9-year-old 
female with juvenile onset HD from the age of 4, with severe bradykinesia, rigidity and 
dystonia at time of biopsy (HD iPSC Consortium 2012). Reprogramming was conducted by 
lentiviral transduction of Oct4, Sox2, Klf4 and cMyc. For both cell lines, normal karyotypes 
and expression of pluripotent stem cell markers were confirmed. All cell cultures were 
maintained in a humidified incubator (37˚C, 5% CO2).   
 
iPSCs were cultured in feeder-free conditions on 6-well plates (Corning) coated in vitronectin 
(0.5 µg/cm2; Gibco, Life Technologies) and fed with E8 Flex medium. Medium was changed 
daily, and cells were passaged using ReLeSR every 3-5 days (or at 80% confluence). For 
passaging, cells were washed once with PBS pH 7.4 and the ReLeSR added before incubation 
at 37˚C for 5 minutes. The dissociation reagent was removed by aspiration and fresh E8 Flex 
medium added to gently detach the colonies by homogenisation with a pipette. The mixture 
was transferred to a 15 ml Falcon tube and centrifuged for 3 minutes at 1000 rpm. The 
supernatant was aspirated, and cell pellet re-suspended in warm E8 Flex for plating.  
 
2.2.2 Maintenance of THP-1 monocytes  
THP-1 monocytes were a kind gift from Dr Shane Wainwright (Cardiff University). The cells 
were cultured with monocyte maintenance medium (see section 2.1.1) in non-adherent T75 
flasks. The cells were seeded at a density of 2x105 cells per ml and re-suspended in 19 ml of 
media. Once concentration exceeded 1x106 cells per ml, they were collected by centrifugation 
(1000 rpm for 3 minutes) and split in a 1:5 ratio into T75 flasks. 
 2.3 Directed differentiation of iPSCs into microglia-like cells 
2.3.1 Differentiation of human iPSCs into embryoid bodies (EBs) 
Day 0: iPSC colonies grown to confluence on 6-well plates were washed with 1x PBS pH 7.4 at 
room temperature, ReLeSR was added (1 ml per well) and the cells placed in incubator. After 
2-3 minutes, the dissociation reagent was aspirated, and the side of the plate was lightly 
tapped for 1-2 minutes to allow colonies to dislodge. Following this step, 2ml of warm E8 
medium was gently added to each well to allow the aggregated cells to form floating EBs and 
the plate returned to the incubator for one day.  
 
Day 1: EBs were carefully transferred to a 15-ml tube and allowed to settle by gravity. The 
supernatant medium was removed and replaced with E8 + 50 ng/ml BMP-4, 50 ng/ml VEGF 
and 20 ng/ml SCF. EBs were cultured in E8-3G media for 7 days, with a 50% media change 
every two days.   
2.3.2 Differentiation of EBs into monocyte-like macrophage precursor cells  
E8-3G- cultured EBs were collected and further differentiated to make ‘factories’ by seeding 
15 EBs into one well of a 6-well plate in X-VIVO15 media supplemented with 50 ng/ml M-CSF 
and 25 ng/ml IL-3. The culture media from the factories was changed weekly. After 
approximately 2 weeks, non-adherent (monocyte-like) myeloid cells would become visible in 
the supernatant media of the factories, were harvested weekly and the culture media 
replenished. For harvesting, the supernatant was passed through a 40 µm cell strainer, 
centrifuged for 3 minutes at 1000 rpm and the resulting pellet gently re-suspended for use in 
assays described below or plated onto glass coverslips or tissue-culture plates.  
 
2.3.3 Induction of microglia-like phenotype   
Non-adherent myeloid cells harvested from the factories were plated at a density of 2-3 x 105 
cells per well and 10,000 onto PDL-treated (100 µg/ml in borate buffer) tissue culture 6-well 
plates and glass coverslips respectively, pre- coated with 5 µg/cm2 fibronectin. The cells were 
cultured in XVIVO15 medium supplemented with 10ng/ml GM-CSF and 100 ng/ml IL-34. The 
medium was changed after 7 days and cells incubated in standard culture conditions for 14 
days, prior to being used for experiments.  
 2.4 Functional assays  
Name Supplier  Catalogue number 
Aß1-42 peptide California Peptide Research 641-15 
Reverse Aß42-1 Tocris 3391 
HFIP Sigma Aldrich H-8508 
Bafilomycin A1 Sigma Aldrich B1793-10UG 
Cytochalasin D Sigma Aldrich C8273-1MG 
pHrodo red E. coli bioparticles Life Technologies P35361 
Live Cell Imaging Solution  Life Technologies A14291DJ 
96-well black-walled µ-clear 
microplates 
Greiner Bio-One 655097 
ClearView 96-well Migration 
plates 
Essen BioScience 4582 
ClearView 96-well reservoir 
plates  
Essen BioScience 4600 
Seahorse XF Cell Mito Stress 
Test 
Agilent Technologies 103015-100 
Seahorse XF96 V3 PS cell 
culture microplates 
Agilent Technologies 101085-004 
Seahorse XF calibrant Agilent Technologies 100840 
Seahorse XF 1.0 M Glucose 
solution 
Agilent Technologies 103577-100 
Seahorse XF RPMI Medium pH 
7.4 
Agilent Technologies 103576-100 
 Seahorse XF96 sensor 
cartridge  
Agilent Technologies 102601-100 
Filipin Sigma Aldrich F9765 
Ibidi 8-well µ-slides  Thistle Scientific  80826 
Lysenin Antiserum  Peptide International NLY-14802-v 
LipidTOX Red Phospholipidosis 
Detection Reagent  
Invitrogen H34351 
Complement C1q  Merck Millipore 204876-1MG 
Lipopolysaccharide Sigma Aldrich  L2654-1MG 
IL-4 PeproTech 200-04 
ADP Sigma Aldrich A2754-500MG 
CX3CL1 BioLegend 583404 
Table 2.5 List of material, media and consumables used for functional assays.  
 
2.4.1 Stimulation with amyloid beta oligomers and reverse amyloid beta  
Synthetic Aß1-42 peptides were resuspended in ice-cold HFIP (or 1,1,1,3,3,3,- 
hexafluoropropan-2-ol), by adding 222 µl to 1mg and aliquoted into microcentrifuge tubes 
 (100 µl = 0.45 mg). Each aliquot was dried overnight under a stream of N2 gas to allow HFIP 
evaporation (and stored long term at -80˚C). The resulting peptide films were dissolved to 5 
mM Aß stock by adding 20 µl DMSO to 0.45 mg peptide. The peptide stock was further diluted 
to 100 µM in phenol red-free F-12 medium and the suspension incubated at 4˚C for 24 hours 
to allow oligomerisation. Following incubation, the Aß mixture was centrifuged in the cold for 
10 min at 14,000 rpm to pellet out any fibrils. The supernatant was collected as Aß oligomeric 
preparation, diluted in phenol red-free medium before use.       
 
2.4.2 Phagocytic uptake of pHrodo red E. coli bioparticles   
This assay was used to measure the formation of acidified phagosomes: as the pHrodo red E. 
coli bioparticles reach the acidic environment of the phagosome (pH 4.5-5.5), the intensity of 
the fluorescence is greatly enhanced, enabling direct quantification of phagocytosis in real-
time. First, pHrodo red E. coli bioparticles were resuspended to 1mg/ml in Live Cell Imaging 
Solution. The mixture was homogenised, transferred to glass vial and sonicated for 5 min prior 
to each experiment.  
Precursor cells collected from differentiation factories were plated onto 96-well PDL-treated, 
black walled µ-clear flat bottom microplates at a density of 20,000 cells/well in a 100 µl 
suspension and differentiated to microglia for 14 days. Before the assay, the growth medium 
was removed and replaced with 75 µl of live cell imaging solution. After 10 µg per well of 
pHrodo E. coli was added, the microplates were transferred into the IncuCyte S3 live-cell 
imaging system (Essen BioScience), housed inside a 37˚C/5% CO2 incubator. The microplates 
were imaged in the IncuCyte for 4-6 hours with a 20x objective. At least four images per well 
were taken every 15 or 20 min and analysis carried out using the IncuCyte S3 Base software. 
Red channel acquisition was 400 ms and phase contrast masking and cell segmentation was 
applied to exclude cells from background, with an area filter of 50 µm2 to exclude objects. 
Background red channel noise was subtracted using Top-Hat correction with a radius of 20 
µm and a threshold of 2 red corrected units (Kapellos et al. 2016). As a positive control for 
inhibited phagocytosis, cells were pre-treated for 1 hour with 10 µM of the actin 
polymerisation inhibitor cytochalasin D or bafilomycin A1, an inhibitor of the phagolysosome 
V-ATPase.  
 
 2.4.3 IncuCyte S3 chemotaxis assay  
The chemotaxis assays were conducted with IncuCyte ClearView 96-well Migration plates, 
featuring a low pore density membrane that separates an upper and lower chamber and 
requires cells to migrate across the membrane surface to reach a pore. Prior to cell plating, 
both sides of the IncuCyte ClearView plate membrane were coated with fibronectin: 150 µl 
per well was added to an IncuCyte ClearView 96-well reservoir plate and 20 µl was added to 
the insert wells, before the insert wells were gently placed onto the reservoir plate. The 
migration plate was then incubated at 37˚C for 30 min before being allowed to cool down to 
room temperature for another 30 min. The fibronectin was then aspirated from both the 
reservoir plate and insert and replaced with 200 µl of D-PBS to the reservoir plate. Microglia 
precursor cells were then seeded into each well of the insert plate in 60 µl at 3000 cells per 
well and allowed to settle on the membrane at room temperature for 15-30 min. The cells 
were differentiated to microglia within the plate for 14 days, with a media change after 7 
days.  
On the day of the assay, chemoattractants were made to desired concentrations in XVIVO 
medium, with 200 µl added to the appropriate wells of a reservoir plate and the insert plate 
carefully placed onto the chemoattractant-containing reservoir plate. The migration plate 
was transferred to the IncuCyte S3 system for scanning. 10x objective, phase channel scans 
of both the top and bottom sides of the insert were scheduled every 30 min for 24 hours. 
Migration was quantified by the IncuCyte analysis software as the appearance of in focus cells 
on the bottom of the well and the surface area they occupied (total phase object area in µm2 
/well).    
 
2.4.4 Seahorse XFe96 assays for mitochondrial bioenergetics and glycolytic flux 
The Seahorse XFe96 Analyser measures oxygen consumption rate (OCR) and extracellular 
acidification rate (ECAR) over a specified time period and at particular time intervals as a way 
of assessing mitochondrial respiration (via cellular oxygen consumption) and glycolytic proton 
efflux. Using the manufacturer’s standardised protocol for the Seahorse XF Cell Mito Stress 
Test, cell respiration can be measured under basal conditions and subsequent exposures to 
the ATP coupler oligomycin, the uncoupler carbonyl cyanide-p-
trifluoromethoxyphenylhydrazone (FCCP), and the complex I inhibitor Rotenone. Oligomycin, 
 which acts by inhibiting the proton channel of the ATP synthase (complex V), is used in this 
protocol to calculate the percentage of oxygen consumption allocated to ATP synthesis. 
Treatment with FCCP, which disturbs the transport of hydrogen ions across the mitochondrial 
membrane, affects the mitochondrial membrane potential and results in a rapid increase in 
OCR. Lastly, rotenone injection leads to a shutdown of mitochondrial respiration. Therefore, 
each administered compound allows the assessment of different aspects of mitochondrial 
respiration, including basal respiration, maximal respiration, spare respiratory capacity, 
proton leak and ATP production.       
The optimal seeding density and test compound concentrations were determined during 
preliminary experiments to identify the optimal number of cells required to detect a sufficient 
shift in OCR and ECAR. The Seahorse XF Cell Mito Stress test, which assays mitochondrial 
respiration, generates a bioenergetics profile, whereby each injected drug allows different 
properties of mitochondrial respiration to be measured.    
 
20,000 microglia precursor cells per well were seeded onto PDL-coated Seahorse XF96 V3 PS 
cell culture microplates and differentiated for 14 days in XVIVO with IL-34 and GM-CSF. Prior 
to plating, the plates were coated with fibronectin. Cells were seeded in a 80 µl suspension 
of Seahorse XF RPMI media pH 7.4 supplemented with 10 mM glucose, 1 mM sodium 
pyruvate and 2 mM L-glutamine and allowed to adhere to the plate for 1 hour at room 
temperature to allow for even distribution across the well before being moved to a humidified 
5% CO2 incubator at 37˚C. Four wells were kept empty to serve as background control.  
The day prior to the experiment, the Seahorse XFe96 Analyser was turned on to allow the 
temperature to stabilise. 200 µl of Seahorse XF calibrant was added to the Seahorse XF96 
sensor cartridge and kept in a non-CO2 incubator overnight. The day of the experiment, the 
hydrated cartridge was loaded with the test compounds oligomycin (2µM, 25 µl), FCCP 
(2.5µM, 25 µl) and antimycin A/rotenone (0.5µM, 25 µl) diluted in pre-warmed Seahorse XF 
RPMI media at a 10x concentration to dose delivered to cells. The cartridge was then inserted 
into the Seahorse XFe96 machine and the Seahorse XF Cell Mito Stress test protocol set up 
for calibration according to the manufacturer’s instructions. While the machine was 
calibrating, the cell culture microplate was removed from the 37˚C CO2 incubator, the XVIVO 
growth medium removed, the cells washed once with Seahorse XF calibrant and incubated 
with 175 µl per well of Seahorse XF RPMI assay medium for 45-60 min at 37˚C in a non-CO2 
 incubator. Following calibration and assay medium incubation, the cell culture microplate was 
inserted into the analyser and the Seahorse XF Cell Mito Stress test protocol was run: 3 
successive readings (every 5 min) of basal respiration, followed by a drug injection sequence 
of oligomycin, FCCP and rotenone/antimycin A with 3 sequential readings every 5 min under 
condition.  
 
2.4.5 Cholesterol staining 
Cholesterol staining was performed using filipin, a cytochemical cholesterol-specific probe  
(Te Vruchte et al. 2004). 14-day differentiated microglia on PDL-treated and fibronectin-
coated 8-well µ-slides were washed once with PBS and fixed in 4% PFA for 15 min followed 
by three PBS washes. Cells were incubated with 125 µg/ml filipin (diluted in XVIVO medium) 
for 30 min in the dark at room temperature, after which the filipin-containing media was 
removed, and cells washed in PBS. Imaging was performed using a Zeiss Axio Imager A1 
microscope in conjunction with an Axiocam High-Resolution Camera and Axiovision software 
v4.8.    
 
2.4.6 Sphingomyelin staining 
The sphingomyelin-specific stain used for these experiments was lysenin (0.1 µg/ml; Peptide 
International). Microglia cells plated on Ibidi chamber slides were washed with PBS once, 
fixed with 4% PFA and then stained with the sphingomyelin stain lysenin overnight (diluted in 
PBS + 1% BSA + 0.1% saponin). Following overnight incubation, cells were washed with PBS 
three times, incubated with lysenin anti-serum (1:500 dilution in PBS) at room temperature 
for 1 hour before incubation with a fluorescent secondary antibody (1:500 dilution in PBS) at 
room temperature for 30 min. Incubation medium was removed, Hoechst nuclear staining 
was applied followed by two PBS washes. Cells were imaged with a Zeiss Axio Imager A1 
microscope and High-Resolution Camera and Axiovision software v4.8.     
 
2.4.7 Phospholipid staining 
Phospholipidosis was analysed using LipidTOX Red Phospholipidosis Detection Reagent (Nioi 
et al. 2007). Microglia differentiated on Ibidi chamber slides were washed once with PBS and 
incubated with LipidTOX (1:1000 dilution in X-VIVO medium) for 4h to detect 
 phospholipidosis. Subsequently, the media was removed, and nuclei were stained with 
Hoechst before images were obtained with Zeiss Axio Imager A1 microscope and High-
Resolution Camera and Axiovision software v4.8. LipidTOX was excited at 543 nm and its 
emission was detected at 594 nm.  
2.5 Flow Cytometry  
Fluorescence-activated cell sorting (FACS) was carried out for the analysis of cell surface 
molecules on the non-adherent cells collected from supernatant of differentiated factories as 
described above. Cells were washed in 0.1% BSA in PBS, centrifuged at 1000 rom for 3 minutes 
and the resulting pellet was re-suspended in 200 µl of 0.1% BSA in PBS. For single-colour 
staining, 5 µl of the conjugated antibody or isotype-matching control (with the same 
fluorophore, from the same manufacturer) was added to the suspension and the mixture 
incubated at room temperature in the dark for one hour. For two-colour staining, two 
antibodies or two isotype controls (attached to different fluorophores) were added together. 
Following primary staining, the cells were washed twice with 0.1% BSA in PBS and centrifuged, 
before being transferred to 5 ml round bottom tubes (BD Falcon) in 200 µl of 0.1% BSA in PBS. 
Fluorescence was measured using a BD LSR Fortessa and data analysed using FlowJo software.  
The following antibodies and isotype controls were used.  
Antibody Clone Supplier  Catalogue number  
CD14-APC 61D3 eBioscience 17-0149-41 
CD11b-APC  ICRF44 eBioscience 17-0118-42 
CD45-FITC  2D1 eBioscience  11-9459-42  
CD34-PECy7  4H11 eBioscience 25-0349-42 
IgG1κ-APC APC isotype control eBioscience 17-4714-81 
IgG1κ-FITC FITC isotype control eBioscience 11-4714-81 
IgG1κ-PECy7 PE-Cy7 isotype control eBioscience 25-4714-80 
Table 2.6 List of conjugated antibodies used for flow cytometry analysis experiments.    
2.6 Immunocytochemistry  
2.6.1 Immunocytochemistry  
Non-adherent myeloid cells were collected from the differentiated factories and plated onto 
glass coverslips. Cultured cells were washed in 1xPBS pH7.4, fixed with 4% paraformaldehyde 
(PFA) for 15 min at room temperature and washed 3 times with PBS. Fixed cells were 
 incubated with blocking buffer (3% goat/chicken/donkey serum, 0.1% Triton-X in PBS) for 1 
hour at room temperature before overnight incubation at 4˚C with primary antibodies (see 
list below) diluted in blocking buffer. Following overnight incubation, cells were subjected to 
3 washes of 5 min, followed by a 1-hour incubation at room temperature, protected from 
light, with fluorescent secondary antibodies diluted in blocking solution. Coverslips were 
subsequently incubated with Hoechst at 1:5000 in blocking buffer and mounted on 
microscope slides. Images were taken using an Olympus BX61 fluorescent microscope.      
The ICC primary and secondary antibodies used were as follows:  
1˚ antibody Host Dilution Supplier  
CD34 Mouse anti-human 1:100 Abcam AB6330 
CD45 Mouse anti-human 1:100 R&D Systems MAB1430 
P2RY12 Rabbit anti-human 1:100 Abcam AB188968 
IBA-1 Goat anti-human 1:100 Abcam AB5076 
TGFBR1 Rabbit anti-human 1:50 Abcam AB31013 
TMEM119 Rabbit anti-human  1:100 Abcam AB185333 
CX3CR1 Rabbit anti-human 1:100 Bio-Rad AHP1589 
Table 2.7 List of primary antibodies used for immunocytochemistry.     
 
2˚ antibody  Dilution  Supplier  
Alexa Fluor goat anti-mouse IgG 488  1:400 Invitrogen A11001 
Alexa Fluor goat anti-mouse IgG 594 1:400 Invitrogen A11032 
Alexa Fluor goat anti-rabbit IgG 594 1:400 Invitrogen A11037 
Alexa Fluor goat anti-rabbit IgG 488 1:400 Invitrogen A11034 
Alexa Fluor chicken anti-goat IgG 594 1:400 Invitrogen A21468 
Alexa Fluor chicken anti-rabbit IgG 488 1:400 Invitrogen A21441 
Alexa Fluor chicken anti-mouse IgG 594 1:400 Invitrogen A21201 
Table 2.8 List of secondary antibodies used for immunocytochemistry.     
 
2.6.2 Cytocentrifugation  
Cells were washed and fixed as described. To make cytospins, 1x105 cells were spun at 800 
rpm for 1 min through pre-wet filters onto glass slides using a Centurion CYT04 centrifuge 
before staining as described in section 2.6.1.   
 2.7 RNA extraction and qRT-PCR  
For RNA extraction, samples were harvested and lysed in RLT buffer (RNEasy Mini kit, Qiagen) 
containing 10 µl/ml ß-mercaptoethanol. Total RNA was extracted according to the 
manufacturer’s protocols. The concentration and purity of the extracted RNA samples were 
measured by spectrophotometry (Nanodrop).  
2.7.1 PowerUp SYBR Green qRT-PCR  
Reverse transcription was carried out using Superscript II kit, with 1 µg template RNA in a 20 
µl reaction volume. The resulting cDNA samples were diluted 1:5 by adding 80 µl of deionised 
water and readied for qRT-PCR. Each qRT-PCR reaction, comprising 1 µl of the diluted cDNA 
product in a 20 µl volume, was placed in a thermocycler set up with the cycling parameters: 
25˚C for 10 min, 42˚C for 50 min and 70˚C for 15 min.  
RT-qPCR was carried out on a CFX Connect Real Time System (Bio-Rad) using PowerUp SYBR 
Green Master Mix (Applied Biosystems). Quantification of target gene transcripts was carried 
out using primers designed and validated with established efficiencies between 90 and 105%. 
Primers were specifically designed following these parameters: Tm close to 60˚C and qPCR 
product between 80 and 120 bp.   
 
 
 
 
 
The qPCR reaction mix was added to a 96-well plate, which was centrifuged for 1 minute at 
1500 rpm and put through the cycling program described below.   
qPCR component Volume  
10 µM Primer mix 1 µl 
PowerUp SYBR Green Master Mix 10 µl 
RNAse-free deionised water 8 µl 
cDNA 1 µl 
Step Temperature Time Cycle 
UDG activation 50˚C 2 min Hold 
Polymerase activation 95˚C 2 min Hold  
Denaturation 95˚C 15 sec  
40 Annealing/extension 60˚C 1 min 
    
Stage Step Ramp rate Temp Time 
 Step 1 1.6˚C/sec 95˚C 15 sec 
  
For analysis, the delta-delta CT method was used to determine relative gene expression 
values, with 3 biological replicates. Each biological replicate was analysed in triplicate.  
 
2.7.2 Fluidigm High Throughput qRT-PCR  
Reagent  Catalogue number  Supplier 
Random hexamers C1181 Promega  
Fluidigm Reverse 
Transcription Master Mix kit 
100-6300 Fluidigm 
Preamp Master Mix kit 100-5580 Fluidigm 
Exonuclease I  M0293S New England BioLabs 
TE buffer 12090015 Invitrogen 
Fluidigm 96.96 Dynamic Array 
IFC chip  
BMK-M-96.96 Fluidigm 
96.96 Dynamic Array DNA 
Binding Dye and Assay 
loading reagent kits 
100-3400 Fluidigm 
SsoFast EvaGreen Supermix 
with low ROX 
172-5211 BioRad 
20X DNA Binding Dye Sample 
Loading Reagent 
100-3400 Fluidigm 
Control line fluid 89000021 Fluidigm 
Table 2.8 List of consumables used for Fluidigm qRT-PCR.     
 
Samples were harvested and RNA extraction carried out as described above. cDNA synthesis 
was performed using 100 ng of total RNA and random hexamers with the Fluidigm Reverse 
Transcription Master Mix kit. According to the manufacturer’s instructions, samples had to 
undergo a round of preamplification prior to use with the high throughput array. 1.25 µl of 
each cDNA sample was pre-amplified using the Preamp Master Mix along with 0.5 µl of the 
pooled gene primers (500 nM per primer). The preamplification reactions (see table 2.8) was 
carried out using a 2 min 95˚C denaturation step and 10 cycles of 15s at 95˚C and 4 min at 
Melt curve stage Step 2 1.6˚C/sec 60˚C 1 min 
Step 3 (dissociation) 0.15˚C/sec 95˚C 15 sec 
 60˚C. The pre-amplified samples then underwent a clean-up step with Exonuclease I, where 
2 µl of diluted Exo I at 4U/µl was added to each 5-µl preamplified reaction. The mixtures were 
put on a cycling program of digestion at 37˚C for 30 min and inactivation at 80˚C for 15 min. 
Following this treatment, the pre-amplified reactions were diluted 5 times using TE buffer.    
Component Vol per reaction (µl) Vol for 96 reactions + 20% overage* (µl) 
PREAMPLIFICATION PRE-MIX 
Preamp Master Mix 1.00 115.2 
Pooled Gene primers 0.50 57.6 
DNase-free H2O 2.25 259.2 
cDNA 1.25 - 
Total  5.00 - 
Table 2.8 Preamplification reaction using Fluidigm Preamp Master Mix. *20% overage for ease of pipetting.  
 
For the high throughput qPCR, a Fluidigm 96.96 Dynamic Array IFC chip, which is formatted 
to run reactions for 96 samples and 96 genes, was used (Spurgeon et al. 2008). The primer 
reaction or assay mixes (see table 2.9) were prepared on a 96-well PCR plate using the 96.96 
Dynamic Array DNA Binding Dye and Assay loading reagent kits. The forward and reverse 
primers were first combined in microcentrifuge tubes before being added to loading reagent 
and TE DNA suspension buffer in individual wells of a 96-well plate. The plate was later 
vortexed for 30 sec and centrifuged at 1000 g for 1 min before pipetting into the IFC inlets.  
Component  Vol per inlet (µl) Vol for 50 µl stock 
2x Assay Loading Reagent 2.5 25 
1X TE buffer 2.25 22.5 
100 µM Forward + Reverse primers 0.25 2.5 
Total  5 50 
Table 2.9 Fluidigm 96.96 IFC primer reaction mix preparation. Final concentration of each primer is 5 µM in the 
inlet and 500 nM in the final reaction. For ease of pipetting, mixtures were made up as 50 µl stocks.  
The sample reaction mixtures containing preamplified and Exo I-treated cDNA were prepared 
as shown in table 10 using SsoFast EvaGreen Supermix with low ROX and 20X DNA Binding 
Dye Sample Loading Reagent. The sample pre-mix was made up in a microcentrifuge tube 
being aliquoted as 3.3 µl per well of a 96-well plate, to which each preamplified cDNA sample 
was added. The cDNA sample mixture plate was vortexed and centrifuged as above before 
loading onto the IFC inlets. 
 Component Vol per inlet + 20% overage  
(µl) 
Vol for 96.96 IFC for 60 samples 
(µl) 
SAMPLE PRE-MIX 
2X Sso fast EvaGreen  3.0 360 
20X DNA Binding Dye 0.3 36 
Preamplified & Exo I-treated cDNA 2.7 - 
Total  6.00 - 
Table 2.10 Fluidigm 96.96 IFC sample reaction mixture preparation.  
Having prepared the sample and assay mixes, the chip was first primed after control line fluid 
was injected into each accumulator on the IFC. Following the priming script, 5 µl of primer 
assay mix and 5 µl of sample were loaded into their respective inlets of the 96.96 IFC chip and 
the chip placed in the HX controller for automatic loading and mixing. After loading, the chip 
was moved to the BioMark HD Real-Time PCR System (Fluidigm). The cycling program was GE 
Fast 96x96 PCR+Melt v2.     
Segment Type Temp (˚C) Duration (sec) BioMark HD Ramp rate (˚C/s) 
1 Thermal mix 
70 2400 5.5 
60 30 5.5 
2 Hot Start  95 60 5.5 
3 PCR (30 cycles) 
96 5 5.5 
60 20 5.5 
4 Melting curve 
60 
3 
1 
60-95 1˚C/3s 
Table 2.11 Cycling parameters for BioMark HD Real-Time PCR platform for use with 96.96 IFC chip.  
Post chip run qPCR data analysis was initially done using the BioMark Gene Expression Data 
Analysis software, which analyses individual data points and generates Ct values using “pass” 
and “fail” scores. Fail data points, which feature melting curves with aberrant Tm or from 
non-specific amplification, were removed after this initial analysis. Raw Ct values were then 
downloaded from the software as a data frame, and subsequently processed using Singular 
Analysis Toolset (Fluidigm), which runs the R script ‘fluidigmSC”. This script performs a series 
of differential gene expression analysis such as ANOVA, PCA, tSNE and hierarchical clustering 
to identify differentially expressed genes of interest. Gene expression values are generated 
as log2 expression counts, converted from Ct values above the recommended background 
default of 24 (Livak et al. 2013).   
 2.7.3 qRT-PCR primers   
 
Gene Forward Reverse 
Nestin GTTCCAGCTGGCTGTGGAGGC GCTGCTGCCGACCTTCCAGG 
Brachyury TCAGCAAAGTCAAGCTCACCA CCCCAACTCTCACTATGTGGATT 
Flk1 GGCCCAATAATCAGAGTGGCA CCAGTGTCATTTCCGATCACTTT 
RUNX1 CTGCCCATCGCTTTCAAGGT GCCGAGTAGTTTTCATCATTGCC 
CD34 TGGACCGCGGCTTTGCT CCCTGGGTAGGTAACTCTGGG 
CD45 CATTTGGCTTTGCCTTTCTG TTCTCTTTCAAAGGTGCTTGC 
IBA1 GCTGAGCTATGAGCCAAACC TCATCCAGCCTCTCTTCCTG 
Kir2.1 GGTTTGCTTTGGCTCAGTCG GAACATGTCCTGTTGCTGGC 
NaV1.6 GGCAATGTTTCAGCTCTACGC ATTGTCTTCAGGCCTGGGATT 
TREM2 CTGGAGATCTCTGGTTCCCC AGAAGGATGGAAGTGGGTGG 
CSF1R TATGTCAAAGACCCTGCCCG GTGAGCAGACAGGGCAGTAG 
CD11b GAAAGGCAAGGAAGCCGGAG TGGATCTGTCCTTCTCTTAGCCG 
TMEM119 CTTCCTGGATGGGATAGTGGAC GCACAGACGATGAACATCAGC 
ABCA7 GCTGAGGAACTTGACCAAGGTAT CCTGCTCCATTCACACCCAG 
PLCG2 AACTGCAGACTTCGAGGAGC AGGGGCTTTCACGACGTTAT 
INPP5D CTGCGTGCTGTATCGGAATTG AAGAACCTCATGGAGACGCC 
SREBF2 AGGCAGGCTTTGAAGACGAA AGCTTCCCTGTGATGTGCAG 
IL-1ß TTCGAGGCACAAGGCACAA TGGCTGCTTCAGACACTTGAG 
TNF GCCCATGTTGTAGCAAACCC TATCTCTCAGCTCCACGACA 
IL-6 ACCCCCAATAAATATAGGACTGGA TTCTCTTTCGTTCCCGGTGG 
TGFß1 GGCTGTATTTAAGGACACCCGT GACACAGAGATCCGCAGTCC 
IL-10 AAGACCCAGACATCAAGGCG AATCGATGACAGCGCCGTAG 
P2RY12 GGAGCTGCAGAACAGAACACT AGTTGCCAAACCTCTTTGTGATA 
GAS6 ACC TGACCGTGGGAGGTATT GTGTCTTCTCCGTTCAGCCA 
ABCA1 ACTGGTTTGGCGAGGAAAGT CAGCTTCAAGTGGGTGGGTT 
LRP1 CTCGGATGAGCCCAAGGAAG TCACCGCAATCGTTGTCGTA 
FASN GTGCCCTGAGCTGGACTACT AAGCCGTAGTTGCTCTGTCC 
HMGCS1 GACTGTCCTTTCGTGGCTCA GAAAGAGCTGTGTGAAGGATAGA 
HMGCR TCGGTGGCCTCTAGTGAGAT ACAAAGAGGCCATGCATTCG 
PPARG ACAAGGCCATTTTCTCAAACGAG CAAAGTTGGTGGGCCAGAATG 
LDLR ACCACAGAGGATGAGGTCCA GTCATCCTCCAGACTGACCATC 
CX3CR1 TGGGGCCTTCACCATGGAT GCCAATGGCAAAGATGACGGAG 
  Table 2.12 List of primers used for Fluidigm qRT-PCR. For rest of the list, see appendix 6. 
 2.8 CRISPR/Cas9-mediated mutation of ABCA7 gene 
2.8.1 CRISPR guide RNAs design and preparation  
Single guide RNAs (gRNA) targeting the ABCA7 gene were designed using the Wellcome 
Sanger Institute and Deskgen CRISPR design tools, with focus on reducing off target effects 
such as modification of unintended genomic sites. The Alt-R CRISPR-Cas9 system (Integrated 
DNA Technologies or IDT) was used because of its high editing efficiency compared to vector 
constructs (Kim et al. 2014; Zuris et al. 2015). This method forms a ribonucleoprotein (RNP) 
complex by combining a S.p. Cas9 Nuclease (1081058 – IDT) with a target crRNA and a 
fluorescently labelled ATTO 550 tracrRNA (1075928 – IDT). Delivery of the activated RNP 
complex causes double-stranded DNA cleavage of the target DNA by Cas9, activating the non-
homologous end joining system (NHEJ). The gRNAs chosen for the study were mapped onto 
coding exons 2 (Ex2P1) and 8 (Ex8P1) of the ABCA7 gene and were predicted to have minimal 
off-target effects in the genome.      
gRNA name Target region Sequence 
Ex2P1 Exon 2 GGAAGAATTTCATGTATCGCCGG 
Ex8P1 Exon 8 CACTGCTGCAGAGACCCCGAGGG 
 
To generate the RNP complex, each crRNA oligo and tracrRNA was resuspended to 200 µM in 
nuclease-free duplex buffer (IDT). Then, a cRNA:tracrRNA duplex was formed by combining 
each oligo with a tracrRNA in equimolar concentration: 1.7 µl crRNA + 1.7 µl tracrRNA + 1.7 
µl of nuclease-free duplex buffer. The reaction mixture was heated at 95˚C for 5 min and 
allowed to cool at room temperature. To assemble the RNP complex for each oligo, the 
reaction mixture below was set up and incubated for 20 min at room temperature prior to 
transfection. The Cas9 nuclease was made up by diluting 3.1 µl of 10 µg/µl Cas9 stock with 
1.9 µl Cas9 storage buffer (10 mM tris-HCl pH 7.4, 300 mM NaCl, 0.1 mM EDTA, 1mM DTT).  
Component   Volume (µl) 
cRNA:tracrRNA complex (1µM) 2.5 
Cas9 nuclease (6.2 µg/µl) 2.5 
Total volume 5  
  
 2.8.2 Cell culture, transfection and selection of targeted clones   
Kolf2 iPS cells were grown to 70-80% confluence and maintained in E8 medium, as described 
before. On the day of transfection, media was removed and replaced with E8 media 
containing 10 µM ROCK inhibitor for 1-2 hours before transfection. Cells were washed once 
with PBS pH 7.4 and dissociated with pre-warmed accutase for approximately 5 min (Life 
Technologies). E8 media containing ROCK inhibitor was added to inactivate the accutase, the 
mixture homogenised, centrifuged at 1500 rpm for 3 min and counted with 1 million cells 
being used. Cells were then resuspended in 100 µl of nucleofection buffer, made up of 78 µl 
P3 buffer and 22 µl supplement from the P3 Primary Cell 4D-Nucleofector Kit. 5 µl of each 
assembled RNP was added to the suspension, which was then transferred to an Amaxa 
cuvette. The cuvette was gently tapped onto a flat surface to eliminate bubbles. Cells were 
transfected with RNP complexes by electroporation using the Amaxa 4D Nucleofector system 
(program CA137). Following nucleofection, the cells were allowed to recover for ~ 10 min at 
37˚C, before addition of pre-warmed E8 + ROCK inhibitor media and plating onto a culture 
dish pre-coated with vitronectin. 24 hours post nucleofection, the transfected cells were FACS 
sorted to select for the top 10% of the most fluorescent cells, for increased editing efficiency. 
Briefly, the transfected cells were washed in PBS and dissociated as single cells with accutase, 
as above. The cells were then centrifuged and resuspended in 500 µl in E8 media + ROCK 
inhibitor into FACS tubes for sorting in a FACS ARIA Fusion (BD Biosciences) using the tracrRNA 
ATTO550. The sorted cells were collected in a FACS tube containing 1 ml of E8 + ROCK 
inhibitor, replated onto a 10 cm tissue culture dish pre-coated with vitronectin in order to 
obtain single cell clones. The following day, the culture media was changed to E8 medium and 
thereafter the cells were fed every other day, being monitored daily for the formation of 
colonies. Around 7 days after transfection, single colonies were cut in half and picked onto 
two separate 96-well plates by using a P20 pipette set at 10 µl – cells grown one plate were 
used for genomic DNA extraction and PCR screening to detect successful excision of the target 
region (see table 2.13 below). The corresponding 96-well plate was used for clonal expansion.  
PCR primer Target region Sequence 
Ex2F Exon 2 ATTGGTTTACTCCACCCCTGGG 
Ex2R Exon 2 GAGTCGTTGAAGTTGCTCAGGC 
Ex8F Exon 8 ctttgcctctcagagcctcagt 
Ex8R Exon 8 GGAAACCGAGGTCAGTCACTCA 
  
PCR component   Volume (µl) 
5x colourless GoTaq Flexi buffer 10 
25 mM MgCl2 solution 5 
10 µM dNTPs 1 
Ex2F2 Primer 1 
Ex8R6 Primer 1 
Extracted DNA with DNA lysis buffer  1 
GoTaq DNA polymerase 0.25 
Nuclease-free water to 50 
Table 2.13 ABCA7 KO PCR screening reaction.  
For genomic DNA extraction, cells in 96-well plates were washed once with PBS before 
addition of DNA lysis buffer (see section 2.1.4) supplemented with 2% proteinase K. 50 µl of 
DNA lysis buffer was added per well and the mixture incubated at 55˚C for 4 hours or 
overnight. This was followed by inactivation at 95˚C for 30 minutes, where each extracted 
DNA sample was diluted 1 in 10 in 10 mM Tris pH 8.0. The diluted and inactivated DNA sample 
was then used for PCR assay outlined below. The PCR cycling parameters were set up as 
follows: 
Step Temperature Time Cycle 
Initial denaturation 95˚C 2 min 1 
Denaturation 95˚C 15 secs  
30 Annealing 60˚C 45 secs 
Extension 72˚C 1 min 
Final extension 72˚C 5 min 1 
 
96-well plate clones found to carry the successful mutation after PCR screening were 
subjected to sub-cloning. To do this, the cells were washed with PBS and incubated with 
accutase for 5 min to ensure a single cell suspension. Pre-warmed E8 media was added to the 
cell suspension to inactive the accutase and the mixture centrifuged at 1000rpm for 3 min. 
The cells were then re-suspended in E8 + ROCK inhibitor media before plating at very low 
density in a vitronectin-coated 10 cm culture dish. This allowed the cells to expand from single 
cells, before individual colonies from the dish were picked, grown and expanded in 24-well 
plates before another round of PCR screening. All expanded sub-clones were also kept as 
 frozen pellets. The PCR-amplified DNA were separated by agarose gel electrophoresis using 
2% gels.   
2.9 RNA Sequencing and Analyses 
2.9.1 RNA Sequencing library construction and sequencing 
Samples used for RNA sequencing (RNA-seq) were harvested using RLT buffer from RNeasy 
Mini Kit before total RNA was extracted from lysates following the protocols of the 
manufacturer. RNA-seq was performed at the Genomics Research Hub of Cardiff University 
School of Biosciences by Angela Marchbank. RNA integrity was measured for all samples with 
the Agilent Bioanalyser 2100 (Agilent Technologies) and samples with RNA integrity number 
above 8 were retained for library construction. The Illumina TruSeq mRNA stranded protocol 
was used to perform cDNA synthesis from all samples and generate poly-A mRNA libraries. 1 
µg of RNA was used to construct RNA-seq libraries. Libraries were then assessed for their 
quality with the Agilent 4200 TapeStation (Agilent Technologies) and sequenced as single-end 
75 bp reads on the Illumina NextSeq500 sequencer, generating 40 million reads per sample.     
 
2.9.2 RNA-seq read mapping, gene counts estimation and differential gene expression 
analysis  
RNA-seq reads (fastq files) were first trimmed using Trimmomatic (version 0.35) (Bolger et al. 
2014) and then mapped to the GRCh38.89 reference human genome using STAR (version 
2.5.1b) (Dobin et al. 2013). Transcripts were assembled before raw read counts per gene were 
generated using the software FeatureCounts (Liao et al. 2014). Transcripts with at least 1 
count per million in at least one sample were considered to represent expressed genes and 
retained for further downstream analysis, otherwise removed. Differential gene expression 
analysis was carried out with the Bioconductor package DESeq2 (release 3.6) to generate gene 
expression values as FPKM (Fragments per Kilobase of transcript per Million mapped reads) 
(Love et al. 2014). The Benjamini-Hochberg (BH) multiple testing correction procedure, which 
decreases false discovery rate, was employed to compute adjusted p-values. Principal 
component analysis of the normalised expression counts was performed using the R function 
“prcomp” and plotted with “ggplot”. Hierarchical clustering heatmap based on normalised 
gene expression counts was conducted using the R function “pheatmap”.  
  
2.9.3 Comparative Gene Set Enrichment Analysis of iPSC-derived microglia  
Single-ended RNA-seq data for human cortical neurons, astrocytes and myeloid cells (Zhang 
et al., 2016) was retrieved from Gene Expression Omnibus (accession GSE73721). The 
downloaded raw fastq files were processed along the same pipeline as described above to 
produce raw gene counts. These were combined with values from our data to estimate 
normalised gene expression counts with corresponding adjusted p-values. Genes with p-
adjusted < 0.05 were chosen to carry out a comprehensive Gene Set Enrichment Analysis 
(GSEA) of the stem cell-derived microglia datasets. GSEA analyses whether enrichment of 
differential expression among gene sets relates to biological hypotheses and pathways 
(Subramanian et al. 2005). GSEA orders all genes according to their differential expression 
statistic, and tests whether genes in a specific gene set have a higher overall rank than would 
be expected by chance. A pathway set was chosen consisting of Gene Ontology (GO) (Harris 
et al. 2004), Kyoto Encyclopaedia of Genes and Genomes (KEGG) (Kanehisa et al. 2012), 
Reactome (Croft et al. 2014), BioCarta and NCI pathway interaction database (Schaefer et al. 
2009). Upregulated and downregulated genes in iPSC-derived microglia were assessed 
separately.   
2.9.4 iPathwayGuide Impact Analysis    
Pathway Impact Analysis was run using AdvaitaBio iPathwayGuide 
(https://www.advaitabio.com/ipathwayguide.html) to identify significantly impacted 
pathways. This method utilises a systems biology approach and incorporates the classical 
probabilistic aspects of analysis (e.g. GSEA) with important biological factors: “the magnitude 
of the expression changes of each gene, the position of the differentially expressed genes on 
the given pathways, the topology of the pathway that describes how these genes interact, 
and the type of signalling interactions between them” (Draghici et al. 2007; Donato et al. 
2013).  
This method analyses DE gene datasets in the context of pathways from the KEGG database 
(Kanehisa et al., 2012), gene ontologies from Gene Ontology consortium database (Ashburner 
et al. 2000) and miRNAs from the miRBase (Release 21). The pathways are then scored 
according to two criteria: (i) the over-representation of DE genes in a given pathway and (ii) 
the perturbation of that pathway computed by propagating the measured expression 
 changes across the pathway topology. These criteria are taken account to calculate two 
probability values: pORA and pAcc. pORA expresses the probability of observing the number 
of DE genes in a given pathway that is greater than or equal to the probability by random 
chance. The second probability pAcc is calculated based on the amount of total accumulation 
measured in each pathway and the sum of all of all absolute accumulations of the genes in a 
given pathway. The probability values are then combined into one final pathway score by 
calculating a p value using Fisher’s method, corrected for multiple comparisons by False 
discovery rate (FDR).    
 
2.9.5 Upstream regulator analysis   
Upstream regulator analysis was performed using the Ingenuity Pathway Analysis (Ingenuity 
Systems, Qiagen). This program predicts potential upstream regulators and mechanistic 
networks that explain the gene expression changes observed in a dataset, by calculating P-
values of overlap and activation z-score statistics. The P-value of overlap establishes whether 
there is a statistically significant overlap between gene expression changes in a dataset and 
the genes affected by an upstream regulator (regulators with p value of < 0.01 qualified). The 
activation z-sore considers the direction of gene expression changes and is used to predict 
whether regulators are activated or inhibited in the dataset. Generally, a z-score of > 2 or < -
2 is regarded as significant. A cut-off of 0.01 was used to decide which genes were included 
in this analysis.      
2.10 Statistical analysis  
Statistical analysis of Fluidigm qRT-PCR data was carried out using GraphPad Prism 7.0 
software. Data were represented as average log2 expression values generated by Fluidigm 
analysis R package (see section 2.7.1). When comparing the log2 expression from multiple 
conditions against a control group, one-way ANOVA with Dunnett’s post hoc comparison was 
used. For assessing data from experiments with independent variables and one continuous 
dependent variable, a two-way ANOVA with Tukey’s post hoc multiple comparisons test was 
carried out. Asterisks representing significance are defined as follows: ns – not significant; P 
> 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001.   
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3. TRANSCRIPTOMIC AND 
FUNCTIONAL VALIDATION OF HUMAN 
IPSC-DERIVED MICROGLIA 
3.1 Introduction  
Animal models have been invaluable in advancing our understanding of 
neurodegenerative diseases such as Alzheimer’s and Huntington’s disease (Götz & 
Ittner 2008; Laferla & Green 2012). Much has been gained from animal studies, 
including the now recognised importance of research focusing on the role of 
neuroinflammation, and specifically microglia in those disorders (see section 1.1). 
Nonetheless, the emphasis needs to shift towards elucidating the phenotypic 
characteristics of diseased microglia, as well as how they can be harnessed to treat 
disease. Indeed, it can be argued that the failure of several clinical trials and paucity 
of new therapies (Cummings et al. 2014) highlight a necessity for improved disease 
models that bridge the gap between the clinic and animal models.   
In that respect, advances in stem cell technology since the advent of induced 
pluripotent stem cells (iPSCs) (Takahashi & Yamanaka 2006; Okita et al. 2007; 
Takahashi et al. 2007) have revolutionised in vitro disease modelling, leading to the 
development of several reliable protocols for differentiation of iPSCs into neurons and 
astrocytes (Krencik et al. 2011; Serio et al. 2013; Shaltouki et al. 2013). Prior to the 
beginning of this study, there were no published protocols for in vitro differentiation 
of microglia. As established through lineage tracing studies, microglia arise from 
primitive yolk-sac derived haematopoietic precursors during embryonic development 
that colonise the developing brain (Ginhoux et al. 2010). Therefore, any strategy for 
microglial differentiation would require mimicking the steps leading to yolk sac 
haematopoiesis (Ginhoux et al. 2013). Based on this rationale, a number of microglia 
differentiation protocols have since been reported (Muffat et al. 2016; Abud et al. 
2017; Haenseler et al. 2017; Pandya et al. 2017). The protocol used in this study (see 
35  
section 2.3) was adapted from work by (Karlsson et al. 2008; van Wilgenburg et al. 
2013), who showed that monocyte-like primitive macrophage precursors can be 
derived from human stem cells. The differentiation method involves culturing 
embryoid bodies (EBs) in serum-free and feeder-free medium containing the 
cytokines IL-3 and macrophage colony-stimulating factor (M-CSF) to promote the 
formation of the non-adherent myeloid cells in the culture supernatants. These 
macrophage precursors are then harvested from the culture medium and 
differentiated to a microglial phenotype by the addition of two growth factors: the 
astrocyte-derived granulocyte M-CSF (GM-CSF) and IL-34, which have been shown to 
induce a ramified microglia phenotype from human monocytes (Ohigdani et al. 2014). 
In the CNS, IL-34 is produced by neurons and is required to maintain microglial survival 
(Wang et al. 2012; Greter et al. 2012). This protocol compares favourably to the others 
mentioned in its simplicity and straightforwardness, while it involves little 
manipulation other than a simple weekly harvest of the macrophage precursors, 
compared to a trituration-based method (Muffat et al. 2016) and rounds of FACS-
sorting (Pandya et al. 2017).    
3.2 Aims  
This chapter set out to characterise microglia differentiated from iPSCs using the 
protocol described in section 2.3. Two cell lines of different genetic backgrounds Kolf2 
and HD109 were used, enabling an appraisal of the efficacy and reproducibility of the 
differentiation protocol. Using RNA sequencing, the transcriptome profile of the 
differentiated microglia was investigated, with emphasis on the differences between 
macrophage precursors and microglia highlighted here.  
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3.3 Results 
3.2.1 Human iPSC-derived microglia cells express characteristic microglial 
markers 
Figure 3.1 displays a schematic of the differentiation process, including the time 
course and changes in culture conditions through the early parts of the protocol. Split 
into three parts, the early stages of the protocol involve the formation of EBs and 
culture in E8-3G medium to induce mesoderm layer differentiation. Preliminary 
experiments indicated that E8-3G-treated EBs were committed to the mesoderm 
lineage, increasing expression of Brachyury, a transcription factor required for 
mesoderm layer formation and haematopoietic stem cell differentiation. Similarly, 
this treatment was found to increase expression of the haematopoietic stem cell 
marker CD34 and of RUNX1, a transcription factor that regulates haematopoietic stem 
cell differentiation (data not shown). Taken together, these results indicated a definite 
switch upon EB formation and culture with VEGF, BMP4 and SCF.    
 
Figure 3.1 Schematic representation of the protocol for the differentiation of human iPSCs 
into macrophage precursor cells. 
Feeder-free iPSCs were enzymatically dissociated using ReLeSR to form embryoid bodies (A), which were 
subsequently cultured in E8 medium with 50 ng/ml BMP-4, 50 ng/ml VEGF and 20 ng/ml SCF (or E8-3G) for 7-10 
days to allow the EBs to form cystic structures. EBs were further differentiated by seeding 6-8 EBs into a well of 6-
well plate cultured in X-VIVO15 media supplemented with M-CSF and IL-3. Under these conditions, EBs adhere to 
the culture surface and begin to spread, forming factories (B). As the factories continue to differentiate, there is 
formation of phase bright cells, which increase in number and are shed from their factory colonies, allowing them 
to be harvested from the supernatant weekly (C). Scale bars represent 50 µm. 
 
In the second stage of differentiation, non-adherent cells produced in the supernatant 
of differentiation factories were harvested and assayed for expression of various 
myeloid-specific markers by immunocytochemistry (Figure 3.2). Cytocentrifugation 
and immunostaining of the cells revealed a highly homogeneous population of cells 
where typical myeloid surface antigens CD45 and CD11b were expressed. 
Interestingly, the supernatant cells were also positive for CD34, suggesting that they 
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were still undergoing maturation. This trend was similar in both the HD109 and Kolf2 
differentiated cells (Figure 3.2).   
 
Figure 3.2 Schematic representation of the protocol for the differentiation of human iPSCs 
into macrophage precursor cells. 
Representative images of non-adherent myeloid cells formed during M-CSF and IL-3 directed differentiation of 
HD109 and Kolf2 iPS cell lines. The cells were shed into the culture supernatant of the differentiated factories and 
harvested before cytospin and staining for the expression of haematopoietic markers CD34 (green), CD11b (red) 
and CD45 (green). Scale bar represents 50 µm. 
Next, the non-adherent myeloid cells harvested at different time points from the 
differentiation factories (weeks 3 and 5) were analysed for the expression of CD34, 
CD45, CD14 and CD11b by flow cytometry (Figure 3.3). The majority of the HD109 
harvested cells were positive cells at week 3 (82%), whereas CD34 expression was 
negligible (Figure 3.3A). Cells harvested two weeks later displayed a similar FACS 
profile, with an equally high proportion of CD45+ CD14+ double positive cells (80%), 
while CD11b expression was measured at 15% (Figure 3.3B). An immortalised human 
monocytic cell line THP-1 (Tsuchiya et al. 1980), featuring high CD45 and CD11b 
expression, was then used to confirm the monocyte-like antigen profile of the 
supernatant cells (Figure 3.3C).  
Flow cytometry analysis was extended to Kolf2 supernatant cells harvested at weeks 
3 and 5 from the differentiation factories, with similar results. CD45 and CD14 
expression at both time points was measured at over 90%, with CD34 equally low at 
1% (Figure 3.3 D-E). CD11b was also expressed at around 30% for the two harvests, 
showing that the phenotype of the monocyte-like supernatant cells does not vary 
greatly over the course of a differentiation.  
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Figure 3.3 Non-adherent supernatant cells harvested from microglia differentiation factories are positive for haematopoietic markers.   
(A) A high proportion of HD109 supernatant cells harvested from M-CSF & IL-3 differentiation factories at week 3 expressed the myeloid markers CD45 and CD14 (95% and 
82%). CD34 expression in the cells harvested from the same differentiation factories was less than 1%. Co-expression of CD45 and CD14 showed a large population of 82%. 
Gates were defined by using the appropriate isotype control antibodies. (B) Staining for HD109 supernatant cells harvested from the same differentiation factories at week 
5 showed a similarly high proportion of CD45+ (over 85%), CD14+ cells (78%) produced in the culture supernatant. Double staining for CD45 and CD11b showed that 15% of 
the harvested cells were double positive. (C) Expression of CD45 and CD11b in the HD109 and Kolf2 supernatant cells was compared to the myeloid control cell line THP-1 
monocytes, which express high levels of CD45 (over 90%) and CD11b (57%). (D) Differentiation factories set up from Kol2 iPSCs produced a population of monocyte-like 
myeloid cells at week 3 expressing high levels of CD45 and CD14 (both, at over 90%), with CD11b expression measured at 27% and CD34 at 1%. Red peaks denote antigens 
and blue peaks denote isotype controls. (E) Kolf2 supernatant cells harvested from the same differentiation factories at week 5 displayed a similar FACS profile to those from 
week 3. Representative of three independent experiments. 
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As previously mentioned, the neuron-derived cytokine IL-34 is vital for the 
development and maintenance of microglia in the brain, where it binds to the colony-
stimulating factor-1 receptor (CSF1R), whose ablation results in loss of microglia 
(Erblich et al. 2011). Moreover, a recent study demonstrated that stimulation with IL-
34 and GM-CSF can induce a ramified phenotype in blood monocytes (Ohgidani et al. 
2014). Therefore, to induce an in vitro microglial phenotype, Kolf2 and HD109 
macrophage precursor cells (Macpre) were cultured in XVIVO15 media supplemented 
with 10 ng/ml GM-CSF and 100 ng/ml IL-34 for 14 days, before being stained for the 
canonical macrophage/microglia markers TMEM119 and IBA1 (Figure 3.4).     
 
Figure 3.4 Differentiation of macrophage precursor cells with GM-CSF and IL-34 induces a 
microglial-like phenotype.  
Confocal images of HD109 (A) and Kolf2 (B) microglia-like cells, which were plated on PDL-treated fibronectin-
coated coverslips and cultured in XVIVO + GM-CSF + IL-34 for 14 days. MG cells were fixed and stained with 
TMEM119, a cell marker of unknown function highly specific to human and mouse microglia, and the 
macrophage/microglia marker IBA1.   Scale bars represent 20 µm.  
 
  
A 
B 
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3.2.2 Transcriptomic profiling of human iPSC-derived microglia reveals a 
microglial signature   
Following confirmation that the iPSC-derived IL-34 and GM-CSF-treated microglia cells 
(MG) express microglial markers such as IBA1 and TMEM119, RNA sequencing was 
employed to profile the transcriptome of the in vitro differentiated by comparing it to 
the macrophage precursor cells. Samples used for this experiment were drawn from 
three independent differentiations. Correlation analysis showed clear separation 
between the macrophage precursor cells and the IL-34 differentiated microglial cells 
for both genetic backgrounds (Figure 3.5A). Crucially, a disease effect on top of the 
cell type segregation was apparent between the Kolf2 and HD109 samples, as shown 
by the principal component analysis plot (see chapter 4). When compared to their 
respective macrophage precursor cells, differential gene expression analysis (fold 
change of 2 and p-value 0.05) demonstrated a total of 935 and 605 differentially 
expressed (DE) genes in the Kolf2 (Figure 3.5B) and HD109 MG cells (Figure 3.5C) 
respectively. In total, IL-34 and GM-CSF treatment of the respective precursor cells 
increased expression of 374 and 240 genes in Kolf2 MG and HD109 MG cells 
respectively. In contrast, 561 DE genes were downregulated in the Kolf2 WT cells, 
compared to 365 in the HD109 iPSC-derived microglia (Figure 3.5 B-C).   
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Figure 3.5 Transcriptomic profiling of Kolf2 and HD109 iPSC-derived microglia demonstrates a microglial signature in the in vitro cells.     
Differential gene expression was carried out using DESeq2 to generate normalised expression counts. Biological replicates were used for comparative analysis to compute 
significant differentially expressed genes at fold change of 2 and Benjamini-Hochberg p value-adjusted < 0.05.  
(A) Principal component analysis of Macpre and MG cells shows a cell-type specific segregation between Macpre samples and MG samples. PCA was performed using 
“prcomp” and plotted with “ggplot”. (B) Differentiation of Kolf2 Macpre cells into MG cells with IL-34 and GM-CSF resulted in 935 DE genes, with 374 upregulated (log2 fold 
change > 1) and 561 downregulated genes (log2 fold change < -1). (C) Treatment of HD109 Macpre cells with GM-CSF and IL-34 resulted in a total of 605 DE genes in HD109 
MG cells, with 240 upregulated and 365 downregulated genes. The majority of microglia sensome genes were found to be comparably expressed between the Macpre and 
MG cells, except the genes highlighted as green dots on the volcano plots. (D) Differentially expressed microglia sensome genes between Macpre and MG samples. A pseudo-
count, log2 transformed measure of normalised gene expression counts (FPKM+1) was used to compare expression levels between samples (Abud et al. 2017). (E) Canonical 
microglia genes were highly expressed in Kolf2 and HD109 Macpre and MG cells. (F) Levels of the purinergic receptor P2RY12 and surface protein CX3CR1 were surprisingly 
low in all the Kolf2 and HD109 samples. Data analysed by DESeq2 and Benjamini-Hochberg multiple correction procedure used to compute adjusted p-values. * p < 0.05, ** 
p < 0.01, *** p < 0.001. ns – not significant. n=3 independent differentiations.     
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To assess whether a microglial signature could be detected in our Kolf2 and HD109 
microglia cells, a number of complementary analyses were undertaken. Firstly, the 
expression of microglia sensome genes was compared between Macpre and MG 
samples. For this purpose, a list of ~190 ‘microglia sensome’ genes, identified in recent 
publications to be associated with microglia (Hickman et al. 2013; Butovsky et al. 2014; 
Grabert et al. 2016; Galatro et al. 2017), was compiled and included PRRs, 
chemoattractant and chemokine receptors, purinergic and cytokine receptors, cell-to-
cell interaction and ECM-protein receptors as well as various endogenous transporters 
(see Table 1.1 in section 1.2.3 for examples of genes included in the list). The majority 
of sensome genes showed similar expression in Macpre and MG cells, with only a 
handful showing differential expression between the respective MG and Macpre cells, 
highlighted as green dots on the volcano plots (Figure 3.5 B-C). Of those genes, the AD 
risk gene ABI3, transmembrane receptor STAB1 and sodium/calcium transporter 
SLC24A3 were significantly downregulated in HD109 and Kolf2 MG compared to 
Macpre samples, along with the inflammatory-associated transcription factor FOS. 
Conversely, mRNA levels of IL1A, the cytokine released in response to injury were 
higher in the MG cells (Figure 3.5D). Key canonical microglial genes such as C1QA, 
GAS6, GPR34, PROS1, MERTK, TREM2 and SLCO2B1 were strongly expressed, and at 
comparable levels in both cell types (Figure 3.5E). Surprisingly, the microglial surface 
proteins P2RY12 and CX3CR1 were found to be expressed at low levels (Figure 3.5F), 
with CX3CR1 significantly downregulated in the Kolf2 MG vs Macpre (log2FC = -5.547 
& p-value of 1.59 x 10-4) but not in HD109 MG vs Macpre cells (log2FC = 2.479 & p-
value of 0.113).  
 
Secondly, the transcriptomics data was evaluated for expression of markers of 
leukocytes and tissue macrophages and comparisons made with expression of 
sensome genes. Markers for T cells (CD3, CD32), B cells (CD19) and dendritic cells 
(CD123) were not expressed at detectable levels. Other lowly expressed genes 
included CD68 (the phagocytic-promoting lysosomal protein highly expressed in 
monocytes and macrophages), the carrier protein FABP4 and the serine protease 
SERPINB2 (Figure 3.6A). Many recently recognised microglia-specific genes, rather 
than belonging to a particular biological pathway, are mostly implicated in host 
46  
defence and regulation of immune response. Correspondingly, the iPSC-derived MG 
cells expressed high levels of LGMN (a cysteine protease involved in the MHC II 
pathway of bacterial peptide processing), SQLE (ER-localised enzyme that catalyses 
squalene oxidation, a rate-limiting step in sterol biosynthesis), the lysosomal protease 
cathepsin D and the purinergic receptor P2RX4, highly expressed in the nervous 
system where it has been implicated in inflammation activation and synaptic 
strengthening (Baxter et al. 2011; de Rivero Vaccari et al. 2012) (Figure 3.6B). The 
presence of immune-related transcripts highly expressed in macrophages was 
nevertheless notable in the Macpre and MG cells, including scavenger receptors 
(MSR1 and MARCO) and proteins such as TLR8 (endosomal PRR for viral ssRNA - 
(Cervantes et al. 2012)), IFITM (IFN-induced antiviral proteins that inhibit viral entry 
into the cytoplasm - (Bailey et al. 2014)) and the chemokine receptor 1 (CCR1), which 
enables recruitment of effector immune cells to an inflammation site and has been 
recently identified as enriched in a subpopulation of embryonic microglia  (Hammond 
et al. 2018) (Figure 3.6C). Also expressed by the in vitro MG cells were a host of 
immune alertness genes, including inhibitory (CD33, CD47, TREM2) and classically 
activating molecules such as CD163 and TLR2, suggesting that the cells are in an 
immune vigilant and competent state, capable of reacting to pathogenic stimuli 
(Figure 3.6C). Several transcription factors and regulators have been identified as part 
of the core human microglial transcriptome and these were evaluated in the HD109 
and Kolf2 stem cell-derived cells (Figure 3.6D). While the cells expressed low mRNA 
levels of the dendritic cell-associated transcription factor FLT3 (Figure 3.6A), microglia-
specific TFs SPI1, IRF8 and MEF2C were found in relatively high levels, along with the 
inflammatory associated regulators IRF5 and TRIM22 (interferon-induced) (Figure 
3.6F). Similarly, the cells showed robust expression of the ubiquitous MHC class I 
regulator NLRC5 and the MHC class II regulator CIITA (Meissner et al. 2010), stressing 
the importance of interactions between microglia and other immune cells.  
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Figure 3.6 iPSC-derived microglia display low expression levels of leukocyte markers, but high levels of immune alertness genes.  
Expression of markers for T cells (CD3, CD32), B cells (CD19) and dendritic cells (CD123) was undetected in HD109 and Kolf2 samples. (A) The macrophage genes CD68, 
SERPINB2 and FABP4 were expressed at low levels in Macpre and MG cells, along with the dendritic cell TF FLT3. (B) Newly identified MG-enriched genes P2RX4, LGMN, SQLE 
and CTSD were expressed at comparable levels in the MG and Macpre samples from both Kolf2 and HD109 cells. (C -D) In vitro macrophage precursors and microglia express 
high levels of macrophage-associated scavenger receptors (MSR1, MARCO), TLR proteins (TLR2, TLR8), viral entry IFITM proteins and immune alertness proteins (CCR1, CD33, 
CD47, CD163). (E) iPSC-derived macrophage precursors and microglia cells express several microglia-specific transcription factors such as SPI1, MEF2C, IRF8 and TRIM22. MG 
cells express higher levels of MHC II transcription regulator CIITA.   
 
Expression levels are represented as log2 transformed FPKM counts. Data analysed by DESeq2 and Benjamini-Hochberg multiple correction procedure used to compute 
adjusted p-values. Asterisks denote statistical significance: * < 0.05, ** < 0.01, *** < 0.001, ns – not significant. n=3 independent differentiations.         
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In the final step of analysis, the microglia sensome list described above was employed 
to run a microglial signature enrichment analysis via Gene Set Enrichment Analysis 
(GSEA), in order to find out how the Kolf2 and HD109 iPSC-derived microglia compared 
to other brain cell types, namely brain myeloid cells, neurons and astrocytes. With the 
sensome gene list as the gene set of interest, GSEA was carried out using Fisher’s exact 
test, to determine whether the sensome gene set was significantly enriched in the MG 
samples compared to primary brain cell type samples. Due to lack of availability and 
failure to acquire good quality primary tissues, publicly available datasets were used. 
Direct transcriptomic comparisons to primary samples and microglia derived from 
recently published differentiation protocols (Muffat et al. 2016; Abud et al. 2017) were 
intended but not undertaken given differences in cell culture conditions and 
sequencing platforms – any potential gene expression changes may have reflected all 
those factors, as much as variations according to cell types.  
 
Instead, the enrichment analysis described here below was carried out by identifying 
commonly DE genes in the iPSC-derived microglia cells when compared to human 
cortical neurons, astrocytes and myeloid cells from the (Zhang et al. 2016) dataset, 
chosen as the sequencing platform used by the authors closely matched our own. 
Enrichment analysis for the microglia sensome gene set by Fisher’s exact test was 
calculated, with the results shown in Table 3.1. In sum, both HD109 and Kolf2 iPSC-
derived microglia were significantly enriched for microglia-specific genes, relative to 
neurons, astrocytes and cortex myeloid cells.  
 Kolf2 iPSC-microglia  HD109 iPSC-derived microglia 
Comparison Odds ratio p-value Odds ratio p-value 
MG vs cortex neurons 2.79 1.57 x 10-10 2.84  5.4 x 10-11 
MG vs cortex astrocytes 5.47 2.66 x 10-23 5.54 3.8 x 10-24 
MG vs cortex myeloid cells 3.51 2.18 x 10-15 4.04 3.08 x 10-18 
Table 3.1 Enrichment analysis of microglia sensome genes in iPSC-derived microglia. Dataset used for 
this analysis was the gene list generated by comparative analysis of iPSC-derived microglia against primary 
neurons, astrocytes and myeloid cells.  
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The expression of several MG markers was further validated by Fluidigm qRT-PCR, 
with differential gene expression analysis carried out using the R package “Singular 
Analysis Toolset” (see section 2.7.1). Gene expression values are represented as log2 
expression normalised to the reference genes GAPDH, ß-actin, SDHA, HPRT1, UBC and 
HMBS. Compared to THP-1 monocytes, ANOVA comparisons showed that the iPSC-
derived microglia significantly expressed higher levels of CABLES1 (p < 0.01) and 
TMEM119 (p< 0.05), as well as GPR34 and C1QA (both at p< 0.01). Transcript levels 
were comparable between macrophage precursor and microglia samples, confirming 
RNA-seq data (Figure 3.7 A-B). Equally, the expression of these genes did not vary 
significantly across the two genetic backgrounds of Kolf2 and HD109. However, 
CX3CR1 was significantly downregulated in the MG samples compared to THP-1 (p < 
0.05) and Macpre samples. Moreover, P2RY12 and MERTK expression was lower in 
THP-1 (p< 0.01) but higher in precursor macrophages and microglia cells (Figure 3.7C). 
The family of sialic acid-binding immunoglobulin-like lectins or SIGLECs is made up of 
cell surface receptors that have important homeostatic functions in microglia, in 
particular immunosuppression and neuroprotection. They have been shown mediate 
a number of processes including activation, phagocytosis and inflammasome 
formation through cytoplasmic Immunoreceptor Tyrosine-based Inhibitory or 
Activation Motif or ITIM/ITAM domains (MacAuley et al. 2014). Examples include 
CD33, the neuroprotective SIGLEC11 and SIGLEC12, as well as the AD risk gene TREM2, 
which is associated with the ITAM TYROBP, which recruits and phosphorylates the 
tyrosine kinase SYK to activate cellular responses such as phagocytosis (Takahashi et 
al. 2005). As shown in Figure 3.7D, macrophage precursor and microglia samples from 
both cell lines expressed similarly high levels of TREM2, SYK and TYROBP, while mRNA 
levels of the neuroprotective SIGLEC12 were lower in comparison.    
 
RNA-seq analysis for the enrichment of Alzheimer’s disease-associated risk genes 
showed that the majority of these genes were comparably expressed in the Kolf2 
microglia and their precursor cells (Figure 3.8A). This observation was confirmed using 
qPCR, with results showing that the Macpre and MG express risk genes such as PLCG2, 
CR1, CD33, INPP5D and CD2AP at levels comparable with THP-1 monocytes, with only 
APOE being significantly upregulated in the in vitro derived cells at p< 0.001 (Figure 
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3.8 B-C). This confirms that iPSC-derived microglia can be used to study the influence 
of these genes on microglia function and AD risk in vitro.      
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Figure 3.7 Validation of expression of canonical microglia genes in iPSC-derived microglia by Fluidigm qRT-PCR. 
Kolf2 and HD109 MG were differentiated for 14 days in IL-34 and GM-CSF and all samples assayed by Fluidigm qRT-PCR. Ct values generated by the Fluidigm BioMark qPCR 
software were analysed using the R package “fluidigmSC” to gene expression values, represented here as mean Log2 Expression. Log2 Expression was normalised, during 
analysis, to reference genes GAPDH, ß-actin, SDHA, HPRT1, UBS and HMBS. (A) TMEM119 and CABLES1 are upregulated in Macpre and MG samples compared to THP1, while 
levels are comparable between HD109 and Kolf2 Macpre and MG samples. (B) iPSC-derived Macpre and MG cells express significantly higher levels of C1QA and GPR34 than 
THP1 monocytes. CX3CR1 is downregulated in the MG samples (Kolf2 & HD109) compared to THP1 and Macpre cells. (C) Expression P2RY12 and MERTK is significantly 
upregulated in macrophage precursors and microglia compared THP1. Levels between HD109 and Kolf2 cells did not vary significantly. (D) Macpre and MG cells express 
members of the SIGLEC family such as SIGLEC12, CD33 and TREM2 and their associated receptors.  
 
Statistical analysis used two-way ANOVA with Tukey’s multiple comparisons test. Asterisks denote statistical significance: * < 0.05, ns – not significant. n=3 biological replicates 
for all samples, except THP1 (n=2).  
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Figure 3.8 iPSC-derived microglia express Alzheimer’s disease risk genes.  
(A) Heatmap of 29 genes with variants associated with late onset Alzheimer’s disease showed that the Kolf2 Macpre and MG express several immune genes at similar levels. 
Heatmap and hierarchical clustering based on normalised gene expression counts from RNA-seq data. Data plotted using R function “pheatmap”. (B) Validation of APOE, 
CLU, ABI3 and PLCG2 expression in HD109 and Kolf2 Macpre and MG cells by Fluidigm qRT-PCR. Changes in expression did not show a significant difference between Macpre 
and MG cells. APOE is upregulated in Macpre and MG cells compared to THP1 (p< 0.001). (C) Levels of CR1, CD33, INPP5D and CD2AP in microglia are comparable to expression 
in THP1 monocytes. Log2 Expression normalised to reference genes. Statistical analysis used two-way ANOVA with Tukey’s multiple comparisons test. Asterisks denote 
statistical significance: * < 0.05, ** < 0.01, *** < 0.001, ns – not significant. n=3 biological replicates for all samples, except THP1 (n=2). 
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3.2.3 Functional analysis and validation of Kolf2 iPSC-derived microglia   
Microglial activation is mediated by a complex interaction of cellular signals, 
metabolism and their surrounding microenvironment. They can therefore assume 
diverse phenotypes. Stimulation by LPS results in an M1 phenotype and is associated 
with expression of pro-inflammatory cytokines.  Conversely, microglia can be 
stimulated by IL-4 to an M2 phenotype, for resolution of inflammation and tissue 
repair (Biswas & Mantovani 2012). Though this dichotomous nomenclature doesn’t 
faithfully represent the spectrum of microglial polarisation states and phenotypes, it 
remains a useful tool for in vitro assays (see section 1.2.5). Thus, in order to 
functionally validate the capacity of iPSC-derived microglia to show both M1 and M2 
polarisation states, the inflammatory response of Kolf2 cells under stimulation with 
LPS and IL-4 was investigated. 14-day-differentiated cells were incubated with 1 µg/ml 
LPS or 50ng/ml IL-4 for 24 hours.  
 
LPS-activated gene expression is mediated through TLR4 signalling and involves the 
activation of several pathways including NFB and STAT1, which induce the release of 
pro-inflammatory cytokines and chemokines such as IL-1ß, TNF-, IL-6 and CCL2. qPCR 
results revealed that LPS increased expression of IL-1ß (though this didn’t reach 
significance at p = 0.058), while reducing mRNA levels of the neuroprotective 
molecules CD22 and SIGLEC12 (Figure 3.9A). The nuclear receptor PPAR plays a 
critical immune role by inhibiting pro-inflammatory gene expression and promoting 
anti-inflammatory processes (Clark 2002). Interestingly, PPAR expression was, after 
CD22, the most significantly downregulated gene post LPS incubation (Figure 3.9A). In 
addition, LPS treatment did not appreciably alter transcript levels of pro-inflammatory 
markers such as IL-6, TNF-, CCL2 and IL-8 (Figure 3.9B), which suggests a diminishing 
immune response after 24 hours of exposure to LPS.     
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Figure 3.9 Functional analysis of iPSC-derived microglial response to immune stimuli. 
(A-B) Kolf2 MG cells were incubated with 1 µg/ml LPS for 24 hours. LPS incubation led to decreased 
expression of the anti-inflammatory PPAR and neuroprotective genes CD22 and SIGLEC12. M1 pro-
inflammatory markers such as IL-1ß, TNF- and ICAM1 showed a trend towards upregulation. (C-D) 
Kolf2 MG were stimulated with 50 ng/ml IL-4 for 24 hours to induce a M2 polarisation. This resulted in 
a significant increase of anti-inflammatory genes (CCL17, CCL22, PPAR) while expression levels of M2 
polarisation markers (MRC1, IL-10, CD163) remained constant. (E-F) Incubation of Kolf2 MG cells with 
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1 µM oligomeric Aß1-42 resulted in significant downregulation of both pro- (ICAM1, NLRP3, STAT1, IL-
1ß, IL-8) and anti-inflammatory genes (TGF-ß1, PPAR). (G) Incubation with 1 µM rAß42-1 for 24 hours 
resulted in lower expression of PPAR, CD22 and IL-8. No differences were found in the expression of 
other inflammatory genes. 
    
Log2 Expression normalised to reference genes. Statistical analysis used one-way ANOVA with 
Dunnett’s post hoc comparison. Asterisks denote statistical significance: * < 0.05, ** < 0.01, *** < 0.001, 
ns – not significant. n=3 biological replicates for all samples, except for Kolf2 MG 24h LPS (n=2). 
 
 
Binding of IL-4 to the IL-4 receptor initiates a signalling cascade through the 
transcription factor STAT6 that polarises cells towards an anti-inflammatory 
phenotype typified by increased expression of classical M2 markers such as MRC1, IL-
10 and PPAR (Martinez & Gordon 2014). Stimulation of Kolf2 cells with 50 ng/ml IL-4 
resulted in upregulation of CCL17, CCL22 and PPAR, while mRNA levels of the M2 
markers CD163, IL-10, MRC1 and HLA-DR were not significantly induced (Figure 3.9 C-
D).   
 
Microglia are also activated upon exposure to abnormal protein aggregates, releasing 
cytokines and other inflammatory mediators to induce a cascade of pathways and 
mechanisms thought to contribute to neuronal death (Block et al. 2007). In order to 
measure the microglial inflammatory response to Aß, Kolf2 iPSC-derived microglia 
were stimulated with 1 µM of Aß oligomers (AßO) for 24 hours. This resulted in gene 
expression changes characterised by downregulation of activation molecules such as 
ICAM1, the NLRP3 inflammasome, the interferon regulator STAT1, CD40 (expressed 
on professional antigen presenting cells) and PPAR (Figure 3.9E). The pro-
inflammatory cytokines IL-1ß and IL-8 were also downregulated, while other M1 
markers such as CCL2, IL-6 and TNF- were unchanged (Figure 3.9F). In contrast, the 
anti-inflammatory TGF-ß1 was significantly reduced (p < 0.0042). As a negative control, 
the cells were stimulated with 1µM rAß42-1 for 24 hours, which resulted in PPAR, CD22 
and IL-8 downregulation (Figure 3.9G). Otherwise, the rAß response closely matched 
the unstimulated samples.   
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Figure 3.10 The in vitro microglial response to oligomeric Aß is distinct from M1 and M2 polarisation states.  
(A) 24-hour incubation of Kolf2 iPSC-derived MG cells with 1 µM Aß1-42 oligomers resulted in significantly decreased expression of lipid synthesis genes. (B) Expression of 
cholesterol metabolism regulator ABCA1, which stimulates anti-inflammatory signalling through the PPAR-LXR pathway (NR1H2 and NR1H3), was significantly 
downregulated, along with the Aß receptor LRP1. (C-D) In AßO-treated MG cells, levels of AD CD33, CD2AP, ABI3, APOE, CLU, INPP5D and ABCA7 were significantly decreased.  
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(E) PCA analysis revealed that AßO-treated MG cells clustered away from LPS-treated cells. Additionally, they segregated with IL-4 treated Kolf2 MG cells, despite significant 
differences in expression of lipid and cholesterol metabolism genes (F-G) Treatment of MG cells with Aß oligomers did not induce statistically significant differences in 
expression of canonical microglial genes, except for the downregulation of the phagocytosis-associated C1QA.    
 
Log2 Expression normalised to reference genes. Statistical analysis used two-way ANOVA with Tukey’s multiple comparisons test. Asterisks denote statistical significance: * < 
0.05, ** < 0.01, *** < 0.001, ns – not significant. n=3 biological replicates for all samples, except for Kolf2 MG 24h LPS (n=2). 
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Notably, the ANOVA results highlighted significant decreases in the expression of several 
genes involved in lipid and cholesterol metabolism, including fatty acid synthase (FASN), 
HMG-CoA reductase, HMG-CoA synthase 1 and the sterol response element binding factor 2 
(SREBF2); these genes not only help regulate intracellular cholesterol and are also associated 
with phagocytosis (Iwamoto et al. 2006). Correspondingly, levels of the multifunctional 
receptor LRP1, which acts as a phagocytic receptor for Aß oligomers, were similarly reduced 
following AßO stimulation (Figure 3.10 A-B).  The toxic effects of oligomeric Aß also influenced 
the expression of several AD risk genes, by downregulating CD2AP (p= 0.013), CD33 (p= 0.039) 
and more prominently ABI3, INPP5D, ABCA7, APOE, CLU and PICALM (Figure 3.10 C-D). 
Differences in PICALM, TREM2 and PLCG2 expression levels did not reach significance. This 
pattern of gene expression was found to diverge from the pro-inflammatory LPS Kolf2 
microglial response, as shown by the clear segregation of the LPS-treated samples on the PCA 
plot, generated by using a dataset comprising inflammatory, cholesterol metabolism, 
sensome and AD risk genes (Figure 3.10E). Moreover, oligomeric Aß treatment impacted on 
expression of the MG-specific C1QA, though expression differences in CX3CR1, P2RY12 and 
SIGLEC12 did not reach statistical significance (Figure 3.10F). Other sensome genes including 
the purinergic receptor ADORA3, GPR34, TYROBP and IBA1 were not significantly altered 
following Aß treatment (Figure 3.10G). However, when compared with mRNA levels of IL-4 
treated Kolf2 microglia cells, expression of several sensome genes were found to be 
significantly altered. Overall, the 24h AßO-treated samples seemed to segregate away from 
the IL-4 and LPS-stimulated samples, which suggests that the microglial oligomeric Aß 
response differs significantly from the established M1 and M2 in vitro paradigm.    
3.3 Summary and Discussion  
The work highlighted in this chapter set out to investigate the efficacy and reproducibility of 
the microglia differentiation protocol described in section 2.3. The resulting iPSC-derived 
microglia cells displayed robust expression of microglial markers by immunocytochemistry 
and were enriched for several microglia-exclusive transcripts such as GAS6, C1QA, GPR34 and 
the recently identified immune alertness gene CCR1. RNA sequencing was then used to 
analyse the transcriptome of the in vitro derived cells to establish a microglial signature.   
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This protocol for in vitro microglial differentiation mimics development in the embryo, giving 
rise to a population of monocyte-like primitive macrophage precursor cells (van Wilgenburg 
et al. 2013). The myeloid phenotype of these cells was validated by FACS and immunostaining 
to confirm an expression profile of myeloid markers comparable across two cell lines of 
different genetic background – a wild-type Kolf2 and a Huntington’s disease iPSC line with a 
109 CAG repeat expansion in the HTT gene (HD iPSC Consortium 2012). Recent work has 
elucidated the developmental origin of these in vitro microglia precursor cells, demonstrating 
that they are derived from a RUNX1- and SPI1-dependent lineage distinct from MYB-
dependent monocytes and macrophages (Buchrieser et al. 2017). This makes them closer 
developmentally to yolk-sac-derived precursors of microglia (Ginhoux et al. 2010) and is in 
accordance with the latest findings from fate mapping mouse studies (Mass et al. 2016).  
 
Transcriptomic analysis by RNA sequencing confirmed this close similarity between 
macrophage precursors and IL-34 and GM-CSF-treated microglia cells. Several genes 
identified as exclusive to microglia were expressed at comparable levels in the macrophage 
precursor cells (Figure 3.5). Furthermore, gene set enrichment analysis was used to highlight 
a microglial signature enrichment when the MG cells were compared to other brain cell types 
(see Table 3.1). Nonetheless, this signature reflected the monoculture nature of the in vitro 
cells and featured low expression of CX3CR1, P2RY12 and other genes involved in the 
homeostatic and surveillance functions of microglia (Figure 3.5). In vitro work by Abud et al. 
2017 built on in vivo mouse studies data by Butovsky et al., 2014 to show that TGF-ß removal 
from the microglia differentiating medium strongly influences the microglial transcriptome, 
reducing expression of key markers such as P2RY12, CX3CR1 and TGFßR1. Interestingly, lack 
of TGF-ß also downregulated expression of several key AD-associated genes such as APOE, 
CD33 and BIN1. (Bennett et al. 2018) recently demonstrated that microglial identity is induced 
by brain signalling, emphasising that microglia are highly sensitive to their environment and 
require brain signals to sustain homeostatic gene expression. The authors used a 
transplantation system to assess the survival of various macrophage populations in the 
microglia-deficient mouse brain and crucially found that, though tissue macrophages were 
able to survive and express some characteristic microglial genes, only yolk-sac derived cells 
were able to fully attain microglial identity – emphasising the crucial role of ontogeny on 
correct microglial identity. Similarly, it has been shown that though peripheral macrophages 
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can engraft into the brain, they maintain a unique transcriptional identity divergent to that of 
microglia (Cronk et al. 2018).  
 
No significant differences in the microglial signature of Kolf2 and HD109 microglia cells were 
detected using gene set enrichment analysis, with transcript levels of canonical genes 
expressed comparably between the two cell lines, with a few exceptions (Figures 3.3 & 3.4). 
Fluidigm qPCR validation likewise found a similar pattern of sensome gene expression in the 
IL-34 induced microglia from both cell lines (Figure 3.6), which strongly indicates that the 
expanded CAG track in the HTT gene has no discernible effect on the intrinsic microglia 
sensome. Nonetheless, the variability in the genetic background of the cell lines was reflected 
in the number of differentially expressed (DE) genes in the iPSC-derived microglia samples, 
when compared to their respective macrophage precursors samples. Treatment of the 
precursor cells resulted in the upregulation of 374 DE genes in the Kolf2 microglia, compared 
to 240 genes in the HD109 cells. Similarly, a greater number of genes were significantly 
downregulated in the Kolf2 (561) than in the HD109 microglia (365). This could be attributed 
to a Huntington’s disease effect, whereby the HD109 microglia are developmentally delayed 
in a fashion mirroring the developmental delay in HD iPSC-derived neural stem cells (Mattis 
& Svendsen 2017). However, given the presence of an intact microglial signature in the HD109 
cells, this discrepancy is most likely an artefact of the in vitro differentiation process.   
 
Microglia are capable of adopting various phenotypes. To test the functionality of the in vitro 
derived microglia-like cells, Kolf2 cells were activated with LPS and IL-4, which induce 
polarisation to an M1 and M2 phenotype respectively. LPS challenge for 24 hours was able to 
induce an M1 phenotype, though the characteristically increased expression of several pro-
inflammatory markers did not reach statistical significance. This result suggests that the 
microglial response to LPS diminishes over time and hints at a different M1 polarisation 
phenotype in microglia compared to macrophages, underlining the distinct nature of the 
microglial phenotype. Polarisation to an M2 phenotype using IL-4 was also attempted and 
results showed no alterations in the expression of M2 markers, including the mannose 
receptor MRC1, CD163 as well as HLA-DR and IL-10. Intriguingly, the anti-inflammatory 
nuclear receptor PPAR was upregulated, along with the chemokines CCL17 and CCL22. Again, 
this pattern of gene expression contrasts with expected changes after IL-4 induction in 
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macrophages, though these results compare favourably with reports of decreased sensitivity 
to M2 polarisation in human microglia (Durafourt et al. 2012).  
 
Previous studies carried out within our lab have shown that stimulation with monomeric Aß 
gives rise to a pro-inflammatory response (Emma Cope thesis, 2014). Post treatment with 
oligomeric Aß, Kolf2 microglia segregated away from LPS and IL-4-treated cells, proving that 
the AßO-stimulated phenotype differs from M1 and M2 polarised activation phenotype of 
microglia. Characterised by reduced expression of both pro- and anti-inflammatory genes, 
this inflammatory phenotype also featured the marked downregulation of several AD risk 
genes. These results particularly provide strong evidence linking the microglial response to 
amyloid ß to lipid and cholesterol metabolism, highlighting the PPAR-LXR axis as an 
important player in the regulation of Aß-mediated inflammation. Induction of the anti-
inflammatory PPAR and LXR pathways in mouse macrophages is promoted by LRP1 
signalling, which also inhibits pro-inflammation (Zurhove et al. 2008; May et al. 2013). In 
microglia, LRP1 downregulation results in increased production of pro-inflammatory 
cytokines through the JNK and NFB pathways (Yang et al. 2016). Conversely, activation of 
LRP1 signalling in response to inflammation induces transcription of ABCA1, which regulates 
cellular cholesterol export and the formation of lipid rafts (Xian et al. 2017). The findings that 
stimulation of in vitro microglia with oligomeric Aß aggregates affect LRP1 levels and 
cholesterol metabolism reinforce the notion that cellular cholesterol homeostasis plays a 
crucial role in the inflammatory responses of microglia. One caveat to this approach is the 
fact that this is an acute model of oligomeric Aß toxicity, with 1µM AßO concentration used 
in the experiments. This method has been shown to lead to increased neuronal death in a 
recent study comparing the toxicity of nanomolar and micromolar Aß concentrations to iPSC-
derived neurons (Berry et al. 2018). Dahlgren and colleagues also previously showed that 
oligomeric Aß42 inhibit neural viability significantly more than unaggregated peptides and 
fibrils at nanomolar concentrations (Dahlgren et al. 2002). Therefore, future experiments 
should focus on investigating the effects of more physiological concentrations on the 
microglial phenotype, with particular attention to expression of AD risk genes, immune 
response and cholesterol metabolism genes.   
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Not many studies of stem cell microglia have focused on elucidating the gene expression 
changes associated with in vitro Aß challenge. There is a rationale for carrying out such 
experiments, as a way to study the impact of Aß on specific pathogenic pathways. Abud et al 
2017 demonstrated this when they stimulated their iPSC microglia with fibrillar Aß to show 
that AD risk genes such as ABCA7, APOE, CLU, TREM2 and TYROBP were upregulated by the 
treatment. Equally, the focus of many ongoing studies will be to reveal how iPSC-derived 
microglia interact with AD pathology in vivo, by using humanised tau and amyloid mouse 
models. This exciting avenue of research is set to greatly advance the AD neuroinflammation 
field, and answer pertinent questions, for example regarding the role of microglia in tau 
propagation in AD (Asai et al. 2015; Maphis et al. 2015). Moreover, transplantation of stem 
cell microglia into AD mouse models will allow to investigate the influence of microglia-
enriched risk genes and specific disease-associated mutations on pathology in vivo.  
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4. CHARACTERISATION OF THE CELL-
AUTONOMOUS EFFECTS OF THE HTT 
GENE CAG EXPANSION ON IPSC-
DERIVED MICROGLIA 
4.1 Introduction  
Immune activation in the central nervous system, primarily driven by microglia, is a 
major feature of Huntington’s disease. Inflammation caused by a gain of toxicity of 
mutant HTT represents an important mechanism in HD pathogenesis (Ellrichmann et 
al. 2013), with current evidence suggesting that efficacy of immune system function 
may act as a disease modifier (Crotti & Glass 2015).    
 
Though generally associated with neuroprotection, microglia in HD acquire an 
inflammatory phenotype, resulting in elevated levels of pro-inflammatory cytokines 
in the brains of HD patients and in several mouse models (Dalrymple et al. 2007; 
Silvestroni et al. 2009). Moreover, when stimulated with lipopolysaccharide (a 
component of the bacterial cell wall), HD immune cells cultured ex vivo exhibit an 
exaggerated immune response, secreting higher levels of pro-inflammatory cytokines 
(Björkqvist et al. 2008; Trager et al. 2015). Expression of mutant HTT seems key to this 
pathogenic phenotype. Indeed, Crotti et al. 2014 showed that mHTT-expressing 
microglia in R6/2 and Q175 knock-in mice (Menalled et al. 2012) are primed for an 
enhanced immune response through increased basal expression of pro-inflammatory 
and neurotoxic genes that potentiate neuronal death (Crotti et al. 2014). In particular, 
mHTT expression increased expression and transcriptional activity of the transcription 
factor PU.1, leading to higher expression of PU.1-C/EBP target pro-inflammatory 
genes such as Il6, Irf1, Tnf and Tlr2. The same study also found corresponding higher 
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expression of SPI1 (PU.1), TLR2, IL6 and IRF1 in the striatum of post-mortem HD brains 
in comparisons with matched controls. Elsewhere, mutant HTT has also been detected 
in monocytes and macrophages using time-resolved FRET, where levels tracked 
disease burden (Weiss et al. 2012).       
 
The hyper-reactivity of HD immune cells is also partially mediated through altered 
intracellular signalling pathways centred around NFB, a major regulator of 
inflammatory mediator activation in immune cells. Mutant HTT has been shown to 
interact with the IKK complex, leading to the phosphorylation and degradation of 
IB. This releases NFB from cytoplasmic sequestration, allows its nuclear 
translocation and enhances its activity. Trager and colleagues recently demonstrated 
the reversibility of this cellular dysfunction by using glucan-encapsulated small 
interfering RNA particles to lower mHTT levels in primary monocytes and 
macrophages isolated from patients with HD (Träger et al. 2014). This intervention 
lowered cytokine production in macrophages and led to transcriptional changes in 
monocytes. Interestingly, cytokine production was reduced in siRNA-treated WT cells, 
suggesting that wild-type HTT plays a role in cytokine production.          
 
Wild-type HTT also plays a role in actin remodelling and microtubule dynamics 
(Cattaneo et al. 2005), processes required for a variety of immune functions including 
cytokine trafficking and release (Lacy & Stow 2011), and cell migration. Fittingly, HD 
microglia isolated from YAC128 (yeast artificial chromosome model of human HD gene 
with 128 CAG repeats) and BACHD (bacterial artificial chromosome of human HD gene 
with 97 CAG repeats) mice (Slow et al. 2003; Gray et al. 2008) were shown to exhibit 
impaired migration, while aged BACHD microglia also showed a delayed response to 
laser-induced injury (Wanda Kwan et al. 2012). This deficit was attributed to mHTT-
mediated decreased membrane ruffling and lower levels of the actin-binding protein 
cofilin, which plays an essential role in the regulation of actin polymerisation and is 
required for cell migration (Dawe et al. 2003). The same study also reported that 
monocytes and macrophages isolated from HD patients showed severe impairments 
in migration, agreeing with findings by Munsie and colleagues that revealed deficits in 
actin remodelling in patient-derived HD lymphocytes (Munsie et al. 2011). It is also 
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worth noting that impaired migration has been suggested as an explanation for the 
absence of infiltration of immune cells into the brain in mouse models and HD patients 
(Crotti & Glass 2015).         
A recent RNA-sequencing study of blood-derived monocytes from HD patients found 
a significant enrichment in pro-inflammatory pathway activation in the transcriptome 
of HD monocytes at the basal level (Miller et al. 2016). Functional gene sets associated 
with innate immunity, cytokine production and inflammatory response, especially 
genes related to the NFB pathway, were enriched, adding support to the notion that 
mHTT primes HD myeloid cells.  
4.2 Aims  
Given the overwhelming amount of evidence for pathogenic abnormalities in HD 
immune cells from patients as well as mouse models, experiments in this chapter were 
aimed at characterising the cell-autonomous phenotype of human microglia derived 
from HD iPS cell lines containing 109 CAG repeats. Having established correct 
expression of canonical microglial markers in chapter 3, RNA-sequencing was used 
here to closely examine the transcriptome of the HD109 iPSC-derived microglia and 
compare it to Kolf2 WT microglia. Finally, differentiated HD109 microglia were 
assayed for their inflammatory response to stimulation with LPS to investigate 
whether the HD cells exhibited the exaggerated immune response characteristic of 
HD immune cells.     
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4.3 Results
4.3.1 Transcriptomic analysis of HD109 iPSC-derived microglia  
Gene expression analyses uncovering the transcriptional changes in human HD 
immune cells have been predominantly carried out in peripheral blood cells (Runne et 
al. 2007; Mastrokolias et al. 2015). Indeed, while one study has looked at the 
transcriptome-wide effects associated with mHTT expression in HD patient-derived 
monocytes (Miller et al. 2016), to date no study has conducted a similar analysis of 
human microglia in HD. Therefore, in order to dissect any microglial-specific 
transcriptional changes, microglial cells and their precursors were generated from 
control Kolf2 and HD109 iPS cells for transcriptomic analysis by RNA sequencing.  
 
Using principal component analysis (PCA), a correlation analysis showing the variance 
between data, the samples were shown to segregate by cell type, macrophage 
precursor samples from both cell lines showing orthogonal separation from microglia 
samples from both cell lines (Figure 4.1A). Analysis on the basis of disease indicated a 
distinct disease effect between the respective Kolf2 control and HD109 precursor and 
microglia samples. After processing the RNA sequencing data (see section 2.9), 
differential gene expression analysis was used to calculate the number of differentially 
expressed (DE) genes across the different samples. To investigate the possibility of a 
disease signature common to both HD cell types in comparison with the respective 
Kolf2 samples, a HD-specific meta-analysis was carried out, identifying 421 genes with 
significantly altered expression in both HD cell types vs Kolf2 control (Figure 4.1B). 
These were obtained using a threshold of 0.05 for statistical significance and a log fold 
change of expression with absolute value of at least 1, corresponding to a 2-fold 
change in mRNA expression. Of that total, 196 genes were upregulated compared to 
223 downregulated genes. The gene lists were then inputted into the functional 
annotation tool DAVID (Huang et al. 2008) to uncover any enriched biological themes 
and functionally related gene groups. Among the upregulated genes, gene sets 
relating to ubiquitin conjugation, mitosis, cell cycle, DNA damage, DNA repair and cell 
division were found to be enriched. On the other hand, significantly downregulated 
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gene sets included those associated with cellular organelles such as lysosome, 
endoplasmic reticulum and Golgi membrane (see Table 4.1 below).         
GO term  Fold enrichment  Benjamini corrected p value 
Ubiquitin conjugation  2.398 6.55 x 10-4 
Mitosis 5.035 6.91 x 10-3 
Cell cycle 3.044 1.1 x 10-2 
DNA damage 3.747 3.55 x 10-2 
DNA repair 4.052 3.84 x 10-2 
Cell division 3.400 4.96 x 10-2 
 
Lysosome 4.768 1.02 x 10-2 
Endoplasmic reticulum 2.484 1.12 x 10-2 
Golgi membrane 2.652 3.29 x 10-2 
Table 4.1 GO terms upregulated (top) and downregulated (bottom) in HD macrophage precursor and 
microglia cells. 
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Figure 4.1 Transcriptomic analysis of HD109 microglia by differential gene expression reveals immune pathways likely to be impacted.    
(A) Correlation analysis of Kolf2 and HD109 Macpre and MG cells segregation of the samples by cell type and by genotype, indicating a disease effect. Data presented here 
is same as in Figure 3.5A. (B) Differential gene expression analysis (> 2-fold, p< 0.05) identified a common disease signature in the HD Macpre and MG cells compared to 
Kolf2 samples. 421 genes were significantly altered in both HD Macpre and MG cells vs their respective Kolf2 WT cells - 196 upregulated and 223 downregulated genes. (C) 
Volcano plot highlighting differential expression of 1114 genes (red dots) in HD109 compared to Kolf2 microglia. X axis shows log2 fold change and BH corrected p-values 
shown on Y axis as negative log (base 10) values. n=3 independent differentiations. (D) Analysis of KEGG pathways impacted by differential expression in HD109 MG cells was 
performed by iPathwayGuide Impact analysis package (AdvaitaBio). Top 13 Immune pathways predicted to be affected in HD109 MG include cell adhesion, cytokine-cytokine 
receptor interaction, antigen processing, chemokine signalling and phagosome.   
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The next analysis focused on the microglial-specific differences between the 
transcriptomes of the HD109 and Kolf2 cells. Out of a total of 17039 genes with 
measured expression, DE analysis of the data identified 1114 DE genes (233 
upregulated and 881 downregulated) in HD109 cells compared to Kolf2 control cells 
(Figure 4.1C). The top 20 genes ranked by p-value correction contained several 
immune-related transcripts, including BDKRB1, CALR, CD151 (cell adhesion molecule), 
CTSB, CX3CR1, CXCL1, HLA-A/-B/-H and IL15RA (see appendix 1).  
 
To contextualise the observed transcriptional changes in the HD109 microglia into 
biological relevance, the iPathwayGuide Impact Analysis package (AdvaitaBio) was 
utilised, as it incorporates analyses of pathways, biological processes and miRNAs (see 
section 2.9.4). Following analysis of impacted biological processes, a number of 
immune system themes and processes were represented, including immune 
response, response to stimulus, cell migration, chemotaxis and extracellular matrix 
organisation. Enrichment analysis showed that developmental and cell proliferation 
processes were also heavily represented outside the top 10 enriched GO terms (see 
Table 4.2). Table 4.3 shows the corresponding GO molecular functions. Of the 
enriched molecular functions, membrane receptor binding and activities including 
cytokine, chemokine and other signalling molecules featured prominently. It is worth 
noting that redundancy is a feature of these analyses, due to overlapping gene sets.    
GO Biological process DE genes (#/ALL) FDR-adjusted p value 
Immune response 151/1200 7.783 x 10-11 
Response to stimulus 531/6428 1.503 x 10-8 
Defence response  136/1142 1.503 x 10-8 
Cell migration 128/1055 1.592 x 10-8 
Chemotaxis  71/458 1.592 x 10-8 
Response to external stimulus  173/1602 3.942 x 10-8 
Cell communication  417/4835 5.188 x 10-8 
Inflammatory response 76/538 1.752 x 10-7 
Localisation of the cell 131/1141 1.752 x 10-7 
Regulation of cell migration 82/609 2.83 x 10-7 
Table 4.2 Representation of enriched gene sets in differentially expressed genes in HD109 microglia. 
GO terms list was generated by inputting DESeq2 data frame into iPathwayGuide Impact analysis package.  
70  
GO Molecular function DE genes (#/ALL) FDR-adjusted p value 
Receptor activity 124/910 2.979 x 10-12 
Molecular transducer activity 124/910 2.979 x 10-12 
Transmembrane receptor activity 95/646 4.062 x 10-11 
Transmembrane signalling receptor activity 91/607 4.062 x 10-11 
Signalling receptor activity 97/694 3.520 x 10-10 
Cytokine activity 32/134 3.385 x 10-8 
Chemokine receptor binding 17/41 5.609 x 10-8 
Chemokine activity 15/32 6.77 x 10-8 
Receptor binding  126/1134 6.018 x 10-7 
Collagen binding 18/60 5.01 x 10-6 
Table 4.3 Molecular function gene sets represented in the DE HD109 microglia cells. 
Pathway analysis identified 12 KEGG pathways significantly altered in the HD 
microglia, following FDR correction (Figure 4.1D). A number of immune pathways 
were predicted to be impacted, including cytokine-cytokine receptor interaction 
(KEGG:04060 – FDR = 2.19 x 10-4), antigen processing and presentation (KEGG: 04612 
– FDR = 0.001), hematopoietic cell lineage (KEGG: 04640 – FDR = 0.001), autoimmune 
thyroid disease (KEGG: 05320 – FDR = 0.008), chemokine signalling (KEGG: 04062 – 
FDR = 0.029), allograft rejection (KEGG: 05330 – FDR = 0.029), Staphylococcus aureus 
infection (KEGG: 05150 – FDR = 0.035), phagosome (KEGG: 04145 – FDR = 0.035) and 
complement  and coagulation cascades (KEGG: 04610 – FDR = 0.047). The most 
affected pathway in terms of number of DE genes was cytokine-cytokine receptor 
interaction (36 DE genes), followed by neuroactive ligand-receptor interaction (29 DE 
genes), cell adhesion molecules (24 DE genes) and chemokine signalling pathway (20 
DE genes). 
 
When considering the cytokine-cytokine receptor interaction and chemokine 
signalling pathways together, a pattern of dysregulation becomes evident, whereby 
several chemokines including CCL7, CCL17 and CCL18 and members of the CXC 
subfamily were found to be downregulated compared to just one, CCL24 being 
upregulated, log2FC = 3.284 & p-value of 0.021 (Figure 4.2B). In addition, the 
chemokines (CXCL1, CXCL2, CXCL3, CXCL5, CXCL6) bind the common chemokine 
receptor, IL8RB or CXCR2. On the other hand, only two cytokines were shown to be 
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upregulated in the HD109 stem cell-derived microglia, TNFSF18 (log2FC of 2.657 and 
p-value of 0.026) and TNFSF11 (log2FC of 3.98 & p-value 0.041) (Figure 4.2A). Both are 
members of the TNF ligand family, thought to be important in the regulation of T 
lymphocyte survival in peripheral tissues. The anti-inflammatory IL-10 was found in 
lower levels (log2FC of -1.687 & p-value 0.010) in the HD109 microglia, along with 
CLCF1 or BSF3 (log2FC of -1.503 & p-value 0.036), a member of the IL-6 family which 
induces tyrosine phosphorylation of the IL-6 receptor subunit gp130, LIF receptor beta 
and the transcription factor STAT3. Though most chemokine receptors levels 
remained unchanged, levels of CCR2 (log2FC of 5.688 and p-value 0.010) and CX3CR1 
(log2FC of 9.412 and p-value 1E-06) were significantly upregulated (Figure 4.2B). The 
important adaptor proteins [ADCY9 (log2FC of -1.194 and p-value 0.017), STAT1 
(log2FC of -1.416 and p-value 7.139E-04) and GNG11 (log2FC of -2.17 and p-value 
0.034)] were also downregulated, leading to actin regulation, cytokine production, 
migration and chemotaxis listed among the predicted perturbed processes (Figure 
4.2C). Crucially, levels of CSF1R, the receptor which mediates microglial proliferation 
and survival, were shown to be significantly higher in the HD microglia (log2FC of 1.411 
and p-value 0.020) compared to Kolf2 cells.   
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Figure 4.2 Several immune pathways are predicted to be 
altered in HD109 microglia.     
(A) The TNF family ligands TNFSF11 and TNFSF18 were upregulated 
in HD109 MG, whereas the majority of cytokines including IL-10 
were downregulated compared to Kolf2 MG cells. 
 (B) With the exception of CCL24, the expression of several 
chemokines was downregulated in the HD109 MG cells. The 
chemokine receptors CX3CR1 and CCR2 were significantly 
upregulated in the HD MG cells.  
(C) Dysregulation in chemokine signalling was predicted to perturb 
several processes, including cell migration and chemotaxis, actin 
regulation and cytokine production. Chemokine signalling pathway 
diagram (KEGG: 04062) overlaid with computed iPathway Guide 
perturbation analysis (bold red lines and arrows). Perturbation 
analysis accounts for measured fold change for the gene and for 
the accumulated perturbation propagated from any upstream 
genes. The highest negative perturbation is shown in dark blue, and 
the highest positive perturbation in dark red. 
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 (D) 24 cell adhesion molecules, belonging to the KEGG pathway (04514) were reported as DE in the HD109 MG cells. (E) Differential expression of extracellular matrix-
receptor interaction molecules (KEGG: 04512) in HD109 microglia in comparison to Kolf2 WT cells. (F) The neuroactive ligand-receptor interaction KEGG pathway contained 
29 DE genes in the HD109 microglia.         
 
Bar plots of top-30 genes out of total number of DE genes in a pathway. Upregulated genes displayed in red, downregulated in blue. Box and whisker plots outline the 
distribution of DE genes annotated to the KEGG pathway. Box represents the first quartile, the median and third quartile; outliers are shown as circles.   
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Two closely related pathways were also predicted as dysregulated: cell adhesion 
molecules (KEGG: 04514 – FDR = 2.19 x 10-4) and extracellular matrix-receptor 
interaction (KEGG: 04512 – FDR = 0.001). A number of cell adhesion genes that 
regulate pre- and post-synaptic neuronal interactions as well as interactions between 
neurons and other nervous system cells were altered (Figure 4.2D). Those include the 
neuronal adhesion genes CDH2 (log2FC of -1.866 and p-value 0.006), L1CAM (log2FC 
of -2.626 and p-value 0.003), NLG4Y (log2FC of 1-9.807 and p-value 1 x 10-6) and 
CADM3 (log2FC of -4.139 and p-value 0.001), all significantly downregulated whereas 
CNTN2 was the only neuronal adhesion gene markedly upregulated (log2FC of 8.082 
and p-value 0.044). Also upregulated was the epithelial and tight junction protein 
CLDN10 (log2FC of 6.563 and p-value 0.009) while the claudin family members CLDN1 
(log2FC of -2.798 and p-value 0.018) and CLDN28 (log2FC of -1.133 and p-value 8.118 
x 10-4) and the endothelium adhesion proteins VCAM1 (log2FC of -2.315 and p-value 
0.008) and JAM2 (log2FC of -2.419 and p-value 0.032) were significantly reduced in the 
HD microglia. Notably, several immune-specific cell adhesion molecules were altered, 
with predicted perturbating effects on antigen processing and presentation via the 
MHC I and MHC II pathways (below). Examples include ALCAM, an activated adhesion 
molecule that binds the T-cell CD6 antigen (log2FC of 1.506 and p-value 0.003) and 
CD80, a receptor that binds to T-cells when activated and induces their proliferation 
(log2FC of -1.042 and p-value 0.005).    
The HD109 microglia also displayed significantly lower levels of transcripts coding for 
integrins, receptors that facilitate cell adhesion to the extracellular matrix: ITGA1, 
ITGA2, ITGA3 and ITGA5. Indeed, only ITGB7 levels were higher in HD109 vs Kolf2 
microglial cells (Figure 4.2E).    
 
The KEGG pathway neuroactive ligand-receptor interaction (KEGG: 04080) was 
another predicted to be dysregulated by HD109 microglia. The most perturbed gene 
here was the bradykinin receptor or B1BDKRB1 (log2FC of -5.42 and p-value 1 x 10-6), 
which mediates binding to bradykinin, a peptide released in inflammatory conditions. 
Other downregulated neuroligand receptors were the acetylcholine receptor subunit 
genes CHRNA1 and CHRNA3, the NDMA receptor subunit GRIN3B and the muscarinic 
cholinergic receptor CHRM2 (Figure 4.2F). Additional notable receptors belonging to 
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this pathway that were upregulated in HD microglia included the GABA-A receptor 
subunit GABRA3 (log2FC of 5.026 and p-value 1 x 10-6) as well the glutamate AMPA 
receptors GRIA1, GRIA2 and GRIA4. Intriguingly, transcript levels for the adenosine 
receptors A1 and A2B were markedly lower, while downregulation of the microglial 
sensome gene ADORA3 did not reach statistical significance (log2Fc of -1.018 and p-
value 0.253). Similarly, mRNA levels for the purinergic receptors P2RX6 and P2RY2 
were also lower in the HD109 cells (log2FC of -3.003 and -2.039) whereas P2RX1 
(log2FC of 1.567 and p-value 0.031) and P2RY12 (log2FC of 1.935 and p-value 0.152) 
levels were higher.       
 
Antigen processing and presentation (KEGG: 04612 – FDR = 0.0010) was another 
pathway predicted to be impacted by the transcriptional changes identified in HD109 
microglia (Figure 4.3A). Upon closer inspection, several MHC I and MHC II molecules 
were found in significantly lower levels in the HD in vitro microglia. All MHC class I 
molecules, expressed in nearly all cells and present peptide antigens processed by the 
proteasome and derived from the ER, displayed significantly lower mRNA levels. Of 
the class II pathway, expressed in professional antigen presenting cells, HLA-DOB 
(log2FC of -1.933 and p-value 7.67 x 10-4) was found at reduced mRNA levels in the HD 
MG cells, along with mRNAs for cathepsins B and L. Perturbation analysis predicted 
that these changes would affect presentation of endogenous and endocytosed 
antigens to natural killer (NK) cells.         
The process of phagocytosis, an important function of microglia, was also identified 
among the dysregulated pathways (KEGG: 04145 – FDR = 0.035) (Figure 4.3B). Many 
transcripts in this pathway were shared with the antigen presentation pathway 
described above. The phagocytosis-promoting receptors FCAR, FCGR2B and FCGR2C 
exhibited markedly reduced mRNA levels, along with the scavenger receptor MARCO 
(log2FC of -4.327 and p-value 2.154 x 10-5), the complement receptor C1R and integrins 
ITGA2 and ITGA5. In contrast, three important genes were upregulated in the HD 
microglia compared to Kolf2 WT: the scavenger receptor CD36 (log2FC of 1.262 and p-
value 0.008), the NADPH oxidase 2 gene CYBB, superoxide enzyme that generates 
reactive oxygen species (log2FC of 1.208 and p-value 0.003) and the actin-binding 
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protein coronin 1A, which initiates fusion of the phagosome to the lysosome (log2FC 
of 1.182 and p-value 0.008); perhaps hinting at a compensatory mechanism.  
 
According to the iPathwayGuide Impact analysis, the final pathway predicted to be 
significantly affected was the complement and coagulation pathway (KEGG: 04610 – 
FDR = 0.047), which had 13 DE genes, of which C5 and C7 were upregulated (Figure 
4.3C). CR2, CLU, MASP1, C1S, C1R and VTN were all found to be downregulated in 
HD109 MG cells.  
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Figure 4.3 Phagocytosis and antigen processing and 
presentation are among the top pathways predicted to be 
dysregulated in HD109 iPSC-derived microglia. 
(A) Perturbation analysis by iPathway Guide identified antigen 
processing and presentation as likely affected in HD109 MG. 
Highest negative perturbation shown in dark blue. Changes 
predicted to affect antigen presentation to natural killer cells.   
(B) Phagosome KEGG pathway diagram overlaid with measured 
fold changes for genes including CYBB, CD36 and coronin 
(upregulated) and downregulated receptors such as FCGR2B and 
MARCO. (C) Complement pathway was enriched with 13 DE 
genes in HD109 MG cells.  
 
Bar plots of top-30 genes out of total number of DE genes in a 
pathway. Upregulated genes displayed in red, downregulated in 
blue. Box and whisker plots outline the distribution of DE genes 
annotated to the KEGG pathway. Box represents the first 
quartile, the median and third quartile; outliers are shown as 
circles.   
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To gain further insight into the underlying mechanisms driving the differential gene 
expression observed in the HD109 stem cell-derived microglia, upstream regulator 
analysis was performed using Ingenuity Pathway Analysis software (IPA, Qiagen). This 
software compares gene expression in a dataset with known gene lists regulated by 
specific upstream signalling molecules and networks (p-value of overlap) and predicts 
whether a specific molecule is likely to be activated or inhibited (z score). Using a z 
score of > 2 or < -2 and p value of < 0.01 as cut-offs for ascribing significance, the 
extensive list of predicted upstream regulators was narrowed down to 41, with the 
majority (28 out of 41) found to be significantly inhibited (see Table 4.4) compared to 
13 predicted to be activated (see appendix 3).  
Upstream regulator  Activation z-score P value of overlap Function  
Lipopolysaccharide  -4.272 6.42E-14 
Bacterial cell wall component that elicits 
strong immune response 
NFB complex -4.222 0.0022 
Family of TFs that regulate inflammatory 
response 
TP53 -4.17 1.7E-05 
Tumour suppressor involved in regulation 
of apoptosis 
IFN-2 -4.114 6.16E-05 
Type I IFN cytokine produced by virus-
infected cells 
poly rI:rC-RNA  -3.806 2.05E-05 
Synthetic drug that activates IFN-
inducible genes 
IFN- -3.668 1.04E-10 Immune response-mediating cytokine 
IL1A -3.609 2.15E-03 Pro-inflammatory cytokine 
TNF -3.545 1.53E-15 Pro-inflammatory cytokine 
F2 -3.502 1.94E-03 
Serine protease involved in clotting 
process  
IFN-ß -3.399 7.75E-04 
Type I IFN cytokine involved in innate 
immune response 
Table 4.4 IPA of upstream transcriptional regulators inhibited in HD109 iPSC-derived microglia. IPA 
was used to predict activation of specific transcription regulators that overlap with the transcriptome changes 
observed in HD109 microglia. The upstream regulators were ranked by activation z-score, with a significant p 
value cut-off of < 0.01. The 10 most significant regulators and networks were included in the table above (for the 
remaining inhibited regulators – see appendix 2).    
The top activated regulator in terms of z score was the p38 MAPK kinase inhibitor 
SB203580 (z score of 3.885 and p-value overlap 1.33 x 10-8), followed by the nuclear 
receptor retinoic acid receptor alpha or RARA (z score of 3.414 and p-value of overlap 
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5.41 x 10-7). The cytokine IL1RN, whose expression was upregulated (log2FC of 2.254 
& p-value 0.034), was identified as one of the activated upstream regulators (z score 
of 2.279 and p-value 1.64 x 10-3), along with the growth factor DKK1 (z score of 2.005 
and p-value 1.94 x 10-4). Predictive activation of the transcription factor STAT3, 
previously identified as an activated regulator in HD monocytes (Miller et al. 2016), 
failed to reach significance (z score of 1.12 and p-value 7.29 x 10-4) whereas NKX2-3 (z 
score of 2.103 and p-value 6.63 x 10-6) and MYCN (z score of 2.671 and p-value 7.85 x 
10-4) were predicted as significantly activated.   
In contrast, a large number of cytokines, transcription factors and pathways were 
predicted to be inhibited in the HD109 microglial cells. Top of this list were the LPS 
pathway (z score of -4.272 and p-value overlap 6.42 x 10-14), NFB complex (z score of 
-4.222 and p-value overlap 2.2 x 10-3), TP53 (z score of -4.17 and p-value overlap 1.7 x 
10-5), IFN2 (z score of -4.114 and p-value overlap 6.16 x 10-5), IFN- (z score of -3.668 
and p-value overlap 1.04 x 10-10) and TNF (z score of -3.545 and p-value overlap 1.53 
x 10-15). Several other regulators including IL6, IL1ß, IFN, IL4, ERK1/2, p38 MAPK, 
IRF3, IRF1 and STAT1 were similarly predicted to be significantly inhibited, though 
TLR4 didn’t fit the z score criterion (-1.58 and p-value overlap 6.65 x 10-4). Overall, 
these data firmly suggest that the transcriptional changes observed in the HD109 stem 
cell-derived microglia are associated with inhibition by several upstream regulators.  
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4.3.2 Functional validation of HD109 of iPSC-derived microglia  
Upstream regulator analysis carried out using IPA (see section 4.3.1) projected several 
inflammatory pathways to be inhibited in HD109 MG, including the NFB (Figure 4.4A) 
and LPS pathways (Figure 4.5A). To test this hypothesis, the expression of NFB 
pathway genes in the RNA-seq data was compared to WT Kolf2 cells. Out of a total of 
50 genes, only three were differentially expressed: IL1R1 (log2FC of -1.411 and p-value 
0.018), IL10 (log2FC of -1.687 and p-value 0.01) and STAT1 (log2FC of -1.416 and p-
value 7.14 x 10-4) were downregulated (Figure 4.4B). All other genes in this pathway, 
including important adaptor proteins such as MYD88 were expressed at comparable 
levels in both cell lines, though differences in IL-1ß did not reach statistical significance 
(log2FC 1.115 and p-value 0.241) (Figure 4.4C). The expression of key NFB pathway 
genes was further validated by Fluidigm qRT-PCR and results confirmed RNA-seq data 
observations that mRNA levels of NFB genes did not vary significantly between 
HD109 and Kolf2 microglia samples (Figure 4.4 D-E).      
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Figure 4.4 The expression of NFB pathway genes is unaltered in HD109 microglia compared to WT Kolf2 microglia.      
(A) IPA’s Upstream regulator analysis of the DE genes in the HD109 microglia RNA-seq dataset predicted the inhibition of several inflammatory pathways including the NFB 
complex. Regulators with significantly inferred activation (IL-10, SMAD7 and STAT3) are shown in orange, inhibited regulators (TNF, IL-6, IL-1ß, TGFß1, STAT1 and IRF1) are 
shown in blue. (B) Expression of various components of the NFB pathway was assessed by RNA-seq. No significant differences were found in levels of NFB subunits RELA 
and RELB, as well as the inflammatory activation markers TNF, ICAM1, CCL2 and IRF1. (C) Out of 50 genes in the pathway, three were differentially expressed (downregulated) 
in HD109 microglia: IL1R1, IL-10 and STAT1. RNA-seq expression levels are represented as log2 transformed FPKM pseudo-counts. Data analysed using one-way ANOVA with 
Tukey’s multiple comparison test. Asterisks denote statistical significance: * < 0.05, **  < 0.01, *** < 0.001, ns – not significant. n=3 independent differentiations.  
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(D-E) Fluidigm qPCR validation of NFB pathway genes expression in the HD109 microglia. No statistically significant differences were found in the expression levels of several 
genes between Kolf2 and HD109 iPSC-derived microglia, despite a notable trend towards upregulation. Fluidigm qRT-PCR data are presented as log2 expression normalised 
to reference genes. Statistical analysis used one-way ANOVA with Dunnett’s post hoc comparison. ns – not significant. n=3 biological replicates, except THP-1 (n=2). 
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Mouse model studies have shown how HD immune cells cultured ex vivo exhibit a 
hyper-reactive profile upon LPS stimulation, secreting higher levels of pro- 
inflammatory cytokines compared to controls (Björkqvist et al. 2008; Trager et al. 
2015). Thus, the hypothesis that LPS-stimulation of HD109 microglia may result in a 
hyper-reactive was investigated, with expression of classical M1 markers and LPS 
pathway genes assessed by qPCR. HD109 and Kolf2 microglia were differentiated for 
14 days in IL-34 and GM-CSF, after which the cultures were incubated with 1 µg/ml 
LPS for 4 and 24 hours, as gene expression changes following LPS stimulation peak at 
around 4 hours (Yamamoto et al. 2004; Aung et al. 2006). No notable differences were 
evident in the magnitude of change in expression of activation molecules after 4 hours 
between HD and Kolf2 microglia, which suggests that both cell lines exhibited the 
expected M1 activation or polarisation state. Genes such as IRF1, CCR7, ICAM1, CD40 
and NLRP3 were upregulated to similar levels in both LPS-treated cell samples (Figure 
4.5B). Though these differences were not statistically significant, there was a trend 
towards higher mRNA levels of M1 pro-inflammatory cytokines in unstimulated 
HD109 microglia, including TNF-, IL-8, IL-6, IL-1ß and CCL2. Subsequently, these 
genes were upregulated in response to LPS incubation at 4 hours, with no differences 
in mRNA levels post incubation between the cell lines (Figure 4.5C). However, the 
magnitude of the mRNA increases between the LPS-treated microglia samples differed 
for two genes, TNF- and IL-1ß. For TNF-, mRNA levels increased by a greater 
magnitude in the Kolf2 WT cells (3-fold increase at p = 0.0024) compared to HD109 
cells (2-fold increase at p= 0.0217) (Figure 4.5C). A similar pattern was observed for IL-
1ß, with a 3-fold increase in gene expression for Kolf2 cells (p= 0.0073) versus 2.5-fold 
increase in the HD109 cells (p= 0.0256). The 4h LPS challenge also resulted in higher 
CCL2 expression in HD109 microglia compared to Kolf2, whereas CCL22 expression 
was higher in 4h LPS-treated HD109 compared to 4h LPS-treated WT Kolf2 cells. The 
chemokine CCL18, a cytokine with both immune activation and suppressive 
properties, was equally upregulated by LPS induction in both genotypes (Figure 4.5D). 
Taken together, these observations hint at a tighter regulation of pro-inflammatory 
cytokine production in the HD109 microglial cells.    
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Figure 4.5 The inflammatory response to LPS shows that HD109 microglia are not hyper-reactive.   
(A) The LPS pathway was predicted as inhibited in HD109 MG cells by IPA upstream regulator analysis. Inflammatory regulators such as IL-1ß, TNF, IFN and IFN (shown in 
blue) were among those predictively inhibited whereas IL-10 and STAT3 (shown in orange) were identified as upstream activators. (B) HD109 and Kolf2 MG cells were 
incubated with 1 µg/ml LPS for 4h. No significant differences between HD and WT cells were found in expression levels of M1 polarisation markers following LPS stimulation. 
(C) In response to LPS, and in comparison with Kolf2 WT microglia, HD109 microglia produced similar levels of the pro-inflammatory cytokines TNF-, IL-1ß, IL-6 and IL-8. (D) 
LPS treatment resulted in higher CCL2 expression in HD109 MG cells whereas CCL22 expression was significantly higher in the LPS-treated Kolf2 MG cells than the 
corresponding HD109 cells.  
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(E) Cluster analysis of unstimulated and LPS-treated Kolf2 and HD109 MG cells showed a greater segregation 
between Kolf2 4h and 24h LPS-stimulated samples than for the corresponding HD109 cells. (F-G) LPS-induced 
expression of the anti-inflammatory chemokines CCL17, CCL18 and CCL22 was differentially regulated in Kolf2 
vs HD109 MG cells. In HD109 MG cells, no significant differences were found in the expression of the chemokines 
over a 24-hour course of LPS stimulation. In Kolf2 MG cells, expression of all three chemokines peaked at 4 hours 
post LPS before significantly decreasing at 24 hours. (H-I) LPS treatment significantly affects expression of 
calming molecules in Kolf2 MG but not HD109 cells.  
 
Fluidigm qRT-PCR data are presented as log2 expression normalised to reference genes. Statistical analysis used 
two-way ANOVA with Tukey’s multiple comparisons test. ns – not significant, * < 0.05; ** < 0.01; *** < 0.001. 
n=3 biological replicates, except Kolf2 MG + 24h LPS (n=2).  
 
Next, a PCA plot was used to examine the divergence of all LPS-treated samples from their 
corresponding unstimulated samples. For both cell lines, 4h LPS samples were segregated 
away from 24h samples, with the Kolf2 LPS-treated cells showing greater separation than the 
corresponding HD109 cells (Figure 4.5E). Furthermore, the plot demonstrated that the 4h and 
24h HD109 cells were closely matched to each other and to unstimulated HD109 control cells. 
For the Kolf2 samples, the control cells segregated with the 24h LPS-stimulated cells, which 
were clearly separate from the 4h treated cells. This hinted at significant differences in the 
maximal LPS response at 4 hours of cells from both genotypes. To delve further into these 
differences, the profile of LPS response of both cell lines was compared for meaningful trends. 
Chemokine expression in response to LPS was found to differ in HD109 vs Kolf2. Except for 
increased CCL18 release, all levels of chemokines remain constant over the 24h course of LPS 
treatment in HD109 microglia (Figure 4.5F). In comparison, CCL22, CCL18 and CCL17 were 
upregulated in Kolf2 cells after 4 hours of LPS treatment, with levels decreasing significantly 
thereafter (Figure 4.5G).  
Moreover, LPS stimulation appeared to impact the expression of a number of neuroprotective 
genes in Kolf2 microglia (Figure 4.5H). CX3CR1, CD22 and SIGLEC12, sensing molecules that 
provide a constitutive and calming ‘off’ signal were downregulated in Kolf2 microglia over the 
course of LPS treatment, whereas levels of the same genes remained constant in the control 
and LPS-stimulated HD109 microglia (Figure 4.5I). In conclusion, these experiments 
demonstrated that HD109 microglia did not exhibit a hyper-reactive phenotype in response 
to challenge with LPS.   
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4.4 Summary and Discussion  
In this chapter, a HD iPSC line containing 109 CAG repeats and a WT Kolf2 iPSC line were 
differentiated into microglia and the phenotype of the in vitro derived microglial cells 
characterised using RNA sequencing in order to analyse the microglia-specific transcriptome 
effects of the HD CAG expansion. Gene Ontology analysis revealed that developmental 
processes, including development of the embryo, mesenchyme, vasculature and epithelium 
were among those significantly enriched in the HD109 microglia gene sets. The fact that these 
processes aren’t specific to the nervous or immune system suggests that these transcriptional 
changes reflect development as a whole being altered in HD. Recent studies have shown that 
CAG repeat expansion results in the dysregulation of genes involved in neuronal development 
and dorsal striatum formation (Ring et al. 2015). Similarly, Molero et al. 2009 found that CAG 
expansion-associated developmental abnormalities in neurogenesis in the striatum 
subsequently made medium spiny neurons more susceptible to degeneration in later life 
(Molero et al. 2009). These findings seem to support the notion of HD as a 
neurodevelopmental disorder (Kerschbamer & Biagioli 2016). Genes related to skeletal and 
limb morphogenesis were also represented among the gene sets altered in the HD109 
microglia, likely as a result of non-specific transcriptional changes due to aberrant mutant HTT 
transcription factors interactions. These findings agree with recent RNA-seq data from 
Labadorf et al. 2015, who analysed gene expression in the prefrontal cortex of HD post-
mortem samples and found evidence of a developmental signal, although it was unclear 
which brain cell type was responsible for this signal (Labadorf et al. 2015). The same study 
also uncovered evidence of an enrichment in inflammatory and immune response gene sets 
in HD brains. 
According to pathway impact analysis of the in vitro HD microglia transcriptome data, several 
immune-related pathways were predicted to be dysregulated. Transcripts coding for cell 
adhesion molecules that mediate antigen presentation and immune cell regulation were 
downregulated in HD109 vs Kolf2 cells. Given that microglial cell adhesion molecules play a 
critical role in many processes, including neural tissue development, it was unsurprising to 
note a predicted dysregulation in the KEGG pathway 04080, enriched with genes coding for 
neuroactive ligand-receptor interactions. This may hint at an impairment of HD microglia in 
their capacity to aid the construction and development of neuronal networks. Another 
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pathway impact analysis prediction was the likely perturbation of interactions between HD 
microglia and the extracellular matrix, which are mainly mediated by integrins and cell 
adhesion molecules whose expression was found to be dysregulated. Given that the ECM 
plays a key role in the morphogenesis and maintenance of cell and tissue structure and 
function, these data appear to tally well with reports of neurovasculature disruptions in HD 
patients, R6/2 mouse models and iPSC models of blood-brain barrier (Drouin-ouellet et al. 
2015; Lim et al. 2017; Vatine et al. 2017).  
Chemokine signalling was among the biological pathways revealed to be significantly affected 
by transcriptional changes in HD109 microglia. Chemokines involved in the recruitment of 
blood myeloid cells (CCL7, CCL8, CCL17) were significantly downregulated. mRNA levels of 
CCL24, strongly chemotactic to resting T lymphocytes, was upregulated while levels of T cell 
recruiting chemokines such as CCL1, CCL2 and CCL22 were unchanged. This pattern of 
expression seems to contradict data from previous findings, which have shown that levels of 
chemokines, complement proteins and the anti-inflammatory cytokine IL-10 increase with HD 
burden (Dalrymple et al. 2007; Bjorkqvist et al. 2008; Wild et al. 2011). Equally, these 
observations could be reflective of a dysregulation in chemokine signalling and thus compare 
favourably with reports of a lack of infiltration of blood myeloid cells into the HD brain (Lucin 
& Wyss-Coray 2009; Rocha et al. 2016); a phenomenon previously thought to be a 
consequence of impaired immune cell migration in HD (Wanda Kwan et al. 2012). Finally, 
altered chemokine signalling is likely to affect crosstalk between the HD microglia in the CNS 
and cells of the adaptive immune system, and potentially have an impact on the involvement 
of other immune cells in the striatum. Certainly, this view is supported by predicted deficits 
in the antigen processing and presentation machinery of the HD109 microglia, perhaps an 
adaptation to keep out infiltrating blood immune cells such as cytotoxic T-cells, NK cells and 
monocytes.  
Expression of three important cytokines and chemokine receptors (CCR2, CX3CR1 and CSF1R) 
was increased in HD microglia, perhaps an indication of a proliferative and neuroprotective 
adaptation of the cells to the HD neuronal environment. Interestingly, a recent study showed 
in a rodent brain slice model that mutant HTT aggregation triggered by neuronal stressors led 
to increased IL-34 production and corresponding microglial proliferation, exacerbating 
degeneration of medium spiny neurons (Khoshnan et al. 2017). In addition, deletion of CCR2 
has been shown to hamper microglial accumulation in a transgenic mouse model of 
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Alzheimer’s disease, resulting in higher amyloid burden and increased mortality (El Khoury et 
al. 2007), implying that CCR2-dependent microglial accumulation can be neuroprotective. Of 
course, deletion of the fractalkine receptor CX3CR1 has been shown to regulate microglial 
activation in a mouse model of tauopathy (Bhaskar et al. 2010), while its overexpression 
suppresses activation and diminishes tau pathology (Nash et al. 2013).  
 
The inflammatory response of the HD109 cells was subsequently validated, to investigate the 
hypothesis that HD microglia are primed for an exaggerated response to exogenous stimuli. 
Following stimulation with LPS, both HD109 and Kolf2 cells exhibited the expected M1 
polarisation state featuring a similar upregulation in pro-inflammatory markers including 
CD40, ICAM1 and IRF1. In contrast, the same challenge appeared to induce a maintenance of 
the core microglial phenotype in the HD109 microglia, with neuroprotective and calming 
molecules such as SIGLEC12, CD22 and CX3CR1 being expressed at similar levels during and 
following LPS treatment, whereas the same genes were downregulated in the Kolf2 cells 
(Figure 4.5). Another particular point of difference in the HD109 inflammatory response 
profile was that the increase in TNF- and IL-1ß expression post LPS of a higher magnitude in 
Kolf2 compared to HD109 microglia. All things considered, it appears that the immune 
response of HD109 microglia is more tightly regulated to prevent excessive release of 
deleterious pro-inflammatory cytokines and loss of a neuroprotective signature. Cytokines 
such as TNF and IL-6 are contained in carrier vesicles that are trafficked to the cell surface for 
release (Stanley & Lacy 2010). Upon TLR-mediated LPS stimulation, carrier vesicles 
accumulate in the Golgi prior to release. Several molecules are involved in the vesicular 
transport of TNF-containing vesicles, including the lysosomal cysteine protease cathepsin B 
(Ha et al. 2008), which is downregulated in HD109 microglia. Given the importance of the 
Golgi network in cytokine trafficking, and given the fact that several Golgi and lysosome-
associated proteins were found to be decreased in the HD109 cells, it is plausible that altered 
vesicle transport and trafficking pathways form part of the inhibitory mechanisms that 
regulate cytokine release in HD stem cell derived microglia.     
 
The hypothesis that the HD CAG expansion results in a more neuroprotective microglial 
phenotype is further supported by findings from the upstream regulator analysis, which 
predicted inhibition of several inflammatory pathways and signalling cascades in the HD109 
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microglia (see Table 4.4). In particular, the TNF and LPS pathways, previously shown to be 
dysregulated in HD patient-derived monocytes (Miller et al. 2016), were predicted to be 
inhibited, in comparison with the Kolf2 microglia cells. The NFß pathway, another 
dysregulated pathway in HD immune cells (Trager et al. 2014), was similarly predictively 
inhibited. These results imply a protective anti-inflammatory phenotype in the HD109 cells, 
in stark contrast to the cell-autonomous pro-inflammatory state of HD mouse microglia cited 
in the literature (Crotti & Glass, 2015). This discrepancy intriguingly invites questions about 
the origin of this immune dampening effect – is this effect an accurate reflection of the HD 
microglial phenotype or an artefact of in vitro differentiation? If this is an HD microglia-
specific effect, what are the mechanisms mediating it? The first question is the subject of the 
investigation in chapter 5. To answer the second question, one has to consider the crucial role 
of the brain microenvironment on the microglial phenotype.    
 
Recent studies have intimated that neuronal co-culture highly modulates the transcriptome 
of iPSC-derived microglial cells, suppressing pro-inflammatory signalling pathways relative to 
monocultures (Abud et al. 2017; Haenseler et al. 2017). Despite the lack of neuronal co-
culture in this differentiation protocol, the predicted inhibitory effects observed in our HD 
microglia dataset are evident when compared to the HD macrophage precursors upstream 
regulator analysis dataset (see appendix 4), demonstrating that the neuronal IL-34 is partly 
responsible for this particular inhibitory signal. In addition, it could be argued that in vitro 
microglia are protected from this mutant HTT-mediated priming effect due to their distinct 
ontogeny to other immune cell types. Indeed, the primitive macrophages used as precursors 
for differentiation in this protocol have been shown to arise from a MYB-independent, RUNX1 
and SPI1 lineage (Buchrieser et al. 2017) that is separate from the MYB-dependent wave of 
haematopoiesis that gives rise to monocytes and macrophages (Orkin & Zon 2008). Therefore, 
it is plausible that the distinct ontogeny of microglia combined with the immune-privileged 
nature of the CNS and the fragility of the HD brain environment mediate the immune 
dampening and inhibitory effects observed on the transcriptome of HD iPSC-derived 
microglia.   
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5. EXPLORING THE EFFECTS OF 
CORRECTING THE HD MUTATION ON 
IMMUNE DYSFUNCTION IN IPSC-
DERIVED HD MICROGLIA 
5.1 Introduction  
Huntington’s disease is a fatal neurodegenerative disorder caused by expansion of a 
polymorphic CAG repeat tract in exon 1 of the huntingtin (HTT) gene (MacDonald et 
al. 1993). Though neurodegeneration in the HD brain primarily affects medium spiny 
neurons in the striatum, mutant HTT is broadly expressed, including in immune cells 
where its levels track with disease progression (Weiss et al. 2012). Thus, mutant HTT 
expression in cells of the immune system has been suggested to contribute to HD 
neuropathology. Activation of microglia, the brain’s resident immune cells, as 
evidenced in HD post-mortem brains (Sapp et al. 2001), is not only widespread in 
symptomatic patients, but it also occurs years before disease onset in HD gene carriers 
(Pavese et al. 2006; Tai et al. 2007). Indeed, these pathological microglial changes 
mirror those reported in dysfunctional peripheral immune cells (Dalrymple et al. 2007; 
Bjorkqvist et al. 2008). Several studies have put forward convincing evidence for the 
peripheral and central immune systems acting as modifiers of HD pathogenesis. In 
2012, Kwan and colleagues showed that transplantation of WT bone marrow cells 
attenuates motor deficits, enhances synaptogenesis and lowers plasma cytokine 
levels in HD mice (W. Kwan et al. 2012). An earlier study determined that inhibiting 
the enzyme kynurenine 3-monooxygenase (KMO), a key metabolite in the kynurenine 
pathway, is neuroprotective, resulting in reduced microglial activation, attenuated 
synaptic loss and a prolonged life span in HD mice, despite the inhibitor’s inability to 
cross the BBB (Zwilling et al. 2011). Furthermore, signalling through the cannabinoid 
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receptor 2, expressed in microglia and peripheral immune cells and whose levels 
increase in post-mortem HD brains and mice, was recently shown to modulate 
immune activation (Palazuelos et al. 2009). Administration of a CB2 agonist dampened 
CNS inflammation and inhibited motor defects and synaptic loss in R6/2 HD mice 
(Bouchard et al. 2012).     
 
The development of protocols for the differentiation of human iPSCs into several cell 
types of interest has unlocked new prospects in disease modelling. Nevertheless, one 
challenge of iPSC-based disease modelling that remains is the inconsistency in 
differentiation quality due to variations in genetic background (Kajiwara et al. 2012), 
which may affect the interpretation of in vitro diseased phenotypes. Moreover, the 
impact of genetic background on observed phenotypes in iPSC-based models can be 
substantial, even for a monogenic disease like HD where numerous disease-modifying 
loci alter age of neurological onset (GeM-HD Consortium 2015). This should therefore 
encourage the use of genetically identical control iPSC lines, to increase confidence 
and authenticate observed HTT-specific mechanisms and phenotypes. For this reason, 
work carried out within our lab by Jasmine Donaldson was successful in generating 
isogenic control iPSC lines from the HD109n1 iPSC line, which is heterozygous for the 
HD mutation with one WT allele of 21 CAG repeats and an expanded allele of 109 CAG 
repeats. Using a homologous gene-targeting approach, CRISPR gRNAs were used to 
target the 5’ UTR and exon 1 sequences of the expanded HTT allele. The donor DNA 
featured a piggyBac transposon to allow a footprint-free removal of the selection 
cassette from the targeted locus. Targeted clones were identified by PCR amplification 
of exon 1 of the HTT allele, and following excision of the selection cassette by piggyBac 
transposase, correct footprint-free editing of the HD iPSCs was confirmed by Sanger 
sequencing and SNP array genotyping. In all, three isogenic HD109 corrected clones 
were generated (5H9, 3H2 and 2H1), along with a non-corrected HD iPSC line (11B11) 
that did not undergo piggyBac selection cassette to be used as an additional control 
HD iPSC line. All lines were validated for pluripotency and shown to retain a normal 
karyotype. 
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Successful correction of the HD mutation in iPSCs has been previously reported (An et 
al. 2014; Shin et al. 2016). Efforts to characterise the effects have focused on 
phenotypic abnormalities in iPSC-derived neural stem cells, namely impaired neural 
rosette formation, increased susceptibility to growth factor removal and 
mitochondrial respiration deficits (An et al. 2012; Mattis et al. 2015; Xu et al. 2017). In 
an attempt to assess the effects of HD correction on immune cell function, a study by 
the Tabrizi group used anti-HTT small interfering RNA to demonstrate that immune 
dysfunction and hyperactivity caused by NFB dysregulation can be reversed by 
reducing mutant HTT expression in patient-derived monocytes and macrophages 
(Trager et al. 2014).               
5.2 Aims  
In chapter 4, RNA-seq was used to reveal any microglia-specific transcriptome changes 
associated with mutant HTT expression in the HD109 iPSC-derived cells. Pathway 
analysis identified several immune-related functions and pathways as being 
potentially impaired or dysregulated in these cells. Following on from this earlier work, 
this chapter had two principal objectives. Firstly, isogenic control HD corrected iPSC 
lines were differentiated into microglia in order to study the effects of correcting the 
HD mutation on the gene expression changes reported in the HD109 iPSC-microglia. 
Secondly, a series of experiments aimed to investigate the predicted impaired 
functions of HD microglia, characterise any potential impairments and ascertain the 
extent to which any phenotypic abnormalities were rescued by correcting the 
Huntington disease CAG expansion.   
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5.3 Results 
5.3.1 Does correcting the HTT CAG expansion reverse the gene expression 
changes observed in HD109 iPSC-derived microglia?   
The presence of the expanded CAG track in the HTT gene resulted in widespread 
changes in the transcriptome of the HD109 stem cell-derived microglia, as described 
in chapter 4. In order to disentangle whether these transcriptional changes were 
mutant HTT-specific or due to differences in genetic background between the HD109 
and Kolf2 cells, isogenic control HD corrected iPSC lines were differentiated into 
microglia. As well as the three HD corrected clones (5H9, 3H2 and 2H1), one non-
corrected HD iPSC line (11B11) was also used as control.   
 
Initially, HD corrected microglia were assayed for expression of canonical markers by 
immunocytochemistry. As highlighted in chapter 3, treatment of macrophage 
precursors with IL-34 and GM-CSF results in robust expression of several microglial 
markers. Confocal imaging analysis of microglia derived from isogenic corrected iPSCs 
showed clearly that the IL-34 induced cells were positive for the microglial markers 
IBA1, P2RY12 as well as the leucocyte-specific CD45 (Figure 5.1). Also expressed was 
the microglia-enriched TGFBR1, a protein kinase receptor that binds the astrocyte-
derived cytokine TGF-ß (Schilling et al. 2001) shown to be essential for microglial 
development and maintenance (Abutbul et al. 2012; Butovsky et al. 2014).  
  
96  
 
 
 
 
 
 
 
 
 
 
 
Figure 5.1 HD109 Corrected and non-corrected iPSC-derived microglia express microglial 
markers and display the characteristic ramified morphology of microglia.     
(A-B) Confocal images of microglia-like cells derived from HD109 corrected lines 3H2 (A) and 5H9 (B) shows robust 
expression of MG markers IBA1, TGFBR1, P2RY12 and CD45. (C) Non-corrected HD iPSC-derived MG cells were 
cultured for 14 days in GM-CSF and IL-34, fixed and stained with P2RY12 and CD45. (D) HD109 MG cells express 
the MG-enriched protein kinase TGF-ß receptor 1. Scale bars represent 20 µm.  
 
  
A 
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Next, the expression of microglia-specific markers was analysed by Fluidigm qRT-PCR 
and results showed that genes such as C1QA, GPR34, MERTK, P2RY12 and CABLES1 
were expressed at similar levels in the HD corrected microglia compared to Kolf2 and 
isogenic HD109 cells. Although its expression was decreased compared to THP1 
monocytes, CX3CR1 followed a similar trend to other microglia sensome genes, with 
transcript levels consistent across cells of different genotypes (Figure 5.2 A-B). Also, 
two other sensome genes P2RY12 and ADORA3 found to be differentially expressed 
in the HD109 microglia after RNA-seq data analysis were expressed at comparable 
levels between the different genotypes. 
The expression of AD risk genes in the HD corrected iPSC-derived microglia was 
assessed, with CLU and CR2 being identified as differentially expressed in the HD109 
microglia compared to Kolf2. qPCR results showed that CLU expression did not vary 
markedly between the Kolf2, HD109 and HD109 corrected microglia samples. CR2 
expression was not detected in THP1 monocytes and low in the microglia samples, 
with the highest expression in the HD109 microglia and transcripts levels in the 
corrected HD109 cells matching the low levels in the Kolf2 cells. However, these 
differences did not reach statistical significance (Figure 5.2C).       
 
Findings presented in chapter 4 established that expression levels of NFB genes were 
similar in Kolf2 and HD109 microglia (see section 4.3.2). Expression of the core 
microglial transcription factor PU.1 (SPI1) and its target genes, which is increased in 
HD mouse immune cells, was equally similar. When the same genes were evaluated 
in the corrected HD109 microglia by qPCR, results established that expression of both 
sets of genes were comparable to the WT Kolf2 and HD109 microglia (Figure 5.2 D-E). 
Overall, these results are consistent with the lack of altered NFB signalling observed 
in HD109 microglia and suggest that reversal of the CAG mutation in HD microglia may 
not affect basal activation of pro-inflammatory signalling through NFB.  
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Figure 5.2 The expression of canonical microglial and NFB pathway genes is unaffected by reversal of HD CAG repeat expansion.  
Kolf2, HD109 and HD109 corrected MG cells were differentiated for 14 days in IL-34 and GM-CSF and all samples assayed by Fluidigm qRT-PCR. (A-B) No significant differences 
were found in the expression of microglia-enriched markers between HD109 corrected MG cells, Kolf2 and HD109 MG samples. (C) ABI3, CLU and CR2 were identified as DE 
in HD109 MG compared to Kolf2 by RNA-seq. Validation by qPCR shows comparable expression levels between HD109, Kolf2 and HD109 corrected samples. (D) NFB pathway 
genes are comparably expressed in HD109 and isogenic corrected MG cells. (E) Expression of the TF SPI1 and of its target genes is unaltered in HD109 and following correction 
of the CAG mutation.     
Log2 Expression normalised to reference genes. Statistical analysis by two-way ANOVA with Tukey’s multiple comparisons test. Asterisks denote significance: * < 0.05, ** < 
0.01, *** < 0.001, ns – not significant. n=3 biological replicates for all samples, except for THP1 (n=2).  
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5.3.2 Effects of correcting the HD mutation on the microglial inflammatory 
response under stimulatory conditions  
Having previously established that HD109 microglia exhibited an inflammatory 
activation profile distinct from Kolf2 WT cells, the next set of experiments aimed at 
investigating the immune response of the HD corrected iPSC-derived microglia. 14-
day-differentiated microglia derived from HD109 corrected iPSC were stimulated with 
1 µg/ml LPS for 4 hours, and the expression of pro-inflammatory markers compared 
to 4-hour LPS-treated Kolf2 and HD109 microglia. The activation profile of the 
corrected HD109 microglia was found to be consistent with that of Kolf2 and HD109 
cells, with expected increases in the M1 markers IRF1, CCR7 and ICAM1 that were 
comparable in magnitude between the corresponding unstimulated and 4h LPS 
samples; the only notable difference being that CCR7 mRNA levels post LPS were 
significantly higher in Kolf2 vs corrected HD109 cells (Figure 5.3A). The two main pro-
inflammatory cytokines TNF- and IL-1ß were upregulated after LPS stimulation in all 
three cell lines, with comparable mRNA levels post incubation (Figure 5.3B). 
Intriguingly, differences in the magnitude of these changes were again apparent, with 
a 3-fold upregulation in both genes for the WT Kolf2 and corrected HD109 microglia 
compared to a 2.5-fold increase in TNF- and IL-1ß for the HD109 cells. Inflammatory 
regulation of these two genes may therefore be an indication of the effects of 
correcting the CAG mutation on HD109 microglia. The other pro-inflammatory 
cytokines IL-8 and IL-6 were also upregulated after LPS incubation, with non-
significant variations between the genotypes (Figure 5.3C).  
The genetic background of the cells also seemed to dictate their LPS response. 
Whereas levels of the anti-inflammatory IL-10 and the pro-inflammatory CCL2 were 
unchanged in the LPS-treated Kolf2 cells, these two genes were correspondingly 
upregulated in the HD109 and isogenic corrected microglia (Figure 5.3D). Expression 
of the main anti-inflammatory cytokine IL-10 hinted at a balanced secretion of pro- 
and anti-inflammatory molecules. Fittingly, the upregulation of the chemokines CCL22 
(in Kolf2 microglia only) and CCL18 (in all three samples) after LPS exposure seemed 
to support this idea (Figure 5.3E). To illustrate the segregation between the 
unstimulated and LPS-treated samples, a principal component analysis was carried 
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out, with the results plotted using a t-distributed Stochastic Neighbour Embedding 
(tSNE) (Van Der Maaten & Hinton 2008). The resulting plot showed close proximity 
between HD corrected microglia, HD109n1 and two Kolf2 microglia samples, hinting 
at a close similarity between the unstimulated microglia (Figure 5.3F). The LPS-treated 
samples from all three cell lines formed separate clusters that segregated according 
to genotype, which suggested that LPS treatment resulted in a HD corrected 
phenotype distinct from that observed in the WT Kolf2 and HD109 microglia. This 
therefore hinted at differences between the HD109 and the corrected microglia and 
demonstrated that correction of the CAG mutation on the HD gene had an effect on 
the phenotype of microglia.  
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Figure 5.3 The LPS inflammatory response of HD corrected microglia is similar to that of HD109 microglia.   
(A) 4h LPS stimulation of HD109 corrected MG cells leads to upregulation of IRF1, CCR7 and ICAM1 comparable with Kolf2 and HD109 cells. (B) Despite a trend towards lower 
expression of TNF- and IL-1ß in corrected compared to HD109 MG, no significant differences were found in expression of both genes in the corresponding LPS-treated MG 
samples. (C) Expression of the pro-inflammatory cytokines IL-8 and IL-6 did not vary significantly between the HD genotypes following LPS incubation. (D) LPS-induced changes 
in IL-10 and CCL2 expression are dictated by the genetic background of the MG cells; expression of both genes is upregulated in both HD genotypes and unchanged in Kolf2 
cells. (E) Expression of the anti-inflammatory chemokine CCL18 is significantly increased in LPS-treated corrected MG cells and HD109 MG cells. Kolf2 MG cells upregulate 
CCL18 and CCL22 expression in response to LPS incubation.   
 
Fluidigm qRT-PCR analysis used to generate log2 Expression values normalised to reference genes. Statistical analysis by two-way ANOVA with Tukey’s multiple comparisons 
test. Asterisks denote significance: * < 0.05, ** < 0.01, *** < 0.001, ns – not significant. n=3 biological replicates for all samples.  
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(F) 4-hour LPS stimulation of Kolf2, HD109 and HD109 corrected microglia resulting in clustering effect, 
with MG samples segregating according to genotype.  
tSNE plot generated using “Fluidigm SC” package analysis of raw Ct data. Each data point represents 
one MG sample.  
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5.3.3 HD109 microglia do not manifest transcriptome-associated functional 
deficits in phagocytosis and chemotaxis 
As described in chapter 4, several KEGG pathways were predicted through impact 
analysis to be impaired or dysregulated in HD109 microglial cells. These included 
cytokine-cytokine interaction, chemokine signalling, cell adhesion and ECM-receptor 
interaction as well as phagosome. Two pathways were chosen for functional 
validation: phagocytosis (FDR= 0.035) and chemotaxis (0.029). Levels of chemokines 
such as CCL17 and CCL18 were also downregulated in HD109 microglia, with qPCR 
results confirming that only one gene followed the same trend, with negligible CCL17 
levels in the HD109 and corrected microglia compared to Kolf2. Elsewhere, transcript 
levels of CCL22 and CCL18 in HD109 and corrected cells matched those in Kolf2 cells 
(Figure 5.5A).     
 
Phagocytosis is a key function of microglia, enabling clearance of pathogens, protein 
aggregates and apoptotic cells in the CNS. Differential gene expression identified 
downregulation of several phagocytosis-promoting receptors (FCAR, FCGR2B and 
FCGR2C, C1R, ITGA2, ITGA5, MARCO) in HD109 microglia compared to Kolf2 WT 
microglia. Interestingly, genes coding for the multi-ligand scavenger receptor CD36 
and the enzyme NADPH oxidase or CYBB were upregulated. Validation of CD36 and 
CYBB expression by qPCR indicated that both genes were comparably expressed in the 
Kolf2 and HD microglia from both genotypes (Figure 5.4A). Also downregulated was 
CORO1A, a protein that initiates fusion of the phagosome to the lysosome during 
pathogen killing. These findings seemed to indicate a compensatory mechanism. To 
confirm this observation, phagocytosis of pHrodo red E. coli particles was monitored 
in real time using the IncuCyte S3 live imaging platform, which quantifies the increase 
in red fluorescence triggered by the uptake of pHrodo cells and internalisation into 
the acidic phagosome by professional phagocytes (Kapellos et al. 2016). Microglia 
from Kolf2, HD109 and HD109 corrected iPSCs were seeded on 96-well plates at 
35,000 cells per well, differentiated for 14 days and then incubated with 10 µg pHrodo 
red particles for 6 hours while confocal images were taken every 10 min. All HD 
derived microglial cells (HD109, non-corrected and corrected) displayed a higher rate 
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of uptake compared to Kolf2 microglia, indicating that they retained efficient ability 
to phagocytose bioparticles (Figure 5.4B). Interestingly, Kofl2 WT cells pre-treated 
with the phagolysosome v-ATPase inhibitor bafilomycin A1 were capable of ingesting 
the fluorescent particles, though the final count of phagocytosed particles was 
significantly reduced compared to Kolf2 and all HD genetic backgrounds (two-way 
ANOVA with Tukey’s post hoc test, p<0.0001). This was hypothesised to be due to the 
high cell density in each well (Figure 5.4C). Comparisons between the HD109n1 and 
the HD109 corrected clones showed that correction of the HD CAG mutation had no 
effect on the cells’ ability to phagocytose bioparticles, despite clonal variations in 
pHrodo E. coli bioparticle uptake. This experiment was repeated with a lower number 
of 20 000 plated cells per well (Figure 5.5D). On this occasion, pre-treatment of the 
cells with bafilomycin A1 and cytochalasin D resulted in a larger reduction in 
fluorescence signal, demonstrating that the rate of bioparticle uptake is dependent 
on cell numbers (Figure 5.4E). At the peak of around 6 hours of incubation, MG cells 
from two of the HD109 corrected clones (5H9 and 2H1) ingested more particles than 
cells derived from the isogenic HD109 line. The HD109 corrected clone 3H2 
phagocytosed less particles than cells generated from the parental HD109n1 
(p<0.0001), although this rate of phagocytosis was found to be as efficient as that of 
the HD109 non-corrected iPSC-derived microglial cells (p = 0.5897). To conclude, while 
clonal differences in the kinetics of pHrodo phagocytosis were evident, HD microglia 
have shown to be competent phagocytes of bioparticles.  
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Figure 5.4 Phagocytosis of E. coli bioparticles and chemotaxis are 
not impaired in HD109 iPSC-derived microglia.     
(A) qPCR validation of phagocytosis and chemokine transcripts shows 
expression of CCL17 and CCL22 is higher in Kolf2 MG than HD109 MG. 
CYBB and CD36 expression levels are comparable in HD109 and Kolf2 MG. 
(B) MG cells from HD109 and HD109 corrected iPSCs exhibit a higher rate 
of uptake of bioparticles than Kolf2 MG cells. MG cells were plated on a 
96-well plate at 35,000 per well and incubated with 10 µg pHrodo E. coli 
for 6 hours. For negative control, Kolf2 MG cells were pre-treated with 10 
µM bafilomycin A1 before 1hr before E. coli incubation. (C) End point 
fluorescence values from (B) were plotted. Data presented as mean ± SEM 
from each condition with 8 technical replicates. n=1 independent 
experiment. 
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 (D) HD109 corrected microglia phagocytose E. coli bioparticles as efficiently as microglia derived from the HD109 parental clonal line. MG cells were plated at 20,000 cells 
per well. HD109 MG cells were pre-incubated with 10 µM cytochalasin D for 1hr before E. coli treatment. End point fluorescence values were plotted in (E). Data presented 
as mean ± SEM from each condition or genotype with 8 technical replicates. n=2 independent experiments.     
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(F) HD109 and HD109 corrected MG cells display efficient cell migration in response to stimulation with CX3CL1. (G) End point (12h) values for top membrane index show 
that compared to cytochalasin D-treated MG cells, HD109 and HD109 corrected microglia retain proper chemotactic functions. (H) Chemotactic response of MG cells to ADP 
is unaffected in HD1009 iPSC-derived microglia.       
For pHrodo E. coli phagocytosis assays, red channel fluorescence (400ms) was measured every 10 mins in an IncuCyte S3 live imaging platform. Data was analysed using the 
IncuCyte S3 Base software (see section 2.5.3 for analysis parameters).   
For chemotaxis assays, MG cells were plated and differentiated for 14 days on the upper chamber of 96-well ClearView chemotaxis plates. Cells were stimulated with 200 
ng/ml CX3CL1 or 8 µM ADP to induce migration to the lower chamber of the chemotaxis plate. Phase channel images were taken using IncuCyte S3 every 30 mins for 12-24 
hours and quantified by IncuCyte analysis software. n=1 independent experiment.         
 
Statistical significance was tested using two-way ANOVA with Tukey’s multiple comparisons test. * < 0.05, ** < 0.01, *** < 0.001, **** < 0.0001, ns – not significant. n=1 
independent experiment. 
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Kwan et al. 2012 revealed using myeloid cells isolated from premanifest HD patients 
and early postnatal mouse microglia overexpressing mutant HTT that immune cells 
display mHTT-dependent deficits in migration to chemotactic stimuli. In order to 
characterise any potential impairments in chemotaxis in HD109 iPSC-derived 
microglia, cell migration assays were carried out using the IncuCyte S3 platform (see 
section 2.5.3). Microglial cells from Kolf2, HD corrected and HD109 iPSCs were 
differentiated for 14 days on a 96-well ClearView Chemotaxis, where each well is 
made up of a membrane that contains a lower and upper chamber. Cells are required 
to migrate across the membrane, through 8µm pores to reach the lower chamber, a 
process visualised and quantified in real-time by the IncuCyte analysis software. 
Migration in response to two chemoattractants, CX3CL1 and ADP was assayed. Cells 
stimulated with 200 ng/ml CX3CL1 were shown to be responsive to the chemotactic 
stimulus (Figure 5.4F), as shown by the reduced top membrane index (Figure 5.4G). 
When compared to cytochalasin D-treated MG HD 109 cells, all cell lines were found 
to be efficient at cell migration through the membrane. Interestingly, no significant 
variations in response were found between the HD109 and the corrected iPSC-derived 
microglia. Chemotactic response to ATP was then investigated. Along with CX3CL1, 
sphingosine-1-phosphate (S1P) and lysophosphatidylcholine (lysoPC), ATP and other 
nucleotides are so called “find-me signals” released by cells undergoing apoptosis that 
attract phagocytes towards them (Lauber et al. 2004). Chemotactic response of the 
HD MG cells to 8 µM ADP was quantified and results showed no statistically significant 
differences in the migration of HD109 and HD109 corrected microglia compared to 
Kolf2 WT microglia (Figure 5.4H). Overall, these results suggest that migration and 
regulation of actin remodelling of HD iPSC-derived microglia is not impaired, with no 
rescue effect of the CAG expansion excision on those properties.           
 
5.3.4 HD109 microglia do not exhibit deficits in mitochondrial respiration 
associated with other HD cell types  
Mitochondrial dysfunction has been strongly implicated in HD pathogenesis, with 
impairments in ATP production, mitochondrial basal respiration and glycolysis among 
early reported disturbances in the HD brain (Damiano et al. 2010; Costa & Scorrano 
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2012). Studies in mouse models and post-mortem human brains have described 
mitochondrial impairments in several HD cell types, e.g. primary lymphoblasts, 
fibroblasts and striatal cells (Polyzos & Mcmurray 2017) and stem cell-derived neural 
stem cells (An et al., 2012; Xu et al. 2017). To date, impairments in HD microglia have 
not been extensively reported or characterised. Given the metabolic demands that 
homeostatic and immune functions place on microglia (Cherry et al. 2014), an 
investigation of the bioenergetics profile of HD109 microglia was performed to initially 
compare it to that of WT Kolf2 microglia (Figure 5.5A). For this series of preliminary 
experiments, microglial cells from Kolf2, HD109 and corrected HD109 iPSC lines were 
differentiated in Seahorse XF96 plates and responsiveness to the mitochondrial 
stressors oligomycin, FCCP and rotenone measured to calculate the oxygen 
consumption rate (OCR). The Seahorse XF Cell Mito Stress Test protocol was used (see 
section 2.5.4), which allows the assessment of different aspects of mitochondrial 
respiration, including basal respiration, maximal respiration, spare respiratory 
capacity and ATP production.  
Though earlier results had hinted at the HD109 MG cells exhibiting a lower basal 
respiration rate, the preliminary examinations presented here showed that basal 
respiration was similar between the WT and HD109 microglial cells (Figure 5.5B). 
Microglia derived from the HD109n1 clonal line seemed to exhibit a greater 
mitochondrial spare respiratory capacity compared to cells derived from Kolf2, 
HD109n4 and HD109n5 lines, with a similar pattern emerging in the maximal 
respiration OCR rates between the lines (Figure 5.5C). ATP production rates were also 
comparable between the HD109 and Kolf2 WT MG cells (Figure 5.5D).  
Similarly, the profile of HD corrected iPSC-derived microglia was compared to that of 
HD109n1, the parent clonal line (Figure 5.5E), with preliminary data showing small 
increases in maximal respiratory capacity for two out of three clones (Figure 5.5F), but 
no changes in ATP production or basal respiration (Figure 5.5 G-H). Taken together, 
these preliminary results into the bioenergetics profile of iPSC-derived microglia 
suggest that mitochondrial function may not be impaired in the HD109 microglia. 
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Figure 5.5 Preliminary results show that mitochondrial oxidative phosphorylation is unimpaired in HD109 iPSC-derived microglia.       
MG cells (20,000 per well) were plated and differentiated on Seahorse XF 96-well plates. Oxygen consumption rate (OCR) was measured with sequential injections of 2 µM 
oligomycin, 2.5 µM FCCP and 0.5 µM antimycin A & rotenone. (A-D) Measurements of basal respiration and ATP production show no differences between HD109 and Kolf2 
MG cells. MG cells derived from HD109n1 iPSCs seemed to show greater maximal respiration rate than WT Kolf2 MG cells. Data presented as mean ± SEM from each 
genotype with at least 8 technical replicates; OCR measures normalised to absorbance at 560 nm; n=1 independent experiment.  
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(E-H) Mitochondrial basal respiration, maximal respiration and ATP production rates in HD109 corrected microglia are comparable to measurements in the microglia cells 
derived from the parental clonal line HD109n1. n=1 independent experiment.        
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A complex interplay exists between the immune response and the major metabolic 
pathways of glycolysis, the TCA cycle, fatty acid synthesis and oxidation, amino acid 
metabolism and the pentose phosphate pathway. In particular, changes in the 
metabolites of these pathways have been shown to regulate the innate inflammatory 
response (Galván-peña & O’Neill 2014; O’Neill et al. 2016). For example, Tannahill et 
al. 2013 showed that LPS stimulation of mouse macrophages causes an increase in 
intracellular levels of the TCA cycle intermediate succinate, which subsequently drives 
production of IL-1ß (Tannahill et al. 2013). Stimulation by LPS, which results in an M1 
phenotype and is associated with expression of pro-inflammatory cytokines, is 
accompanied by a shift from oxidative phosphorylation to glycolysis for energy 
production, called the Warburg effect (López-Lázaro 2008). A second aspect of this 
shift during inflammation is mitochondrial dysfunction, whereby mitochondria are 
reprogrammed by undergoing fission, which induces formation of ROS and other 
inflammatory mediators such as NFB (Park et al. 2013; Park et al. 2015). To 
investigate mitochondrial contribution to the energetic demands concurrent with 
inflammation, preliminary experiments were undertaken to study the effects of LPS 
stimulation on the bioenergetics of microglia. Cells were plated and differentiated on 
Seahorse XF96 plates for 14 days. After differentiation, the microglia were stimulated 
in situ with 1 µg/ml LPS for 4 hours before measurements of mitochondrial respiration 
(Figure 5.6A). LPS challenge was found not to cause any changes in ATP production or 
basal respiration in the respective HD109 and Kolf2 microglial cells (Figure 5.6 B-C). A 
similar pattern was observed with microglia derived from the HD corrected iPSC lines 
(Figure 5.6 D-F). When comparing challenged and unstimulated cells, LPS stimulation 
only resulted in subtle differences in the maximal respiration rates (Figure 5.6E). Taken 
together, these preliminary experiments appear to indicate that LPS activation of in 
vitro microglia does not result in deficits in mitochondrial respiration.   
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Figure 5.6 LPS stimulation of iPSC-derived microglia does not seem to impair mitochondrial respiration.       
MG cells (20,000 per well) differentiated on Seahorse XF 96-well plates were stimulated with 1 µg/ml LPS for 4 hours before OCR measurements. (A-C) Measurements of 
basal respiration and ATP production in HD109 and Kolf2 MG cells show that LPS stimulation does not affect mitochondrial function in iPSC-derived microglia. (D-F) Preliminary 
comparisons of mitochondrial respiration measures between HD109 and HD109 corrected microglia suggest that mitochondrial function is unchanged following LPS 
stimulation.  
 
Data presented as mean ± SEM from each genotype with at least 8 technical replicates; OCR measures normalised to absorbance at 560 nm; n=1 independent experiment.  
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5.4 Summary and Discussion  
As described in chapter 4, pathway impact analysis of changes in the transcriptome 
HD109 microglia predicted potential impairments in crucial immune functions such as 
chemotaxis, antigen processing and presentation, phagocytosis. The work undertaken 
in this chapter was thus based on these transcriptomic findings and experiments were 
carried out to characterise any phenotypic and functional abnormalities in the HD109 
microglia. In parallel, isogenic control HD corrected iPSCs, generated by CRISPR-Cas9 
and piggyBac transposon editing, were used to derived microglia, with the aim of 
establishing the extent to which any functional abnormalities observed in the HD109 
microglia could be rescued by correction of the HD CAG expansion mutation.  
 
Differential gene expression of RNA-seq data highlighted decreased expression levels 
of several phagocytosis-associated transcripts in HD109 microglia, prompting 
questions about whether these expression changes could translate to an observed 
phenotype. This was assayed with pHrodo E. coli particles, where no functional 
abnormalities in the HD109 microglia were apparent. The lack of phenotypic 
manifestations of these transcriptional changes was first suggested to be due to the 
likely compensatory upregulation of CD36, CORO1A and CYBB, key genes in the 
phagocytosis pathway. Indeed, the scavenger receptor CD36 is crucial to engagement 
of apoptotic particles and the subsequent actin cytoskeleton signalling that facilitates 
phagocytosis (Stuart et al. 2007). In addition, it has been shown to mediate 
phagocytosis through interactions with TLRs (Erdman et al. 2009). However, qPCR 
validation of CD36 and CYBB revealed that mRNA levels of these two genes were 
similar in the Kolf2 and HD109 microglia. Alternatively, the absence of observed 
phagocytosis deficits may reflect the relatively young age of the microglial cells in the 
monocultures. Since iPSC microglial differentiation mimics embryonic 
haematopoiesis, it is conceivable that these phenotypic abnormalities would not 
manifest at the embryonic stage of microglial development, but rather later as the 
cells age and mature. Another point to consider is that phagocytosis has been shown 
to differ according to macrophage polarisation, whereby a slower rate of phagosome 
acidification and maturation is thought to facilitate antigen presentation (Canton 
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2014). Thus, it could be hypothesised that any phagocytic deficits in the HD109 
microglia would become more apparent upon stimulation with LPS for example. 
Likewise, these deficits could be more evident in the inflamed environment of the HD 
brain, using viable humanised transgenic mouse models. 
 
Similarly, cell migration in response to a chemotactic gradient was not altered in the 
HD109 microglia. Given that these microglial functions were intact in the HD109 
microglia, it was unsurprising to discover that cells derived from corrected HD iPS cell 
lines did not exhibit any impairments when chemotaxis was assayed in response to 
CCL5, ADP and CX3CL1. Despite transcriptomic evidence pointing to the contrary, 
these findings indicate that the CAG track expansion in the HTT gene is unlikely to 
impact the phagocytosis and chemotaxis-associated homeostatic functions of HD 
microglia. However, these results should also be analysed in the context of a recent 
study by Galatro et al. 2018, which analysed the transcriptome of human microglia 
isolated from aged patients and identified several age-related transcriptional changes 
in genes associated with actin cytoskeleton dynamics and cell motility. This could 
mean that ultimately the HD cells have either adapted to their transcriptome or, as 
with the prediction of phagocytic deficits, that the embryonic nature of the HD109 
iPSC-derived microglia is masking manifestations of any potential deficits. Ultimately, 
these findings demonstrate that HD iPSC-derived microglia-like cells are competent 
immune cells capable of phagocytosis and chemotaxis.      
 
There is currently little published data on the direct contribution of metabolic 
pathways to in vivo microglial function, an important area of research, given recent 
mouse model findings that variations in metabolic and bioenergetic pathways 
contribute to regional diversity in microglial population (Grabert et al. 2016). 
Furthermore, mitochondrial dysfunction has been strongly implicated in HD 
pathogenesis, with impairments described in several HD cell types but not microglia 
(Polyzos & McMurray 2017). The hypothesis that HD microglia would exhibit potential 
mitochondrial deficits was investigated in preliminary experiments, with the assay 
results suggesting that in vitro HD microglia did not present deficiencies in 
mitochondrial respiration. This implies that impairments in mitochondrial function 
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may be due to cell type specific effects of mutant HTT. These findings are in contrast 
to reports of impairments in HD iPSCs and iPSC-derived neural precursor cells (Xu et 
al. 2017). However, these results seem to align with our transcriptomic data where we 
found no differences in the expression of genes required for glycolysis and oxidative 
phosphorylation were found in the HD109 microglia dataset compared to Kolf2. They 
also confirm the intact metabolic capacity of HD109 microglia and are in agreement 
with other functional data proving the competency of HD microglia in phagocytosis, 
chemotaxis and inflammatory response. Exploratory mito stress results showed no 
changes in OCR levels in response to LPS activation, indicating that microglia maintain 
mitochondrial function under inflammatory stimulatory conditions in vitro. This 
suggests that the bioenergetic profile of human iPSC-derived microglia is distinct from 
that of mouse microglia (Orihuela et al. 2016; Park et al. 2013; Park et al. 2015) and 
macrophages (Everts et al. 2012; Everts et al. 2014). In those cells, inflammatory 
stimulation is characterised by a metabolic shift towards glycolysis for energy 
production, whereas preliminary results from proton efflux rate experiments hinted 
that microglia undergo a less pronounced glycolytic shift under stimulatory conditions 
(data not shown).  
 
Aberrant NFB signalling, which is mediated by mutant HTT transcriptional activity, is 
a widely reported feature of HD immune cells. In particular, mHTT expression leads to 
increased expression and transcriptional activity of the transcription factor PU.1 (SPI1) 
and results in higher expression of SPI1 target pro-inflammatory genes such as Il6, Irf1, 
Tnf and Tlr2 in microglia isolated from new-born R6/2 mice, with similar findings 
reported in primary microglia derived from Q175/Q175 mutant mice (Crotti et al. 
2014). Fluidigm qRT-PCR was therefore used to validate expression of genes belonging 
to this pathway, with comparisons made between Kolf2, HD109 and HD corrected 
microglial cells. It was found that expression of NFB pathway and SPI1-target pro-
inflammatory genes in the HD109 corrected were expressed at comparable levels to 
those in WT Kolf2 and HD109 microglia. Notably, these results were consistent with 
findings of a lack of pro-inflammatory NFB-mediated signature in the HD109 iPSC-
derived microglia, as described in chapter 4.  
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Mutant HTT expression in mouse models has been shown to have several other cell-
autonomous effects on immune cells. These include a priming effect, such that the 
cells exhibit an exaggerated inflammatory response to exogenous stimuli (Crotti & 
Glass 2015). The same priming effect has been recapitulated in HD patient-derived 
monocytes (Miller et al. 2016). However, qPCR data from the LPS stimulation 
experiments revealed an activation profile similar to that of microglia derived from 
the parental clonal line HD109 iPSCs (Figure 5.3). Yet, principal component analysis of 
the LPS-treated samples showed a separation between HD corrected and HD109 LPS-
treated samples, hinting at slight differences in the immune response of the cells. 
Given that the unstimulated HD corrected microglia clustered together with the 
HD109 microglia, these overall findings suggest that correction of the HTT gene CAG 
mutation did impact on the phenotype of the HD microglia, with these effects evident 
only after inflammatory stimulation.  
Moreover, the LPS experiments indicated that aspects of the immune response of the 
in vitro microglia varied according to the genetic background of the cells. For example, 
whilst unaffected in the HD genotypes, LPS stimulation in the Kolf2 microglia led to 
increased expression of the CCR4 agonist CCL22, an inflammatory chemokine 
associated with M2 polarisation expressed by various cells (Mantovani et al. 2004). 
Likewise, this was noted for the M2a-associated chemokine CCL17 (data not shown), 
which also binds to CCR4 and is induced by production of IL-10 to inhibit M1 activation 
(Katakura et al. 2004). These observations may reflect a genotype-specific divergent 
regulation of immune response in microglia. Still, despite these genetic background-
related differences, there were parallels in the LPS response of the three cell lines, 
centring around the upregulation of activation markers such as ICAM1, IRF1 and CCR7, 
and the pro-inflammatory molecules IL-8 and IL-6. In this regard, the response from 
all three cell lines exhibited a consistent M1 activation profile. Logically, this variability 
in microglial immune response across different iPSC lines highlights the need for 
careful thought and planning of experiments, especially those involving the use of 
non-isogenic control-matched iPSC models.         
LPS exposure was also found to elicit expression of CCL18, induced by anti-
inflammatory cytokines such as IL-4, IL-13 and IL-10 (Politz et al. 2000). The presence 
of this anti-inflammatory signature in an overall pro-inflammatory environment 
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suggests that the gene expression changes evident in the results do not take into 
account and/or may mask the immune response and behaviour at the single cell level. 
It is likely, that individual cells or a subpopulation of cells are driving the expression of 
specific anti-inflammatory mediators. In addition, based on the prediction of potential 
inhibition of specific inflammatory pathways in HD microglia, it may transpire that the 
transcription and inhibitory nuances sought after are more apparent at the level of 
the single cell, but may be masked overall. Therefore, future experiments should 
endeavour to investigate the transcriptome of LPS-treated HD109 and HD corrected 
iPSC-derived microglia at the single cell level, in combination with comparisons of bulk 
samples of HD corrected and HD109 iPSC-derived microglia. In addition, a proteomics 
approach using mass spectrometry analysis of culture supernatants could be 
integrated to these experiments, by assessing whether any gene expression changes 
observed at the transcriptomic levels match protein and cytokine expression at the 
level of the secretome.  
 
Finally, it should be noted that while the results described herein have considered the 
downstream effects of their immune response, the transcriptomic data hinted at 
complex changes upstream of HD microglia’s immune response genes. These could 
include transcription factor interactions and regulatory gene networks, which could 
be the focus of future transcriptomic studies of HD109 and corrected iPSC-derived 
microglia. Several analysis tools are available to help with these imputations, for 
example weighted gene co-expression network analysis or WGCNA, which can be used 
for finding clusters of highly correlated genes and identifying patterns of expression 
(Langfelder & Horvath 2008). Another example is the Bioconductor package 
CoRegNet, which analyses large-scale gene expression datasets and imputes the 
transcriptional co-regulator networks responsible. It integrates data from ChIP and TF 
binding sites (Nicolle et al. 2015). These packages could be used in conjunction with 
the upstream regulator analysis from IPA to build a more complete map of the 
transcriptional changes specific to the HD microglia.
119  
6. INVESTIGATION OF THE EFFECTS OF 
ABCA7 LOSS-OF-FUNCTION IN 
HUMAN IPSC-DERIVED MICROGLIA
6.1 Introduction  
Phagocytosis is an important and highly complex process central to several biological 
processes, including development, tissue homeostasis and innate immunity. 
Mechanistically, it involves the recognition and ingestion of particles larger than 0.5 
µm into membrane-bound vacuolar structures known as phagosomes. It is primarily 
performed by professional phagocytes, a subset of cells that comprises monocytes, 
macrophages, dendritic cells, neutrophils, eosinophils and osteoblasts (Rabinovitch 
1995). Phagocytes express a spectrum of distinct receptors that mirrors the diversity 
of particles they encounter, ranging from foreign pathogens such as bacteria and yeast 
to apoptotic cells.  
As the resident phagocytes of the CNS, microglia express a range of PRRs, 
PAMPs and DAMPs (see section 1.2.4) that facilitate particle recognition, engagement 
and initiation of appropriate downstream signalling. Their phagocytic ability is thus 
crucial in modulating their response to apoptotic or damaged neurons (Stolzing & 
Grune 2004; Fraser et al. 2010), harmful protein aggregates such as amyloid beta (Ard 
et al. 1996), as well as the capacity to shape neural circuits (Paolicelli et al. 2011; 
Schafer et al. 2012). Following on from the notion of microglial phagocytosis being 
essential to normal brain health, variants in phagocytosis-related genes such as 
TREM2 and CD33 have been identified as risk factors for Alzheimer’s disease 
(Kleinberger et al. 2014; Griciuc et al. 2013).  
 
First identified as a risk factor for AD by two genome-wide association studies in 2011 
(Naj et al. 2011; Hollingworth et al. 2011), and later by Lambert et al. 2013, ABCA7 is 
one of four risk loci significantly associated with plaque burden in Alzheimer’s disease, 
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alongside CR1, APOE and CD2AP (Shulman et al. 2013). The common ABCA7 GWAS 
risk allele rs3764650G, located in intron 13, is associated with reduced expression in 
the brain and increased plaque burden (Vasquez et al. 2013), suggesting that lower 
levels of ABCA7 protein may underline increased disease risk. Fittingly, rare loss-of-
function coding variants were found in a Belgian cohort by Cuyvers et al. 2015, 
demonstrating that several ABCA7 coding mutations segregate with disease in an 
autosomal dominant manner. Some of these findings were replicated in an Icelandic 
cohort (Steinberg et al. 2015), while a recent study by the European Early-Onset 
Dementia consortium identified ten novel deleterious ABCA7 mutations (Figure 6.1) 
(Roeck et al. 2017). Le Guennec et al. 2016 performed a meta-analysis of recently 
published data from France and Belgium cohorts to find that ABCA7 rare loss-of-
function variants of ABCA7 account for around 3% of AD cases (Le Guennec et al. 
2016). These and more recent early onset AD findings from  Bellenguez et al. 2017 
provide strong genetic evidence that ABCA7 mutations significantly contribute to AD 
risk (Bellenguez et al. 2017).  
 
Figure 6.1 Schematic representation of rare loss-of-function variants in ABCA7.  
Loss-of-function variants identified by Steinberg et al. 2015, Cuyvers et al. 2015 and Roeck et al. 2017.  
fs denotes frameshift mutations; * denotes nonsense mutations. Figure adapted from Cuyvers et al. 
2015; Aikawa et al. 2018.  
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ABCA7 encodes ATP-binding cassette transporter A7, a member of the ABC 
transporter superfamily involved in the transport across cell membranes of a variety 
of substrates ranging from small molecules such as amino acids and sugars to larger 
compounds including peptides, oligonucleotides and lipids (Dean & Annilo 2005). Its 
expression can be detected in several tissues including thymus, spleen and the brain, 
where it is most abundant in microglia (Kim et al. 2006). Structurally, ABC transporters 
are organised into four functional units: two nucleotide-binding domains (NBDs) and 
two transmembrane domains (TMDs). The NBDs or ATP-binding cassettes are highly 
conserved in sequence and structure across all ABC transporters, with each composed 
of seven motifs that include the Walker A, Walker B and ABC signature LSGGQ motif 
(Beek et al. 2014). The -helices of the two TMDs are arranged such that they form a 
transmembrane pore accessible either from the cytoplasm (inward-facing 
conformation) or the outside of the cell (outward-facing conformation) (Rees et al. 
2009).  
 
ABCA7 has previously been shown to regulate phagocytosis of apoptotic cells. Jehle et 
al. 2006 demonstrated that Abca7+/- mice-derived macrophages exhibit a deficiency in 
the phagocytosis of apoptotic Jurkat T cells and neutrophils. Similarly, Iwamoto and 
colleagues have shown that siRNA-knockdown of ABCA7 in BALB/3T3 fibroblasts 
significantly reduces phagocytic activity (Iwamoto et al. 2006). Studies assessing 
ABCA7 function in AD mouse models have shown that ABCA7 deletion increases 
amyloid plaque load (Kim et al. 2013; Li et al. 2015; Sakae et al. 2016). Importantly, 
ABCA7 deficiency has been shown to impair Aß phagocytosis in mouse macrophages 
and microglia, suggesting that ABCA7 may play a role in phagocytic clearance of 
amyloid from the brain. However, given the lack of direct mechanistic evidence for 
the link between ABCA7 and microglial phagocytosis, more work is required to further 
our understanding of the role of ABCA7 in microglia and of its contribution to the 
pathogenesis of Alzheimer’s disease.   
6.2 Aims  
The objective of this chapter was to investigate the function of ABCA7 in human 
microglia derived from iPSCs. ABCA7 single and double allele KO iPSC lines were 
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generated by CRIPSR-Cas9 genome editing and validated. Microglia were 
subsequently differentiated from the successfully generated ABCA7-edited clones and 
the cells used to analyse the effects of these ABCA7 mutations on phagocytosis, 
immune response and lipid metabolism.  
6.3 Results 
6.3.1 Generation of ABCA7 KO iPSC lines by CRIPSR-Cas9   
The full length (type I) ABCA7 encodes a protein of 2146 amino acids (Abe-Dohmae et 
al. 2006). Ikeda et al. 2003 detected a splicing variant of the protein (designated type 
II), with a translation initiation codon between exon 5 and 6 of the full-length isoform. 
This novel N-terminus in type II ABCA7 is thought to affect both the size, subcellular 
localisation and lipid release function of the protein. To generate a loss-of-function 
allele of ABCA7 in iPSCs, two CRISPR guide RNAs were designed to target the coding 
exons 2 (Ex2P1) and 8 (Ex8P1) in the N-terminus of the protein. The guide RNAs were 
chosen as they were predicted to have no potential off-target sites – this was 
confirmed by using the Cas-OFFinder algorithm (Bae et al. 2014) 
(http://www.rgenome.net/cas-offinder/). In addition, this combination of gRNAs 
would result in a successful excision of a 2.4kb region at the 5’ end of the gene and a 
subsequent frameshift mutation (Figure 6.2A).   
Following transfection and the first round of single colonies picking and screening (see 
section 2.8.2), 9 clones were initially identified as potential ABCA7 positive KO by PCR 
screening, from which four (2G, 7G, 11H and 12H) were chosen for sub-cloning onto 
10 cm culture dishes (Figure 6.2B). A total of ~ 200 single sub-clones were picked from 
this pool (48 colonies per clones) and PCR screened for successful ABCA7 excision. A 
number of potential KO positive sub-colonies were identified by PCR screen, from 
which 4 mutant clones were expanded and re-screened to confirm excision of the 
intervening DNA between exons 2 and 8 (Figure 6.2C). The PCR fragments from these 
screens were sequenced to reveal the Cas9 cleavage sites on ABCA7 exon 2 and exon 
8 loci. Sequencing results revealed a great degree of variability in the Cas9 cleavage 
sites between clones. Cleavage resulted in identical sequences for two clones 11H-7C 
and 11H-11B, with the Cas9 cleaving the target sequence 5 base pairs upstream of the 
PAM sequence and the insertion of two base pairs (Figure 6.2D). In both cases, the 
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mutation would result in a premature stop codon. Sequencing for the third single KO 
clone 11H-9G showed the Cas9 cut site to be 3 base pairs upstream of the PAM 
sequences in both exons 2 and 8 (Figure 6.2E), resulting in a frameshift mutation, as 
verified using the CRISPR-mediated indel detection tool CRISPR-ID (Dehairs et al. 
2016).   
 
ABCA7 double KO alleles were generated using the same strategy, by submitting the 
ABCA7 heterozygous clone 11H-11B to a round of transfection, picking and screening, 
followed by sub-cloning and expansion of potential double KO positive clones. PCR 
screening showed the presence of single 500 bp bands indicative of successful excision 
of the target region between the exons 2 and 8 of ABCA7 gene (Figure 6.2F). The 
double KO clones identified in this way were subsequently sequenced: clones T2-9G 
and T2-11B returned similar sequences, as shown in Figure 6.2G. On the other hand, 
sequencing for the T2-1F and T2-1G clones revealed the Cas9 cut site for the exon 8 
Ex8P1 guide RNA to be located three base pairs upstream of the PAM site, with the 
exon 2 cut site five base pairs upstream of the CGG sequence (Figure 6.2H). To further 
differentiate between heterozygous and homozygous ABCA7 mutants, an additional 
PCR screen was carried using the Ex2F forward primer and Ex2R reverse primer, which 
binds in the guide RNA-targeted region (Figure 6.2I). PCR products of 800 bp could be 
detected for WT Kolf2 and ABCA7+/- cells, with no bands detected for the homozygous 
clones T2-1F, T2-9G and T2-11B.         
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Figure 6.2 CRISPR/Cas9-edited generation of ABCA7 knock out mutants in Kolf2 iPS cells.   
(A) Guide RNAs (Ex2P1 and Ex8P1) were designed to target exons 2 and 8 at the N-terminal end of ABCA7 in Kolf2 iPSCs. Successful Cas9 cleavage would result in deletion of 
a 2.4kb region that could identified by PCR screen using Ex2F and Ex8R primers flanking the target DNA sequence to give a knock out PCR fragment of 500 bp and WT fragment 
of 2400 bp. (B) Following transfection and picking of single colonies in a 96-well plate, 9 clones were identified as potential KO clones by the initial PCR screening – targeted 
efficiency of 9%. From those potential clones, four (2G, 7G, 11H and 12H) were selected for sub-cloning on 10 cm TC dishes and single colonies picked for further screening. 
(C) 200 sub-clones were picked and screened, with four 11H sub-clones identified as potential ABCA7+/- mutants. (D) Sequencing analysis showed Cas9 cleavage sites for 11H-
7C and 11H-11B ABCA7+/- mutants were 5 bp upstream of PAM sites, with 2 bp insertion. The mutated DNA sequence would result in the insertion of a premature stop codon 
in the translated protein.  
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(E) Sequencing for the ABCA7+/- mutant 11H-9G revealed the Cas9 cleavage sites to be 3 bp upstream of the PAM sites, leading to a frameshift mutation. (F) ABCA7-/- mutants 
were generated by transfecting the heterozygous mutant 11H-11B, followed by colony picking and sub-cloning. PCR screening identified seven T2 homozygous clones, by the 
presence of 500 bp bands of stronger intensity than the heterozygous 11H ABCA7+/- mutants. (G-H) Sequencing analysis of the homozygous T2 clones identified variability in 
the Cas9 cleavage sites between the different clones. (I) PCR screens revealed differences between ABCA7 heterozygous and homozygous clones, using the Ex2R reverse 
primer that binds in the guide RNA-targeted region. For heterozygous clones, the reaction would yield a PCR product of 800bp while no band would be produced for 
homozygous clones.    
 
I 
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6.3.2 Validation of ABCA7-edited iPSC-derived microglial cells  
Having generated the ABCA7 mutant iPSC lines, microglia were derived from the 
edited iPS cells before the expression of canonical MG markers was confirmed by 
immunostaining (Figure 6.3 A-B). Expression of MG-specific transcripts CABLES1, 
C1QA and GPR34 was also measured by qPCR, with comparisons showing significant 
upregulation in the microglial samples compared to THP1 monocytes and comparable 
expression across the ABCA7 genotypes (Figure 6.3C). Validation of protein expression 
in the ABCA7-edited MG cells by immunocytochemistry and western blotting was 
attempted over the course of the study, but no suitable antibodies could be found. As 
a result, Fluidigm qRT-PCR analysis was used to assess reduction of ABCA7 mRNA 
expression in the ABCA7 mutant microglia generated from the heterozygous KO 
clones 11H-7C and 11H-11B as well as the homozygous KO clones T2-1G, T2-9G and 
T1-11B. Principal component analysis showed a clear separation between samples 
from the double KO microglia and Kolf2 WT microglia, while the ABCA7+/- mutants 
segregated with the Kolf2 WT samples (Figure 6.3D). Gene expression results revealed 
no significant differences in the ABCA7 mRNA levels between the samples, although 
there was a trend towards lower expression in the homozygous KO samples (Figure 
6.3E). ABCA7 shares sequence homology with ABCA1, the ATP cassette transporter 
essential for the regulation of intracellular cholesterol levels (Kaminski et al. 2000). 
The potential for a compensatory upregulation of ABCA1 after ABCA7 deletion was 
also investigated, with results showing that ABCA1 expression levels did not differ 
between WT and ABCA7-edited MG cells (Figure 6.3E).       
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Figure 6.3 Microglia derived from ABCA7+/- and ABCA7-/- iPSCs express canonical microglia markers.   
(A) Confocal images of ABCA7+/- microglia-like cells positive for P2RY12 and CD45. (B) Differentiation of ABCA7-/- clones generated TMEM119+ IBA1+ iPSC-derived microglia. 
Scale bar represents 20 µm. (C) Expression of microglia-enriched genes C1QA, GPR34 and CABLES1 in microglia differentiated from ABCA7-edited Kolf2 iPSCs was validated 
by Fluidigm qPCR. (D) Cluster analysis revealed that ABCA7-/- samples segregated away from WT and ABCA7+/- samples.    
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 (E) ANOVA comparisons revealed no significant differences in ABCA7 mRNA expression between 
ABCA7+/-, WT and ABCA7-/- Kolf2 microglia. Levels of the related ATP transporter ABCA1 were similarly 
unchanged in the ABCA7-edited MG cells. Log2 Expression normalised to reference genes. Statistical 
analysis used two-way ANOVA with Tukey’s multiple comparison test. Asterisks denote statistical 
significance: * < 0.05, ** < 0.01, *** < 0.001, ns – not significant. n=3 biological replicates for all 
samples, except for THP-1 (n=2), Kolf2 ABCA7+/- MG (n=2).      
 
Next, the impact of the ABCA7+/- mutations generated on the microglial immune 
response was investigated. ABCA7+/- cells were differentiated on 6-well plates for 14 
days and stimulated with 1 µg/ml LPS for 4 hours or 50 ng/ml IL-4 for 24 hours. Under 
control unstimulated conditions, both ABCA7+/- and WT MG cells expressed 
comparable mRNA levels of M1 activation markers. Following LPS treatment, only 
three markers CCR7, TNF- and IL-1ß were significantly upregulated in the Kolf2 
ABCA7+/- cells vs control ABCA7+/- cells (p < 0.01) (Figure 6.4A). In contrast, transcript 
levels of several other activation markers were significantly upregulated in the LPS-
treated WT Kolf2 cells (p < 0.001), including the chemokines IL-8, CCL18 and CCL22 (p 
< 0.01) and the inflammation-induced adhesion molecule ICAM1 (Figure 6.4B). This 
suggests that though the LPS-treated cells displayed the classical M1 phenotype, the 
ABCA7 mutations restricted the magnitude of the induced pro-inflammatory 
response.  
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Figure 6.4 The inflammatory response of iPSC-derived microglia to LPS and IL-4 stimulation is influenced by ABCA7 deleterious mutations.   
(A) Stimulation of Kolf2 ABCA7+/- MG cells with 1 µg/ml LPS for 4 hours resulted in increasing expression of three M1 markers, TNF-, IL-1ß and CCR7. Compared to WT 4h 
LPS-treated MG cells, this pro-inflammatory response was markedly restrained, as demonstrated by higher expression levels of those three genes in the corresponding 
Kolf2 WT LPS samples. (B) Expression of ICAM1, IL-8, CCL18 and CCL22 was unchanged in the ABCA7-edited MG cells after the same LPS challenge, whereas the same genes 
were significantly upregulated in 4h LPS-stimulated WT MG cells. (C) Kolf2 WT and ABCA7+/- MG cells were stimulated with 50 ng/ml IL-4 for 24 hours. Cluster analysis 
showed that the M2 phenotype of ABCA7-edited IL-4 treated MG cells was markedly different from that of IL-4 treated WT Kolf2 MG cells. (D) IL-4 stimulation resulted in 
lower expression of the anti-inflammatory genes (PPAR and NR1H2) and M2-specific markers (MRC1 and CD163) in the ABCA7+/- MG cells compared to WT MG cells. (E) 
The pro-inflammatory genes CCL2, ICAM1 and NLRP3 were expressed at lower levels in compared to WT MG cells. (F) Differences in the expression of ABCA7 and 
cholesterol-associated genes were statistically significant between WT and ABCA7+/- MG cells after treatment with IL-4.  
 
Log2 Expression normalised to reference genes. Statistical analysis used two-way ANOVA with Tukey’s multiple comparison test.  
 
Asterisks denote statistical significance: * < 0.05, ** < 0.01, *** < 0.001, ns – not significant. n=3 biological replicates for all samples, except for Kolf2 ABCA7+/- MG (n=2); 
Kolf2 ABCA7+/- MG + 4h LPS (n=2); Kolf2 ABCA7+/- MG + 24h IL-4 (n=2).       
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This immune response-altering effect was more apparent with stimulation with IL-4, 
which induces an M2 phenotype. As shown by the PCA plot in Figure 6.4C, the 
inflammatory phenotype of the ABCA7+/- cells was markedly different from that of WT 
microglia after IL-4 treatment, with a distinct segregation based on expression of 
several immune response genes. This difference was particularly illustrated by the fact 
that the M2-specific markers PPAR- and CD163, and the nuclear factor NR1H2 (or 
LXR-ß), which showed a trend towards upregulation in the WT IL-4 stimulated cells, 
trended towards downregulation in the corresponding ABCA7-edited MG cells (Figure 
6.4D). In addition, the pro-inflammatory markers ICAM1, NLRP3 and CCL2 showed a 
trend towards reduction in the IL-4-treated ABCA7 mutant microglia, while IL-1ß 
reduction was found to be statistically significant. Crucially, the differences in 
expression levels of these genes were significant when comparing WT and ABCA7+/- 
IL-4 treated cells (Figure 6.4E). It is also worth noting that, following IL-4 stimulation, 
levels of ABCA7 and the cholesterol related transcripts SREBF2 and LRP1 were lower 
in ABCA7+/- cells vs WT cells (Figure 6.4F). Taken together, these results showed that, 
along with pro-inflammation, M2 anti-inflammatory responses were likely to be 
affected by ABCA7 loss-of-function mutations.     
 
6.3.3 ABCA7 loss of function impairs phagocytosis in iPSC-derived microglia  
ABCA7+/- and ABCA7-/- microglia cells were functionally validated for their capacity to 
phagocytose pHrodo red E. coli particles. 96-well plate differentiated microglial cells 
(20,000 per well) were incubated with 10 µg pHrodo particles and red channel 
fluorescence measurements were taken every 15 minutes for 4 hours in the IncuCyte 
S3 live imaging platform (see section 2.5). pHrodo red fluorescence was found to be 
markedly reduced in ABCA7+/- and ABCA7-/- cells compared to Kolf2 WT microglial cells 
(Figure 6.5A). Quantification of the endpoint fluorescence indicated that ABCA7 
homozygous and heterozygous mutant microglia cells ingested significantly fewer 
particles than WT Kolf2 cells (p <0.0001) (Figure 6.5B). Pre-treatment of the WT cells 
with 1 µM bafilomycin A1 resulted in ablation of the fluorescent signal, confirming 
that phagolysosome acidification is a prerequisite for this process. Tellingly, ABCA7 
mutant cells showed a higher rate of particle uptake than the inhibitor-treated cells, 
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except for one ABCA7-/- clone T2-1F where the difference was non-significant. 
Differences in rate of particle uptake were also uncovered between the three different 
ABCA7-/- clones, which individually ingested significantly fewer particles (p< 0.0001) 
than the single ABCA7+/- clone studied in this experiment. Therefore, these preliminary 
results suggest that microglial phagocytosis of red E. coli bioparticles is considerably 
impaired by genetic modification of ABCA7, implying that ABCA7 is essential for 
phagocytosis of pathogenic particles.      
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Figure 6.5 Phagocytosis of pHrodo E. coli bioparticles seems to be impaired by ABCA7 heterozygous and homozygous KO mutations in preliminary 
examinations.    
iPSC-derived MG cells plated at 20,000 per well were incubated with 10 µg pHrodo E. coli for 4 hours. (A) For negative control, WT MG cells were pre-treated with 10 µM of 
bafilomycin A1 for 1 hour before E. coli treatment. (B) End point fluorescence values from the experiment in (A) were plotted. Data are presented as mean ± SEM from each 
genotype or condition with 8-16 technical replicates. n=1 independent experiment.  
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Figure 6.6 Stimulation with the apoptotic molecule C1q induces intracellular accumulation of phospholipids and cholesterol in iPSC-derived microglia.      
Kolf2 WT and ABCA7+/- MG cells were cultured on PDL-treated and fibronectin-coated Ibidi 8-well chamber slides before stimulation with 10 µg/ml C1q for 1 hour. (A) MG 
cells were incubated with the phospholipidosis detection reagent LipidTOX for 4 hours. Fluorescence images were taken with a high-resolution microscope – LipidTOX was 
excited at 543 nm and its emission detected at 594 nm. (B) Following C1q stimulation, MG cells were incubated for 30 mins with 125 µg/ml of the cholesterol-specific probe 
filipin. Fluorescence images were taken at 300nm.   
Scale bars represent 20 µm.   
Phospholipids Phospholipids Cholesterol 
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6.3.4 Is ABCA7 involved in intracellular lipid trafficking?  
ABCA7 has been reported to exert its phagocytosis-mediating activity in mouse macrophages 
through recruitment to the cell surface of the low-density lipoprotein receptor-related 
protein 1 or LRP1, with both proteins colocalised to phagocytic cups when the cells were 
stimulated with C1q (Jehle et al. 2006). C1q is expressed on apoptotic cells, where it binds to 
LRP1 on phagocytes, initiating uptake of apoptotic cells (Ogden et al. 2001).  
Particle engulfment by phagocytes is a tightly orchestrated process that requires several 
proteins operating in concert to generate approximately 100 lipids in order to replenish the 
cell membrane expended during initial engulfment (Aderem 2002). This rapid rate of lipid 
synthesis is accompanied by increased transcription of many proteins, including the LDL 
receptor, fatty acid synthase and the cholesterol synthesis enzymes 3-hydroxy-3-
methylglutaryl CoA synthase and 3-hydroxy-3-methylglutaryl CoA reductase (Castoreno et al. 
2005). In order to explore the dynamics of cell membrane biogenesis and lipid metabolism 
during microglial phagocytosis, lipid trafficking assays focusing on two species (cholesterol 
and phospholipids) were carried out. Microglia differentiated from WT and ABCA7+/- cell lines 
were cultured on Ibidi 8-well chamber slides and incubated with 10 µg/ml C1q for 1 hour 
before staining for cholesterol and phospholipids with filipin and LipidTOX respectively (see 
section 2.5). High resolution images showed that unstimulated microglial cells exhibited low 
levels of phospholipids, with the LipidTOX staining enclosed in intracellular puncta (Figure 
6.6A). Upon stimulation with C1q, cells exhibited a noticeable intracellular accumulation of 
phospholipids, indicative of an increased rate of lipid synthesis. Crucially, no differences in 
staining pattern were observed between WT and single KO microglial cells, suggesting that 
ABCA7 mutations do not affect phagocytosis-mediated synthesis of phospholipids in microglia 
cells (Figure 6.6A). Cholesterol was similarly observed in intracellular punctate structures, as 
shown by staining with filipin (Figure 6.6B). ABCA7+/- and WT microglia treated with C1q for 1 
h showed elevated levels of filipin staining, the accumulation of cholesterol being 
concentrated in intracellular compartments (Figure 6.6B). Though not quantified, cholesterol 
staining in the ABCA7+/- cells was less pronounced compared to WT cells, hinting at an altered 
capacity to regulate cholesterol levels in response to a phagocytic challenge.  
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6.3 Summary and Discussion  
Transcriptomic and gene expression studies described in chapter 3 demonstrated that the 
human iPSC-derived microglia generated using the protocol described in this study express 
several disease-associated risk genes for AD. To validate the suitability of these in vitro 
differentiated cells for modelling the function of microglial-enriched AD risk genes, ABCA7 
was chosen as a candidate gene with the intention of knocking out the gene and studying the 
subsequent effects of these mutations on microglial function. Using CRISPR/Cas9 genome 
editing, ABCA7 mutant clones were generated by excision of a 2.5 kb region at the N-terminal 
end of the protein. Potential heterozygous and homozygous KO clones were identified by PCR 
screening and sequencing.  
 
Validation by Fluidigm qRT-PCR showed that ABCA7 mRNA expression was found to be 
unaltered following genome editing. The mRNA primers used were mapped to the coding 
exons 40 and 41 of the full-length protein, with the forward mRNA primer flanking the exon-
exon boundary for increased specificity. No reduction in ABCA7 mRNA levels in either the 
heterozygous or homozygous mutants suggests that the mutated mRNA transcripts may have 
escaped the nonsense mediated decay machinery. One important limitation of this 
investigation was the failure to validate ABCA7 protein expression and therefore the KO lines 
generated by Western blotting. A number of antibodies were trialled, namely the rabbit 
polyclonal antibody 25339-1-AP from ProteinTech Europe and another rabbit polyclonal 
antibody ARP-43690_P050 from Aviva Systems Biology (USA), which targets the middle region 
of the protein. Neither antibody worked convincingly by producing any bands when Western 
blots experiments were carried out. Recently, a study published the first paper using an 
antibody specific to human ABCA7 (Allen et al. 2017), designed to bind the epitope aa 2096-
2146 in the C-terminus of the full-length protein (LS-C291064, LifeSpan BioSciences - USA). 
This antibody looks like a good candidate for validation of the KO lines generated in this study.  
 
Nevertheless, preliminary functional assays carried out with pHrodo red E. coli bioparticles 
demonstrated a deficit in phagocytosis in ABCA7-edited microglia, showing that ABCA7 is 
required for efficient phagocytosis of bioparticles. In addition, the findings underlined the 
importance of actin remodelling and phagolysosome fusion in microglial phagocytosis, as the 
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use of the respective inhibitors cytochalasin D and bafilomycin A1 resulted in loss of pHrodo 
fluorescence. These observations are in agreement with recent studies of iPSC-derived 
macrophage and microglia phagocytosis performed using similar live cell imaging platforms 
(Kapellos et al. 2016; Brownjohn et al. 2018). Though this study recapitulates previous mouse 
model findings that ABCA7 mediated phagocytosis, another limitation is that only one aspect 
of bioparticle phagocytosis, through engagement of the TLR4 was investigated herein. Future 
experiments would need to establish whether mechanisms of phagocytosis impairment 
through ABCA7 loss-of-function are receptor- and particle-dependent, by challenging cells 
with larger bioparticles such as zymosan, a ligand found on the surface of fungi that stimulates 
TLR2-mediated uptake. Another essential question that has to be answered is whether these 
ABCA7 mutations would affect binding and internalisation of oligomeric Aß, as ABCA7 
deletion in AD mouse models enhances plaque load (Kim et al. 2013; Li et al. 2015; Sakae et 
al. 2016). Given that iPSC-derived microglia were shown to express several Aß receptors 
including TREM2, CD36 and CR1, impairments in Aß phagocytosis would likely point towards 
a general phagocytic mechanism that requires ABCA7.     
 
Studies in mouse macrophages have shown that ABCA7 staining is mostly intracellular 
(Liensel-Nitschke et al. 2005), whereas the protein co-localises with LRP1 following 
stimulation with C1q (Jehle et al. 2006). The latter work also proved that ABCA7 is required 
for signalling through LRP1. The ubiquitously expressed receptor LRP1 regulates a diverse 
range of physiological processes including endocytosis, lipid metabolism and signal 
transduction (May et al. 2005). In macrophages, it promotes anti-inflammatory signalling via 
inhibition of pro-inflammatory gene expression (Zurhove et al. 2008; May et al. 2013). This in 
turn affects polarisation by favouring an M2 anti-inflammatory phenotype. Correspondingly, 
LRP1 downregulation in mouse microglia leads to increased pro-inflammation via JNK and 
NFB activation (Yang et al. 2016). LPS and IL-4 stimulation experiments showed that the 
inflammatory response of microglia was affected by ABCA7 mutations, suggesting that the 
ATP transporter may play a role in microglial anti-inflammatory signalling. ABCA7+/- microglia 
exhibited a more restrained inflammatory response to LPS incubation compared to WT Kolf2 
cells, as indicated by fewer and statistically smaller increases in pro-inflammatory and M1 
activation molecules (Figure 6.4). Similarly, a distinct immune profile was obtained following 
stimulation with the anti-inflammatory cytokine IL-4. These data therefore provide 
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preliminary evidence for the involvement of ABCA7 in both the pro- and anti-inflammatory 
response of microglial cells, perhaps in modulating the appropriate response to pathogens 
and inflammatory stimuli. Given the evidence for LRP1 in this context and that ABCA7 is 
required for LRP1 signalling, it is plausible that ABCA7 exerts its inflammation- and 
phagocytosis-mediating effects through interactions with LRP1 in lipid rafts. Consequently, 
more work is needed to certify these potential links between LRP1 and ABCA7, including their 
intracellular localisation in unstimulated microglia and during phagocytosis. This could be 
done using confocal microscopy, as well as using co-immunoprecipitation assays that could 
enable the identification of proteins and complexes that interact with ABCA7 during 
phagocytosis.     
 
C1q treatment of iPSC-derived microglia resulted in increased intracellular cholesterol and 
phospholipid staining, indicative of a higher rate of lipid and cholesterol synthesis in response 
to or during phagocytosis. Future experiments should aim to quantify these increases and 
assess whether ABCA7 mutations inhibit or enhance these processes. Additionally, ABCA7 
expression is regulated by intracellular cholesterol levels through the SREBP2 pathway, 
whereby its expression is upregulated by cholesterol depletion and downregulated by higher 
cellular cholesterol levels (Iwamoto et al. 2006). A series of experiments focusing on this 
pathway in the ABCA7 KO iPSC lines were planned, with cholesterol depletion to be mimicked 
using the cholesterol-lowering drug mevastatin, an inhibitor of the HMG-CoA reductase 
enzyme (Bamji-Mirza et al. 2016). Preliminary results with Kolf2 WT microglia stimulated with 
10 µM mevastatin (ML-236B, Sigma Aldrich) for 4 hours showed that mevastatin treatment 
significantly increased expression of SREBF2 and the cholesterol-synthesis enzymes fatty acid 
synthase (FASN), low density lipoprotein receptor (LDLR) and HMG-CoA synthase 1 (HMGCS1) 
(see appendix 5). Likewise, experiments assessing the effects of C1q stimulation on gene 
expression of cholesterol pathway genes should be carried out, and comparisons made 
between WT and ABCA7-deficient microglia.   
 
Phagocytosis and clearance of debris is a quintessential and defining function of microglia 
(Gordon & Martinez 2010). Indeed, a growing research area within the field revolves around 
their involvement in synaptic pruning, whereby microglia engulf and eliminate synapses 
during development (Paolicelli et al. 2011; Schafer et al. 2012). Though there is very little 
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evidence for microglial-mediated synaptic pruning after development, proper microglia 
function is critical for the correcting wiring of embryonic brain circuits (Squarzoni et al. 2014). 
Furthermore, microglia have been shown to mediate synaptic loss in AD mouse models 
through the CR3 pathway, a process that precedes plaque deposition and is dependent on 
C1q expression (Hong et al. 2016). Fluorescence imaging of synaptic membrane dynamics has 
been reported using the pH-sensitive pHluorin (Miesenböck et al. 1998; Royle et al. 2008) and 
thus can be adapted for in vitro live imaging assays, by co-culturing microglia with synapto-
pHluorin-expressing iPSC-derived neurons. This would allow to investigate synaptic pruning 
in vitro as well as the effects of ABCA7 mutations on this microglial activity.    
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7. GENERAL DISCUSSION 
7.1 General discussion and future perspectives  
7.1.1 Characterisation of the phenotype of HD109 iPSC-derived microglia  
The accumulation of reactive microglia is a key feature of the HD brain (Sapp et al. 2001), with 
imaging studies going on to demonstrate that this extensive microglial activation is apparent 
long before age of onset in HD gene carriers (Tai et al. 2007) and that it correlates with 
neuronal loss in symptomatic patients (Pavese et al. 2006). Moreover, studies in mouse 
models and post-mortem human brains have shown that HD microglia acquire an 
inflammatory phenotype, resulting in elevated levels of proinflammatory cytokines 
(Dalrymple et al. 2007; Silvestroni et al. 2009). Though microglial activation in the HD brain 
has been relatively well reported, it remains unclear whether this phenomenon is a secondary 
response to neuronal degeneration or mainly down to the cell-autonomous effects of mutant 
HTT expression in immune cells.  
The first aim of this thesis was to investigate the phenotype of microglia derived from a 
Huntington’s disease human iPS cell line containing 109 CAG repeats in the HTT gene. The 
transcriptome of HD109 iPSC-derived microglia was compared to that of WT cells derived 
from a different genetic background by RNA sequencing. The transcriptional hallmarks of 
mutant HTT-associated immune dysfunction, which include NFB dysregulation and higher 
expression of pro-inflammatory SPI1-target genes, were not detected in the HD109 microglia. 
In fact, the findings presented in chapter 4 point towards the notion that the pathogenic 
hallmarks of mutant HTT-expressing microglia, as described in the literature, may not be 
innate to their basal transcriptome.  
 
The study’s focus then turned to assessing whether the pro-inflammatory properties of HD 
microglia would manifest following exogenous stimulation. Surprisingly, results showed that 
the in vitro HD microglia did not exhibit a hyper-reactive activation profile when challenged 
with LPS. When paying close attention to genes belonging to the two HD affected pathways 
of NFB and LPS, no evidence of dysregulation in gene expression were found in those 
pathways, contrary to findings reported elsewhere (Crotti et al. 2014).    
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These results therefore indicate that the transcriptome of human HD microglia may not be 
primed; instead, evidence points towards a distinct neuroprotective signature with several 
pathways highlighted as activated in patient-isolated monocytes predicted to be inhibited. As 
already mentioned, one attractive explanation is that this is down to the impact of the 
neuronal environment, particularly the neuron-derived cytokine IL-34 on the microglial 
phenotype, which illustrates the transcriptional alterations that microglia undergo as they 
populate the embryonic brain. This could be viewed as an adaptation of the HD microglial 
transcriptome to its surrounding neuronal environment, shown to be susceptible to 
degeneration early in neurodevelopment (Molero et al. 2009; Ring et al. 2015). Indeed, the 
fragile HD brain may initially potentiate the phenotype of microglia in HD, potentially 
dampening the priming effects of mutant HTT expression.  
 
Another possibility is that this inhibitory transcriptomic signal represents a human microglial-
specific effect, given that microglia from HD mouse models exhibit activated inflammatory 
pathways. A crucial point of difference between the findings outlined in chapter 4 and those 
of patient-derived monocytes resides in the age of the patient-derived cells from Miller et al. 
2016, where the mean age of participants at the early or moderate stage of the disease was 
48 years old. In contrast, a feature of differentiation protocols is that they seldom give rise to 
adult differentiated cells. Indeed, this remains a great challenge for the iPSC modelling field. 
Given this caveat, it is plausible that differences in transcriptome-wide pathway activation 
from the respective studies reflect different stages of the choreography of inflammation in 
Huntington’s disease.  Furthermore, these findings imply that the basal transcriptome of 
microglia in HD may be non-pathogenic and/or neuroprotective, with gradual changes in 
phenotype towards those reported in mouse models and HD patients with characteristics 
such as increased pro-inflammation, as a likely consequence of exposure to the HD brain 
environment and degeneration in the striatum. One way to test this hypothesis would be to 
use human iPSC-derived microglia from HD and isogenic control lines in combination with 
xenotransplantation compatible WT mice (e.g. MITRG) (Rongvaux et al. 2014) and 
corresponding HD mouse models, along with single cell transcriptomic approaches to 
investigate the effects of both ageing and exposure to the HD brain microenvironment on the 
immune phenotype of human microglia. Such an experiment would answer pertinent 
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questions about the effect of ageing on the phenotype of HD microglia. In addition, this would 
shed a light on the contribution of diseased and non-diseased microglia on inflammatory 
processes in the HD brain, and subsequently on neural degeneration in the striatum.      
 
7.1.2 The effects of correcting the HD CAG mutation on the microglial phenotype  
Comparing iPSC-derived neural stem cells, Xu et al. 2017 recently found that transcriptome 
differences between HD and non-isogenic lines were not detected when comparing HD with 
isogenic corrected line samples, suggesting that those differences resulted from non-HD-
specific effects, a consequence of genetic background variations. The second aim of this thesis 
was therefore to determine the effects of correcting the HD CAG expansion mutation on the 
phenotype of HD109 iPSC-derived microglia. Given the predictions of potential impairments 
in several immune pathways in the HD109 microglia (when compared to WT Kolf2 iPSC-
derived microglia), experiments were carried out to ascertain the HD-specific nature of these 
HD109 transcriptome changes, with comparisons against microglia differentiated from HD 
isogenic corrected iPSC lines. When assayed, the HD109 cells displayed no functional deficits 
in phagocytosis or chemotaxis compared to HD corrected and Kolf2 cells. Similarly, an 
investigation into the immune response of the corrected HD microglia failed to pinpoint 
mutant HTT-specific phenotypic differences in the LPS response of HD109 microglia. Taken 
together, the data point towards genetic background, rather than HD-specific, differences 
between the transcriptome of HD109 and Kolf2 microglia. This is best illustrated by the fact 
that while RNA-seq data showed lower levels of chemokines expressed in HD109 cells 
implying a dysregulation in chemokine signalling, validation by Fluidigm qRT-PCR confirmed 
that these differences were most likely due to genetic background, as the LPS chemokine 
profile of the HD109 microglia post LPS was found to match that of the LPS-stimulated HD 
corrected cells.  
 
The absence of any predicted transcriptome-associated functional dysfunctions in the HD109 
microglia, allied with the lack of manifestation of phenotypic differences with the HD 
corrected cells, could be explained by an absence of mutant HTT expression in the in vitro 
derived HD109 microglia. One way to confirm this hypothesis would be to measure mutant 
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HTT expression by Western blotting, which, due to time constraints, was not undertaken and 
remains a significant limitation of this study.    
Mutant HTT detection has been reported in new-born mice microglia (Crotti et al. 2014), but 
not human microglia, although it was found to be expressed in other immune cells isolated 
from symptomatic HD patients such monocytes, T cells and B cells (Weiss et al. 2012). 
However, it should be pointed out that the characteristics and reactivity of microglia in rodent 
models of Huntington’s disease vary greatly across species. In a recent study, Harrison et al. 
2018 used quinolinic acid lesion models of HD to evaluate differences in survival of engrafted 
tissues in mice and rats and demonstrated that mice models exhibited a lower engraftment 
survival than equivalent rat grafts, and substantially higher microglia activation and 
recruitment to the site of transplantation (Harrison et al. 2018).  The outcome of higher 
mouse microglia reactivity has many implications that are important to consider, not just for 
mouse transplantation studies (since mouse models comprise the majority of transgenic HD 
models) but also for the fields of microglial research in general and in neurodegenerative 
diseases such HD and AD. Additionally, it emphasises a particular disparity in the immune 
response between rodent models that is under-reported in the neuroinflammation field and 
is highly likely to translate into differences with human cells. In turn, it could be argued that 
this could be reflected in the human iPSC models used in this work.  
 
No matter whether mutant HTT expression can be detected in HD iPSC-derived microglia in 
future experiments, the absence of a HD phenotype in these embryonic-like cells 
demonstrates that the cell autonomous effects of mutant HTT on the microglial phenotype 
must be triggered by either intrinsic cellular events (e.g. mutant HTT aggregation or ageing) 
or by extrinsic factors, such as interactions between microglia and the HD brain 
microenvironment. This entails that the presence of the CAG expansion track in the HTT gene 
on its own is insufficient to trigger the manifestation of the pathogenic effects characteristic 
of HD microglia, an observation compatible with reports of increased microglial activation 
with age in HD patients (Pavese et al. 2006; Tai et al. 2007). It also suggests that, rather than 
a causal disease mechanism, microglial activation in HD should be considered as a disease 
biomarker. Nonetheless, this does not preclude from microglia contributing to striatal 
degeneration.   
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This is the first study to evaluate the effects of reversing the HD mutation on immune 
dysfunction in human microglia. Given the extensive evidence for the involvement of 
microglia and other immune cells in HD neuropathology, it is imperative to investigate the 
effects of mutant HTT lowering on HD human immune cells. In addition, this area of research 
is of greater importance in the light of current encouraging developments in human clinical 
trials of the mutant HTT-lowering antisense oligonucleotide-based IONIS-HTTRx (RG6042) 
(Østergaard et al. 2013; Skotte et al. 2014). Preliminary phase 1/2 trials have assessed safety 
of this treatment and confirmed a dose-dependent reduction of mutant HTT in the CSF of HD 
patients, using a single-molecule counting mHTT immunoassay (Wild et al. 2015). Studies in 
HD mouse models had earlier demonstrated that human mutant HTT-targeting antisense 
oligonucleotides produced long-lasting reductions in HTT brain mRNA and protein levels, 
which correlated with improved motor function and survival (Kordasiewicz et al. 2012).  
 
7.1.3 Modelling neuroinflammation with iPSC-derived microglia  
As well as helping to elucidate the pathogenic mechanisms underlying microglial involvement 
in HD, iPSC-based models hold great potential for Alzheimer’s disease. Firstly, they provide a 
good alternative to animal models for drug screening. In vitro microglia can certainly be used 
to develop assays that probe the effects of immunomodulatory therapies on immune 
activation. One aspect of microglial function that can certainly be exploited in this manner, 
using Seahorse assays, is the link between metabolism and inflammatory processes, which 
work in this thesis attempted to investigate. This is especially relevant to AD, with evidence 
for the influence of metabolic processes on microglial function coming from mouse model 
studies by Ulland et al. 2017, where the authors demonstrated that TREM2 deletion disrupts 
microglial function by impairing other metabolic pathways including glycolysis, the TCA cycle 
and the pentose phosphate pathway (Ulland et al. 2017). Indeed, TREM2-deficient mouse 
microglia exhibit mitochondrial impairments including reduced mitochondrial mass and 
increased autophagy.   
 
Secondly, iPSC-derived microglia can and are being used to understand the role of microglia-
enriched disease-associated risk genes in microglial biology, enabling researchers to look at 
both rare and common disease variants. While the former offer an insight into pathological 
mechanisms, the latter allows us to model predisposition to disease, increasing the likelihood 
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of discovering preventative therapies. The advent of CRISPR/Cas9 genome editing, along with 
the progress made in generating patient-specific iPSCs, have opened the door for in vitro 
functional studies in these two contexts.         
  
One important challenge of this microglial differentiation protocol remains that there are 
doubts surrounding the suitability of monocultured in vitro microglia. Reasons for this include 
the lack of elaborate ramifications in the in vitro microglia and the relatively high expression 
of inflammatory genes in the IL-34 and GM-CSF treated iPSC-derived microglia. The first 
observation is partly reflective of the neuronal-free culture conditions, while the second is a 
reported feature of ex vivo microglial culture (Bohlen et al. 2017). Another possibility, 
currently being investigated in our lab, is that the absence of a dampened immune signature 
in the in vitro monocultured microglia cells could represent an artefact of in vitro 
differentiation with GM-CSF, which has been shown to regulate cell proliferation and enhance 
several inflammatory functions (Shiomi & Usui 2015).  
 
Given our rapidly evolving understanding of how the transcriptome, phenotype and functions 
of microglia is modulated by the CNS microenvironment, the findings described in this thesis 
underline the importance of using the appropriate culture conditions that more faithfully 
recapitulate microglia origins, maturation and homeostasis. Therefore, the use of more 
complex model systems such as co-cultures that better mimic the natural microglial habitat 
should be greatly encouraged, where possible. These systems would ideally integrate 
neuronal and astrocytic cell types in order to more faithfully study the effects of the functional 
interactions between the relevant cell types on the phenotypes and functionality of the 
individual cell types.  
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7.2 Concluding remarks  
Immune activation within the CNS is now accepted as a key feature of Alzheimer’s disease, 
Huntington’s disease and many other neurodegenerative diseases. In AD, recent GWAS 
findings highlighting several microglia-enriched genes as disease-associated risk loci have 
focused current research on the role of microglia-mediated inflammation. Using iPSC-derived 
microglia, loss-of-function mutations in ABCA7 have been found to impair phagocytosis and 
regulate microglial inflammatory responses in preliminary studies. Although limited, the 
ABCA7 work in this thesis provides the starting point for more in-depth mechanistic studies 
to explore the role of ABCA7 in microglial biology.   
 
Data from human imaging studies in Huntington’s disease point towards the detrimental 
influence of microglia-mediated neuroinflammatory processes to disease progression. In 
addition, studies in HD mouse models have established that mutant HTT induces pathogenic 
cell-autonomous effects on the phenotype of microglia. Using microglia derived from HD 
iPSCs, this study demonstrates that the pathogenic and inflammatory phenotype of diseased 
HD microglia is not innate to their transcriptome, suggesting that it may therefore be a 
consequence of intrinsic factors or extrinsic interactions with the degenerative HD brain 
microenvironment. In particular, the lack of manifestation of the phenotypic abnormalities 
characteristic of diseased HD microglia in the embryonic-like in vitro microglia suggests that 
the HD microglial phenotype may not be accurately reflected outside of the diseased HD brain 
environment. These findings provide an insight into the limitations of in vitro models of 
microglia, whilst emphasising the need for iPSC-based models that better recapitulate disease 
pathology and subsequently better enable dissecting the contribution of microglia to 
pathogenesis.       
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9. APPENDICES 
Appendix 1. Top 50 differentially expressed genes in HD109 iPSC-derived microglia.  
 
Genes were ranked by p-value correction with  
Symbol LogFC p-value 
LRRC61 -4.101 1.00E-06 
BDKRB1 -5.42 1.00E-06 
CALR -1.127 1.00E-06 
CD151 -1.339 1.00E-06 
CTSB -1.108 1.00E-06 
CX3CR1 9.412 1.00E-06 
DGKG -2.242 1.00E-06 
EVI2A 1.026 1.00E-06 
F3 -2.066 1.00E-06 
F10 -3.127 1.00E-06 
GABRA3 5.026 1.00E-06 
GALNT2 -1.083 1.00E-06 
CXCL1 -2.356 1.00E-06 
GSTM1 8.009 1.00E-06 
HLA-A -1.878 1.00E-06 
HLA-B -1.728 1.00E-06 
HLA-H -2.147 1.00E-06 
ID2 1.159 1.00E-06 
IL15RA -2.306 1.00E-06 
ITGA2 -4.622 1.00E-06 
JARID2 1.027 1.00E-06 
CD82 -1.989 1.00E-06 
MFGE8 -2.753 1.00E-06 
MELTF -3.198 1.00E-06 
MYO10 -2.137 1.00E-06 
P4HB -1.314 1.00E-06 
PRKY -10 1.00E-06 
MASP1 -5.793 1.00E-06 
RPA1 1.079 1.00E-06 
RPS4Y1 -10 1.00E-06 
RRAD -4.167 1.00E-06 
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CCL7 -4.399 1.00E-06 
SLC22A3 -4.6 1.00E-06 
SMPD1 -1.023 1.00E-06 
TAP1 -1.182 1.00E-06 
TCN2 -2.424 1.00E-06 
MEG9 -3.74 1.00E-06 
TIMP1 -3.057 1.00E-06 
FAM155A -2.434 1.00E-06 
UTY -10 1.00E-06 
VTN -4.171 1.00E-06 
ZFX 1.171 1.00E-06 
MIR4458HG -9.571 1.00E-06 
ZFY -10 1.00E-06 
ZNF232 -1.438 1.00E-06 
TFPI2 -6.756 1.00E-06 
KDM5D -10 1.00E-06 
USP9Y -10 1.00E-06 
DDX3Y -10 1.00E-06 
PLOD3 -1.182 1.00E-06 
 
Appendix 2. IPA output of upstream transcriptional regulators inhibited in HD109 
iPSC-derived microglia.  
 
This table contains the rest of the transcriptional regulators identified as inhibited in HD109 
via IPA. 
   
Upstream regulator  Activation z-score P value of overlap 
IL6 -3.348 0.000811 
IFNL1 -3.286 0.000048 
ERK1/2 -3.236 0.000124 
SMARCA4 -3.168 0.0000153 
IRF1 -3.16 0.00513 
P38 MAPK -2.728 0.00112 
Interferon alpha -2.66 0.00000881 
IRF3 -2.655 0.00357 
IL4 -2.591 0.00000563 
IL1B -2.576 1.1E-09 
JAK -2.433 0.000599 
STAT1 -2.374 0.00928 
SREBF1 -2.301 0.00284 
PRL -2.184 7.86E-08 
CCL11 -2.084 0.00000379 
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forskolin -2.082 0.0000173 
VEGFA -2.012 0.0000252 
 
Appendix 3. IPA output of upstream transcriptional regulators activated in HD109 
iPSC-derived microglia.  
 
Upstream regulator  Activation z-score P value of overlap 
SB203580 3.885 1.33E-08 
calphostin C 2.42 2.16E-07 
RARA 3.414 5.49E-07 
NKX2-3 2.103 6.63E-06 
Go 6976 2.97 1.30E-05 
miR-199a-5p  2.72 2.48E-05 
tyrphostin AG 1478 2.397 1.32E-04 
PD98059 2.746 1.86E-04 
DKK1 2.005 1.94E-04 
UDP-D-glucose 2.449 1.61E-09 
MYCN 2.671 7.85E-04 
2-aminopurine 2.165 9.46E-04 
IL1RN 2.279 1.64E-03 
 
Appendix 4. IPA output of inhibited upstream transcriptional regulators specific to 
HD109 iPSC-derived macrophage precursors.  
 
Upstream regulator  Activation z-score P value of overlap 
3-deazaneplanocin -2.561 2.48E-05 
OSM -2.709 1.07E-04 
lipopolysaccharide -3.881 4.60E-04 
enterotoxin B -2.414 1.27E-03 
pyrrolidine 
dithiocarbamate 2.584 1.35E-03 
TGFB1 -2.206 1.37E-03 
IRF7 -2.18 5.04E-03 
TP53 -2.251 5.38E-03 
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Appendix 5. Microglia response to cholesterol depletion 
 
Kolf2 WT microglia were stimulated with 10 µM mevastatin for 4 hours.   
 
 
 
Appendix 6. List of qRT-PCR primers used in this project (continued) 
 
Gene Forward Reverse 
MERTK TCC ATC CGT CCG GAG AGA AA CCC TTG CCT CAG TGA TAG CTC 
C1QA TGG AGT TGA CAA CAG GAG GC ATA TGG CCA GCA CAC AGA GC 
PROS1 ATGACCCGGAAACGGATTATT AGCATTAGTTGACTGACGTGC 
GPR34 CCCAGCTGACACAACCAAGA TGCATTAAAGTTCAGGTTCGCC 
CR1 ATAGCAGGGTCCTTCCTTGAC TTTAGCACGAGGCAGAAGGG 
CR2 AATCGGATCACCAATGGAACCC CTGCAGCAATACCACAAAGGACAG 
SDHA TGG GAA CAA GAG GGC ATC TG CCA CCA CTG CAT CAA ATT CAT G 
HPRT1 TGA CAC TGG CAA AAC AAT GCA GGT CCT TTT CAC CAG CAA GCT 
UBC CGG TGA ACG CCG ATG ATT AT ATC TGC ATT GTC AAG TGA CGA 
HMBS TGC AAC GGC GGA AGA AAA ACG AGG CTT TCA ATG TTG CC 
GAPDH TGC ACC ACC AAC TGC TTA GC GGC ATG GAC TGT GGT CAT GAG 
CD33 TCAACGTCACCTATGTTCCAC CACTCCTGCTCTGGTCTCTTG 
TYROBP CTGCGGAGGCAGCGA GGCCTCTGTGTGTTGAGGTC 
SYK GGGAAAGAAGTTCGACACGC ACATTTCCCTGTGTGCCGATT 
APOE CAGGTCACCCAGGAACTGAG CGGGGTCAGTTGTTCCTCC 
ß-actin CCC AGC ACA ATG AAG ATC AA ACA TCT GCT GGA AGG TGG AC 
PICALM TGGAGTCAACCAGGTGAAAAG GGGTGCGTATTGTGGAAAATG 
CD36 GCCAGGTATTGCAGTTCTTTTC TGTCTGGGTTTTCAACTGGAG 
IL8 ATACTCCAAACCTTTCCACCC TCTGCACCCAGTTTTCCTTG 
IRF1 CAACAGATGAGGATGAGGAAGG GGTTCATTGAGTAGGTACCCC 
ADORA3 CTTATCTTTACCCACGCCTCC CAGGAATGACACCAGCCA 
CLEC7A TGTCACTAAATTCCTGGGATGG ATCAGGTTGGGAAGACACTTG 
SIGLEC12 TCCCTGCAAAACGAGTACAC GGACCTCACTACAACGAAGATG 
CD22 TGTAATAGTTGGTGCTCGTGG AGAAGTCACATTGGAGGCTG 
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177  
CLU ATTCAAAATGCTGTCAACGGG CTTTGTCTCTGATTCCCTGGTC 
ICAM1 CAATGTGCTATTCAAACTGCCC CAGCGTAGGGTAAGGTTCTTG 
FCER1G TCGACTGAAGATCCAAGTGC ACCGCATCTATTCTAAAGCTACTG 
NR1H2 GATGTCCCAGGCACTGATG ACAGACACGGCAAAGCTC 
TLR4 TGCGTGAGACCAGAAAGC TTAAAGCTCAGGTCCAGGTTC 
CD40 AAGCTGTGAGACCAAAGACC ATAAAGACCAGCACCAAGAGG 
CABLES1 TCATTGGTCTGGAAGGTGTG GTTACGGAACTGGGAGAAAGAG 
STAT1 TGAACTTACCCAGAATGCCC CAGACTCTCCGCAACTATAGTG 
MRC1 CACCTTAACAACTGGATTTGCCA TGGTGGATTGTCTTGAGGAGC 
CCL18 CTTGTCCTCGTCTGCACCAT TTGTGGAATCTGCCAGGAGG 
CCL17 CTTCAAGGGAGCCATTCCCC CCTGCCCTGCACAGTTACA 
CCL2 AATCAATGCCCCAGTCACCT CTTCTTTGGGACACTTGCTGC 
CD163 TATTTCTGGAATGGAAAAGGAGGC ATCTTAAAGGCTGAACTCACTGGG 
CCR2 GGTTCAGTTGCTGAGAAGCC GTACTGGGGAAATGCGTCCT 
CYBB GGAATGCCCAATCCCTCAGT AAAACCGCACCAACCTCTCA 
NLRP3 GCGATCAACAGGAGAGACCT TTCAATGCTGTCTTCCTGGCA 
NR1H3 TTCTGGACAGGAAACTGCACC TGGTCATTACCAAGGCACTGT 
SOCS3 GGAGACTTCGATTCGGGACC GGAGCCAGCGTGGATCTG 
CCR7 CTTCCTGTGTGGTTTTACCGC CACAGGCATACCTGGAAAATGA 
CCL22 TACTGGACCTCAGACTCCTGC GAATCATCTTCACCCAGGGCA 
CD68 ATCCCCACCTGCTTCTCTCA CCGAGAATGTCCACTGTGCT 
SPI1 GATCTGACCGACTCGGAGC GTCTTCTGATGGCTGAGGGG 
HLA-DR TTCAGGAATCAGAAAGGACACTC TCTGCATTTCAGCTCAGGAA 
 
 
